WO2005042774A2 - Method for linking sequences of interest - Google Patents
Method for linking sequences of interest Download PDFInfo
- Publication number
- WO2005042774A2 WO2005042774A2 PCT/DK2004/000633 DK2004000633W WO2005042774A2 WO 2005042774 A2 WO2005042774 A2 WO 2005042774A2 DK 2004000633 W DK2004000633 W DK 2004000633W WO 2005042774 A2 WO2005042774 A2 WO 2005042774A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- variable region
- ofthe
- cells
- sequences
- region encoding
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 198
- 210000004027 cell Anatomy 0.000 claims abstract description 512
- 238000003757 reverse transcription PCR Methods 0.000 claims abstract description 154
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 143
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 85
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 72
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 61
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 61
- 108091008874 T cell receptors Proteins 0.000 claims abstract description 45
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims abstract description 45
- 229940072221 immunoglobulins Drugs 0.000 claims abstract description 16
- 230000003321 amplification Effects 0.000 claims description 135
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 135
- 239000000203 mixture Substances 0.000 claims description 127
- 239000013598 vector Substances 0.000 claims description 90
- 239000012634 fragment Substances 0.000 claims description 77
- 239000000427 antigen Substances 0.000 claims description 74
- 230000027455 binding Effects 0.000 claims description 71
- 238000010839 reverse transcription Methods 0.000 claims description 68
- 108091007433 antigens Proteins 0.000 claims description 65
- 102000036639 antigens Human genes 0.000 claims description 65
- 230000014509 gene expression Effects 0.000 claims description 61
- 150000007523 nucleic acids Chemical group 0.000 claims description 39
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 38
- 210000004180 plasmocyte Anatomy 0.000 claims description 36
- 230000008569 process Effects 0.000 claims description 35
- 238000010367 cloning Methods 0.000 claims description 34
- 238000007403 mPCR Methods 0.000 claims description 34
- 239000013604 expression vector Substances 0.000 claims description 32
- 108091008324 binding proteins Proteins 0.000 claims description 31
- 210000004698 lymphocyte Anatomy 0.000 claims description 31
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 29
- 230000000295 complement effect Effects 0.000 claims description 26
- 210000004369 blood Anatomy 0.000 claims description 22
- 239000008280 blood Substances 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 22
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims description 21
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims description 21
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims description 18
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims description 18
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims description 18
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims description 18
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims description 18
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 claims description 18
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 17
- 229940118376 tetanus toxin Drugs 0.000 claims description 17
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 13
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 13
- 210000005087 mononuclear cell Anatomy 0.000 claims description 10
- 206010043376 Tetanus Diseases 0.000 claims description 9
- 210000001185 bone marrow Anatomy 0.000 claims description 9
- 238000005304 joining Methods 0.000 claims description 8
- 210000000265 leukocyte Anatomy 0.000 claims description 8
- 210000004962 mammalian cell Anatomy 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 108091081021 Sense strand Proteins 0.000 claims description 7
- 230000001747 exhibiting effect Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 230000001419 dependent effect Effects 0.000 claims description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000000692 anti-sense effect Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 claims description 2
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 claims description 2
- 239000013605 shuttle vector Substances 0.000 claims description 2
- 102000023732 binding proteins Human genes 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 97
- 108091008875 B cell receptors Proteins 0.000 abstract description 5
- 239000013615 primer Substances 0.000 description 451
- 239000000047 product Substances 0.000 description 88
- 238000007857 nested PCR Methods 0.000 description 87
- 229960000814 tetanus toxoid Drugs 0.000 description 83
- 238000003752 polymerase chain reaction Methods 0.000 description 68
- 239000000872 buffer Substances 0.000 description 39
- 239000012528 membrane Substances 0.000 description 35
- 238000005215 recombination Methods 0.000 description 34
- 230000006798 recombination Effects 0.000 description 34
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 33
- 238000002965 ELISA Methods 0.000 description 32
- 102000014914 Carrier Proteins Human genes 0.000 description 30
- 108020004414 DNA Proteins 0.000 description 27
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 25
- 238000013459 approach Methods 0.000 description 25
- 230000009257 reactivity Effects 0.000 description 24
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 23
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 23
- 239000002299 complementary DNA Substances 0.000 description 23
- 238000013461 design Methods 0.000 description 23
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 21
- 238000012408 PCR amplification Methods 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 20
- 230000001351 cycling effect Effects 0.000 description 19
- 239000002773 nucleotide Substances 0.000 description 19
- 238000003780 insertion Methods 0.000 description 18
- 230000037431 insertion Effects 0.000 description 18
- 238000012216 screening Methods 0.000 description 18
- 230000001580 bacterial effect Effects 0.000 description 17
- 239000000499 gel Substances 0.000 description 17
- 238000002955 isolation Methods 0.000 description 17
- 108020004707 nucleic acids Proteins 0.000 description 17
- 102000039446 nucleic acids Human genes 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 230000002441 reversible effect Effects 0.000 description 17
- 241000588724 Escherichia coli Species 0.000 description 16
- 238000010790 dilution Methods 0.000 description 16
- 239000012895 dilution Substances 0.000 description 16
- 238000002823 phage display Methods 0.000 description 16
- 102100034343 Integrase Human genes 0.000 description 15
- 238000000246 agarose gel electrophoresis Methods 0.000 description 15
- 238000000137 annealing Methods 0.000 description 15
- 229920001817 Agar Polymers 0.000 description 14
- 239000008272 agar Substances 0.000 description 14
- 238000005516 engineering process Methods 0.000 description 14
- 230000035772 mutation Effects 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 13
- 239000002033 PVDF binder Substances 0.000 description 13
- 108010076504 Protein Sorting Signals Proteins 0.000 description 13
- 238000009826 distribution Methods 0.000 description 13
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 13
- 229960005542 ethidium bromide Drugs 0.000 description 13
- 238000011534 incubation Methods 0.000 description 13
- 238000004091 panning Methods 0.000 description 13
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 13
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 239000007795 chemical reaction product Substances 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 210000004408 hybridoma Anatomy 0.000 description 12
- 108091008146 restriction endonucleases Proteins 0.000 description 12
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 11
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 11
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 11
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 11
- 239000011324 bead Substances 0.000 description 11
- 238000010586 diagram Methods 0.000 description 11
- 230000028993 immune response Effects 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 108010006785 Taq Polymerase Proteins 0.000 description 10
- 210000000612 antigen-presenting cell Anatomy 0.000 description 10
- 210000004899 c-terminal region Anatomy 0.000 description 10
- 239000006166 lysate Substances 0.000 description 10
- 230000035800 maturation Effects 0.000 description 10
- 238000013492 plasmid preparation Methods 0.000 description 10
- 230000037452 priming Effects 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 9
- 238000012286 ELISA Assay Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 230000010354 integration Effects 0.000 description 9
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 9
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 9
- 238000005457 optimization Methods 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 230000008707 rearrangement Effects 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 239000011543 agarose gel Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000003161 ribonuclease inhibitor Substances 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 7
- 108091006027 G proteins Proteins 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000013592 cell lysate Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000004520 electroporation Methods 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 230000000521 hyperimmunizing effect Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102000030782 GTP binding Human genes 0.000 description 6
- 108091000058 GTP-Binding Proteins 0.000 description 6
- 239000004677 Nylon Substances 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 229960003669 carbenicillin Drugs 0.000 description 6
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000004602 germ cell Anatomy 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 229920001778 nylon Polymers 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 6
- 229960002766 tetanus vaccines Drugs 0.000 description 6
- 108010046276 FLP recombinase Proteins 0.000 description 5
- 108020004485 Nonsense Codon Proteins 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000002096 anti-tetanic effect Effects 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 238000003491 array Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000037230 mobility Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 101150117115 V gene Proteins 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 240000001082 Bambusa multiplex Species 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000724791 Filamentous phage Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 108010061833 Integrases Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 108010091086 Recombinases Proteins 0.000 description 3
- 102000018120 Recombinases Human genes 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 102000025171 antigen binding proteins Human genes 0.000 description 3
- 108091000831 antigen binding proteins Proteins 0.000 description 3
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002458 cell surface marker Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012411 cloning technique Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 3
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 3
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 3
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 239000011325 microbead Substances 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000007860 single-cell PCR Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 102000034573 Channels Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- CMMBEMZGNGYJRJ-IHRRRGAJSA-N His-Met-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N CMMBEMZGNGYJRJ-IHRRRGAJSA-N 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- DIBZLYZXTSVGLN-CIUDSAMLSA-N Lys-Ser-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O DIBZLYZXTSVGLN-CIUDSAMLSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007596 consolidation process Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000012188 high-throughput screening assay Methods 0.000 description 2
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 2
- 229940097277 hygromycin b Drugs 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000016507 interphase Effects 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 101150040383 pel2 gene Proteins 0.000 description 2
- 101150050446 pelB gene Proteins 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000007030 peptide scission Effects 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 238000002702 ribosome display Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 238000009966 trimming Methods 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101150072531 10 gene Proteins 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100032768 Complement receptor type 2 Human genes 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 208000032163 Emerging Communicable disease Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000034353 G alpha subunit Human genes 0.000 description 1
- 108091006099 G alpha subunit Proteins 0.000 description 1
- 102000034286 G proteins Human genes 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100026215 Immunoglobulin gamma-1 heavy chain Human genes 0.000 description 1
- 101710111858 Immunoglobulin gamma-1 heavy chain Proteins 0.000 description 1
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 description 1
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241001061076 Melanonus zugmayeri Species 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000009344 Penetrating Wounds Diseases 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000769240 Polyozellus multiplex Species 0.000 description 1
- 101710193132 Pre-hexon-linking protein VIII Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101000679735 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L16-A Proteins 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000701955 Streptomyces virus phiC31 Species 0.000 description 1
- 102100035721 Syndecan-1 Human genes 0.000 description 1
- 108010001244 Tli polymerase Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102400001337 VHL family Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 108091005763 multidomain proteins Proteins 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- -1 nucleotide phosphodiester Chemical class 0.000 description 1
- 239000011022 opal Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000003720 plasmablast Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 238000001273 protein sequence alignment Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001478887 unidentified soil bacteria Species 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Definitions
- the present invention relates to a multiplex molecular amplification procedure capable of linking nucleotide sequences of interest in connection with the amplification, in particular polymerase chain reaction (multiplex PCR).
- the method is particularly advantageous for the generation of cognate pair libraries as well as combinatorial libraries of variable region encoding sequences from immunoglobulins, T cell receptors or B cell receptors.
- variable region binding proteins include soluble and membrane-bound forms ofthe B cell receptor (also known as immunoglobulins or antibodies) and the membrane-bound T cell receptors (TcR).
- B cell receptor also known as immunoglobulins or antibodies
- TcR membrane-bound T cell receptors
- immunoglobulins or fragments thereof such as Fab fragments, Fv fragments and single chain Fv (scFv) molecules have been subject to cloning and recombinant expression.
- Fab fragments, Fv fragments and single chain Fv (scFv) molecules have been subject to cloning and recombinant expression.
- scFv single chain Fv
- all other variable region binding proteins can in principle also be cloned and expressed using the same concepts as for antibodies.
- the main restriction in the use ofthe hybridoma technology for making therapeutic antibodies is the absence of a human lymphoma suitable as fusion partners for human B lymphocytes.
- Heterohybridomas i.e., fusion of human B cells with mouse lymphomas
- Human B cells immortalized through infection with Epstein-Barr virus exhibit similar challenges of instability.
- the lack of robust cellular methodology for making human antibodies for therapy can be compensated with more recent advantages in molecular biology.
- the use of combinatorial libraries and phage display allows for generation of large repertoires of antibody clones with a potential diversity in excess of 10 10 .
- variable region encoding sequences for example immunoglobulin heavy chain variable region and light chain variable region encoding sequences
- the variable region encoding sequences which constitute the library can be amplified from lymphocytes, plasma cells, hybridomas or any other immunoglobulin expressing population of cells.
- Current technologies for generating combinatorial libraries involve separate isolation ofthe variable region encoding sequences from a population of cells. Thus, the original pairing of for example immunoglobulin heavy chain variable region and light chain variable region encoding sequences will be lost.
- variable region encoding sequences responsible for a desired binding specificity a considerable amount of screening is necessary. This is typically performed in combination with methods for enrichment of clones exhibiting a desired specificity, such as ribosome display or phage display. Even then, the diversity achieved might not be sufficiently large to isolate variable region encoding sequence pairs giving rise to binding proteins of similar high affinity as those found in the original cells. Further, the enrichment procedures normally used to screen combinatorial libraries introduce a strong bias e.g. for polypeptides of particular low toxicity in E.
- the frequency of clones exhibiting a desired binding specificity is expected to be considerably higher within a library of cognate pairs, than in a conventional combinatorial library, particularly if the starting material cells are derived from a donor with high frequency of cells encoding specific binding pairs e.g. immune or immunized donors. It follows that the size of a cognate pair library will not need to be as large as a combinatorial library: a cognate pair library size of 10 4 to 10 5 clones or even as small as 10 2 to 10 3 clones derived from a donor with a relevant ongoing immune response might very well suffice in order to obtain binding proteins representing a broad diversity of desired binding specificities.
- variable region encoding sequences derived from the same cell are required.
- two different approaches which can achieve cognate pairing of variable region encoding sequences have been described.
- In-cell PCR is an approach where a population of cells is fixed and permeabilized, followed by in-cell linkage of heavy chain variable region and light chain variable region encoding sequences from immunoglobulins. This linkage can be performed either by overlap- extension RT-PCR (WO 93/03151) or by recombination (Chapal, N. et al. 1997 BioTechniques 23, 518-524).
- the amplification process as described in these publications is a three or four step process consisting of i) reverse transcription utilizing constant region primers generating immunoglobulin cDNA, ii) PCR amplification ofthe heavy and light chain variable region encoding sequences utilizing primer sets containing either overlap- extension design or recombination sites, iii) linkage by recombination, if this approach is chosen, iv) nested PCR ofthe products generating restriction sites for cloning. Since the cells are permeabilized there is a considerable risk that amplification products might leak out of the cells, thereby introducing scrambling ofthe heavy chain variable region and light chain variable region encoding sequences, resulting in the loss of cognate pairing.
- the procedure includes washing steps after each reaction which makes the process laborious and reduces the efficiency ofthe reactions.
- the in-cell PCR is notoriously inefficient, resulting in low sensitivity. Accordingly, the in-cell PCR linkage technique has never found widespread usage, and the original study has in fact never been reliably repeated in a way which can be used to verify that the linkage actually occurs within the cell. This, however, is absolutely crucial to avoid scrambling ofthe heavy chain variable region and light chain variable region encoding sequences and thereby disrupting the cognate pairs.
- the process described is a three to four step procedure consisting of i) reverse transcription utilizing oligo-dT-, random hexamer- or constant region primers generating cDNA, ii) fractionating the cDNA product into several tubes and performing PCR amplification on the individual variable chain encoding sequences (in separate tubes) with primer sets containing restriction sites for cloning, iii) nested PCR ofthe products generating restriction sites for cloning (optionally) and iv) linking the heavy chain variable region and light chain variable region encoding sequences from the separate tubes by cloning them into an appropriate vector, which in itself is a multi-step process.
- the present invention provides an efficient method of linking two or more nucleotide sequences of interest, e.g. variable region encoding sequences, utilizing a multiplex molecular amplification procedure, such as multiplex overlap-extension RT-PCR or multiplex RT-PCR followed by linkage by ligation or recombination.
- the method is applicable on a single cell, thereby enabling cloning of cognate pairs in a high-throughput format.
- FIGURE 1 is a diagram illustrating the different types of overlap-extension tails.
- the bold line corresponds to a gene-specific part ofthe primer and the regular line corresponds to the overlapping tail.
- the vertical bars illustrate complementary regions.
- the primers facilitate the linkage of two nucleotide sequences of interest.
- FIGURE 1 (I) illustrates two varieties of the type I overlap-extension tails where only the extension tails overlap, either completely or partially;
- FIGURE 1 (II) illustrates the type II overlap-extension tails where some ofthe 5'- nucleotides ofthe first primer extension tail are complementary to the gene-specific part of the neighboring primer;
- FIGURE 1 (III) illustrates the type III overlap-extension tails where the entire overlap-extension tails are complementary to the gene-specific region ofthe neighboring primer.
- FIGURE 2 is a diagram showing a schematic overview of a multiplex overlap- extension primer mix applicable in the linkage of immunoglobulin variable region encoding sequences.
- the cDNA encoding the light chain (LC) and the heavy chain variable region (V H ) to be linked are illustrated as tubes with indication of their sense strand 5' and 3 'ends as well as the expected size ofthe amplified product.
- the multiplex overlap-extension primer sets used to amplify the encoding sequence are illustrated by the arrows.
- the bended arrow tails with dashed 5' overhangs illustrate the cloning tails.
- the overlap-extension tails are in bold.
- the restriction sites present in the tails are named in connection with the tail.
- the total number of primers in the multiplex overlap-extension primer mix is sixteen, distributed on the outer primers comprising one C ⁇ and one C H I primer and the overlap extension primers comprising six V L and eight VH primers.
- the CH I primer anneal at the 5' end ofthe heavy chain constant domain 1.
- the product resulting from the multiplex overlap-extension RT- PCR is expected to be approximately 1070 bp constituting the entire kappa light chain composed ofthe constant region, joining gene and variable gene (C ⁇ + J L + V L ) and the heavy chain variable region, composed ofthe variable gene, diversity segment and joining gene (VH + D + JH). 5' and 3' indicates the direction ofthe open reading frame. Only a small portion ofthe C H I region encoding sequence is amplified by this multiplex overlap-extension primer mix, because the annealing position ofthe C H _ primer is close to the heavy chain J- region.
- FIGURE 3 is a series of diagrams illustrating the different linking direction ofthe products that can be obtained depending on which primers are equipped with the linkage tail. Solid black illustrates the overlap region. 5' and 3' indicates the direction ofthe open reading frame.
- FIGURE 3A is a diagram illustrating a head-to-head orientation ofthe products.
- FIGURE 3B is a diagram illustrating a tail-to-tail orientation.
- FIGURE 3C is a diagram illustrating a head-to-tail orientation with the light chain encoding sequence first.
- FIGURE 3D is a diagram illustrating a head-to-tail orientation with the heavy chain encoding sequence first.
- FIGURE 4 is a schematic diagram ofthe immunoglobulin expression vector pLLl 13, where the encoding sequences are in a head-to-tail orientation.
- Amp gene encoding for ampicillin resistance.
- pUC ori pUC origin of replication.
- AdMLP Adenovirus major late promoter.
- Human IgGl Sequence encoding for immunoglobulin isotype Gl heavy chain.
- hGH pA Human growth hormone poly A signal sequence.
- bGH polyA Bovine Growth Hormone poly A sequence.
- Human kappa LC Sequence encoding immunoglobulin kappa light chain.
- FRT A Flp recognition target site.
- FIGURE 5 A is an electrophoretic gel showing the results from a two-step multiplex overlap-extension RT-PCR followed by a semi-nested PCR.
- the amplification products are derived from cDNA isolated from single CHO Flp-In pLLl 13 cells. Lanes 1-12 are sample lanes and the arrows indicate correct nested multiplex-overlap-extension RT-PCR products of 1076 bp; Ml is a 100 bp ladder. W is water used as negative control template.
- C is a positive cDNA control template derived from cell-line HB-8501.
- FIGURE 5B is a sketch ofthe gel shown in Figure 5 A, illustrating the relevant fragments from the gel.
- FIGURE 6 is a series of photographs and a graphical representation of electrophoretic gels showing the results from a single-step multiplex overlap-extension RT-PCR reaction without additional PCR amplification. In each panel, Ml is a 100 bp ladder and M2 is a 500 bp ladder.
- FIGURE 6A is an electrophoretic gel showing the amplification products derived from lysate corresponding to 100, 10, 1 or 0 cells. The arrow indicates the overlap-extension product.
- FIGURE 6B is a sketch ofthe gel in Figure 6 A.
- FIGURE 6C is an electrophoretic gel verifying the presence of overlap-extension product in the 100 and 1 cell lanes in Figure 6A.
- FIGURE 6D is an electrophoretic gel showing restriction enzyme cleavage with Nhel and Ncol, respectively, ofthe overlap-extension product from the 1 cell lane in Figure 6C.
- FIGURE 7 is an electrophoretic gel showing the results from a single-step multiplex overlap-extension RT-PCR followed by a semi-nested PCR amplification.
- Ml is a 100 bp ladder and M2 is a 500 bp ladder. Results from multiplex overlap-extension primer mixtures containing either C HI , C H2 .
- FIGURE 8 is an electrophoretic gel showing the results from a single-step multiplex overlap-extension RT-PCR followed by a semi-nested PCR amplification using enriched human B lymphocytes as template. Ml is a 100 bp ladder. Lane 5 and 6 show bands ofthe size expected for the overlap-extension product.
- FIGURE 9 A is a schematic diagram ofthe mammalian expression vectors
- pUC ori pUC origin of replication.
- AdMLP Adenovirus major late promoter.
- EFP Elongation factor promoter.
- AP leader alkaline phosphatase leader sequence.
- VH heavy chain variable region encoding sequence.
- IgGl HC Sequence encoding for immunoglobulin isotype Gl heavy chain constant region.
- rBG polyA Rabbit beta-globin poly A signal sequence.
- bGH polyA Bovine Growth Hormone poly A sequence.
- IgK leader sequence encoding for murine kappa leader.
- IgL (lb or lc) Sequence encoding immunoglobulin lambda light chain family lb or lc.
- FRT A Flp recognition target site.
- Hygromycin gene encoding hygromycin resistance.
- SV40 poly A Simian virus 40poly A signal sequence.
- FIGURES 9B and 9C are ethidium bromide stained agarose gels loaded with PCR products isolated form cell line CHO Flp-In/Em464/01P581 and CHO Flp-In Em464/01P582, respectively.
- Lanes 1 to 4 correspond to total RNA template concentrations of 50 pg, 5 pg, 0.5 pg or 0 pg used for the multiplex overlap-extension RT-PCR reaction.
- M is a 100 bp ladder (New England Biolabs, New England, USA). The arrows indicate the overlap-extension PCR product.
- FIGURE 10 is a flow chart showing the steps applied in order to generate a cognate antibody expression library from which polyclonal or monoclonal antibodies can be expressed.
- FIGURE 11 is a schematic diagram of JSK301, an E. coli vector used to generate a library of Fab vectors by inserting the overlap-extension fragments comprising the cognate variable region encoding sequences into the vector at the indicated Notl/ Xhol restriction sites.
- FIGURE 12 is a schematic diagram illustrating the generation of a library of cognate Fab expression vectors.
- Step I illustrates the insertion of cognate pairs of variable region encoding sequences (VH t -VL] to VHx-VLx) into E. coli vector JSK301 by Xhol-Notl digestion.
- Step II illustrates the insertion of a bacterial promoter and leader cassette (pelB leader-P t opromoter driving the expression of VHx and P lac promoter- pelB leader driving the expression of VLx) by Ascl-Nhel digestion.
- FIGURE 13 illustrate the linkage of ⁇ -, ⁇ - and ⁇ -subunits constituting a G-protein, utilizing single-step multiplex overlap-extension RT-PCR followed by an additional PCR amplification.
- the sizes ofthe individual coding regions are given as well as the size ofthe linked product. Restriction sites introduced by the primer tails during amplification are indicated for the final product.
- FIGURE 14 shows dot plots of an analytic FACS staining of (A) PBMC purified from donor blood; (B) the magnetically sorted non-labelled CD 19 negative cell fraction and (C) magnetically sorted CD 19+ cells fraction. A scatter plot, a CD19/CD38 plot, and a CD38/CD45 plot is shown for each fraction.
- FIGURE 15 shows the CD 19+ fraction from Figure 9 C, which had been stored in liquid nitrogen, thawed and stained with anti-CD 19, anti-CD38 and anti-CD45. Dot plots corresponding to Figure 9C are shown.
- FIGURE 16 shows gates used for sorting on the CD 19+ cell fraction.
- FIGURE 17 is an electrophoretic gel showing the successful multiplex overlap- extension RT-PCR reaction on donor TT03 (row A, well 1-12 from eight 96 well plates). The samples have been applied to the agarose gel in two rows (A and B) with 48 samples in each. The expected size ofthe overlap-extension fragment was approximately 1070bp. The putative overlap-extension fragments are marked with arrows.
- FIGURE 18 shows ELISA analysis of periplasmic extracts from plate G060.
- FIGURE 19 shows ELISA analysis of periplasmic extracts from plate G060.
- the ELISA plate was coated with 10 ⁇ g/ml Ovalbumin (Sigma A-5503), and captured Fab fragments were detected with a HRP-conjugated gt-anti-human Fab-specific antibody.
- FIGURE 20 shows ELISA analysis of periplasmic extracts from plate G060.
- the ELISA plate was coated with Tetanus Toxoid, and captured Fab fragments were detected with a HRP-conjugated gt-anti-human Fab-specific antibody.
- FIGURE 21 shows a one step competition ELISA analysis of periplasmic extracts from plate G060.
- the ELISA plate was coated with Tetanus Toxoid (TT), and soluble TT was added to each well at 10 "7 M in order to compete for the binding of Fab fragments from the bacterial supernatants, to immobilized TT. Captured Fab fragments were detected with a HRP-conjugated gt-anti-human Fab-specific antibody.
- TT Tetanus Toxoid
- FIGURE 22 shows alignment of variable heavy chain protein sequences from TT antigen-binding clones from plate G060.
- the degree of sequence homology was represented by different shadings; 100%, 80% and 60% were depicted with black, grey and light grey, respectively.
- CDR1 is located at alignment position 34 to 41.
- CDR2 is located at alignment position 55 to 73.
- CDR3 is located at alignment position 107 to 127. Premature stop codons were denoted by an asterisk.
- the alignment is divided into 8 separate Figures (a-h) distributed in two rows from left to right with Figure 22a to d in the top row and Figure 22e to h in the bottom row.
- FIGURE 23 shows alignment of variable light chain protein sequence from TT antigen-binding clones from plate G060.
- the degree of sequence homology was represented by different shadings; 100%, 80% and 60% were depicted with black, grey and light grey, respectively.
- CDR1 is located at alignment position 26 to 42.
- CDR2 is located at alignment position 58 to 64.
- CDR3 is located at alignment position 97 to 106. Premature stop codons were denoted by an asterisk.
- the alignment is divided into 8 separate Figures (a-h) distributed in two rows from left to right with Figure 23 a to d in the top row and Figure 23 e to h in the bottom row.
- FIGURE 24 shows a competition ELISA assay for determination of apparent affinities of selected clones from plate G060. Soluble TT dilutions in concentrations from 100 nM to 25 pM (four-fold dilutions) were added to the Fab fragments, thereby competing out the binding ofthe Fab-fragments to immobilized TT. The extents ofthe reactions are given as the ratio ofthe observed binding at a given soluble TT concentration to the binding found when no soluble TT was added to the reactions.
- FIGURE 25 shows a double phylogenetic dot matrix plot showing the intra- and intergenetic relationship between antibody heavy and light chain variable domain sequences.
- Phylogenetic threes of V H and V L sequences are paired in a dot matrix in order to indicate actual pairing of particular V genes.
- the present invention sets out to provide an amplification and linkage process of two or more non-contiguous nucleotide sequences of interest which enables the cloning of such sequences to be fitted to a high-throughput format. This is basically achieved by reducing the number of steps necessary to amplify and link sequences to be cloned.
- One aspect ofthe invention is a method of linking a plurality of non-contiguous nucleotide sequences comprising amplifying, in a multiplex molecular amplification procedure, nucleotide sequences of interest using a template derived from an isolated single cell, a population of isogenic cells or a population of genetically diverse cells and effecting a subsequent linkage ofthe amplified sequences. If the template is an isolated single cell or a population of isogenic cells, the linkage results in a nucleic acid segment comprising nucleotide sequences of interest associated with each other in a cognate manner.
- this multiplex molecular amplification procedure is a multiplex PCR amplification, preferably preceded by a reverse transcription step.
- reverse transcription, amplification and linkage are performed in a single step, using multiplex overlap-extension RT-PCR or alternatively in two steps using multiplex RT-PCR followed by linkage by ligation or recombination.
- a further embodiment ofthe present invention relates to the generation of libraries of cognate pairs comprising linked variable region encoding sequences, in particular heavy chain variable region and light chain encoding sequences or T cell receptor (TcR) alpha chain encoding sequences and beta chain encoding sequences.
- the process involves obtaining a lymphocyte-containing cell fraction from at least one suitable donor and optionally enriching for a particular lymphocyte population from this fraction, for example B lymphocytes or T lymphocytes, depending on whether variable region encoding sequences from immunoglobulins or TcRs are desired.
- the lymphocyte-containing cell fraction or the enriched cell fraction is distributed into an array of vessels, obtaining one cell in each vessel.
- the array of single cells are subjected to a reverse transcription (RT) step or an alternative cDNA generating procedure, using the nucleic acids derived from the population of single cells as template.
- the RT step is followed by multiplex molecular amplification procedure and linkage of pairs of variable region encoding sequences generated from each cell according to one ofthe methods ofthe present invention.
- the cloning techniques disclosed in the present invention omit laborious and inefficient cloning approaches and additionally reduces the risk of contamination and loss of diversity during multiple cloning steps.
- Another aspect ofthe invention relates to libraries of cognate pairs produced by the multiplex molecular amplification and linkage process.
- the initial library of cognate pairs (parent library) generated by the method ofthe present invention can be subjected to screening, thereby generating a sub-library of cognate pairs encoding target-specific binding protein variable domains or full-length binding proteins.
- the libraries and sub-libraries ofthe present invention can be used in the expression of recombinant monoclonal or polyclonal proteins, where the original binding affinities and specificities present in the donor are preserved.
- cognate pair describes an original pair of non-contiguous nucleic acids of interest that are contained within or derived from a single cell.
- a cognate pair comprises two variable region encoding sequences which together encode for a binding protein variable domain and which gene sequences are derived from the same cell.
- a cognate pair can for example be comprised of an antibody variable heavy chain encoding sequence associated with a variable light chain encoding sequence from the same cell, or a T cell receptor ⁇ chain encoding sequence associated with a ⁇ chain encoding sequence from the same cell.
- a library of cognate pairs is a collection of such cognate pairs.
- hot-start polymerase describes polymerases that are inactive or have very low activity at temperatures used for reverse transcription. Such polymerases need to be activated by high temperatures (90 to 95°C) to become functional. This is for example an advantage in single-step RT-PCR procedures, since this prohibits interference ofthe polymerase with the reverse transcriptase reaction.
- the term "isogenic population of cells” describes a population of genetically identical cells.
- an isogenic population of cells derived by clonal expansion of an isolated single cell is of interest in the present invention.
- isolated single cell describes a cell that has been physically separated from a population of cells corresponding to "a single cell in a single vessel". When distributing a population of cells individually among a plurality of vessels, a population of isolated single cells is obtained. As specified in the section entitled “Template sources” the proportion of vessels with a single cell is not necessarily a 100% in order to call it a population of single cells.
- Terms derived from "link” or “linkage” in relation to amplification describes the association ofthe amplified nucleic acid sequences encoding the nucleic acid sequences of interest into a single segment.
- a segment comprises nucleic acid sequences encoding a variable domain, e.g. an antibody heavy chain variable region associated with an antibody light chain variable region encoding sequence, derived from the same cell.
- the linkage can either be achieved simultaneously with the amplification or as an immediate step following the amplification. There are no requirements to the form or functionality ofthe segment, it may be linear, circular, single stranded or double stranded.
- one ofthe nucleic acid sequences of interest may be isolated from the segment if desired, one ofthe variable region encoding sequence may for example be isolated from a cognate pair segment.
- one ofthe variable region encoding sequence may for example be isolated from a cognate pair segment.
- the linkage is preferably a nucleotide phosphodiester linkage.
- linkage can also be obtained by different chemical cross linking procedures.
- PCR polymerase chain reaction
- LCR ligase chain reaction
- SDA strand displacement amplification
- ssRNA single stranded RNA
- dsDNA double stranded DNA
- multiplex PCR describes a variant of PCR in which two or more target sequences are amplified simultaneously, by including more than one set of primers in the same reaction, e.g. one primer set adapted for amplification ofthe heavy chain variable region and one primer set adapted for amplification ofthe kappa chain variable region in the same PCR reaction. Additionally a primer set adapted for amplification ofthe lambda chain variable region may be combined with these primer sets.
- multiplex RT-PCR describes a multiplex PCR reaction, which is preceded by a reverse transcription (RT) step.
- the multiplex RT-PCR can either be performed as a two-step process with a separate RT step prior to the multiplex PCR, or as a single-step process where all components for both RT and multiplex PCR are combined in a single tube.
- RT reverse transcription
- the terms “multiplex overlap-extension PCR” and “multiplex overlap-extension RT- PCR” implies that the multiplex PCR or multiplex RT-PCR is performed utilizing a multiplex overlap-extension primer mix to amplify the target sequences, thereby enabling simultaneous amplification and linkage ofthe target sequences.
- a plurality of vessels describes any object (or collection of objects) which enables the physical separation of a single cell from a population of cells.
- This may be tubes, multiwell plates (e.g. 96-well, 384-well, microtitter plates or other multiwell plates), arrays, microarrays, microchips, gels, or a gel matrix.
- the object is applicable for PCR amplification.
- polyclonal protein refers to a protein composition comprising different, but homologous protein molecules, preferably selected from the immunoglobulin superfamily. Thus, each protein molecule is homologous to the other molecules ofthe composition, but also contains one or more stretches of variable polypeptide sequence, which is/are characterized by differences in the amino acid sequence between the individual members ofthe polyclonal protein.
- polyclonal proteins include antibody or immunoglobulin molecules, T cell receptors and B cell receptors.
- a polyclonal protein may consist of a defined subset of protein molecules, which has been defined by a common feature such as the shared binding activity towards a desired target, e.g.
- a population of genetically diverse cells refers to a cell population where the individual cells in the population differ among each other on the genomic level. Such a population of genetically diverse cell is for example a population of cells derived from a donor, or a fraction of such cells, e.g. a B lymphocyte or a T lymphocyte containing cell fraction.
- the term "primer set” is used interchangeably with the term “primer pair” and describes two or more primers which together are capable of priming the amplification of a nucleotide sequence of interest (i.e., one member of a cognate pair).
- a primer set ofthe present invention might be designed to prime a family of nucleotide sequences containing variable region encoding sequences. Examples of different families are antibody kappa light chains, lambda light chains, heavy chain variable regions, and ⁇ , ⁇ , ⁇ , or ⁇ T cell receptor variable regions.
- a primer set for the amplification of a family of nucleotide sequences containing variable region encoding sequences often constitutes a plurality of primers where several primers can be degenerate primers.
- sequence identity is expressed as a percentage which indicates the degree of identity between to nucleic acid sequences over the length ofthe shortest ofthe two sequences. It can be calculated as (N re f - N d if)x 100/N re f, wherein N re f is the number of residues in the shorter ofthe sequences, and wherein N d i f is the total number of non-identical residues in an N ref long optimally aligned match between the two sequences.
- nucleotide sequences of interest are variable region encoding sequences, this will result in a combinatorial library of linked sequences. If, on the other hand, the nucleotide sequences of interest encode for a non- diverse heteromeric protein the randomly linked sequences will appear similar to sequences linked from a single cell.
- template derived from an isolated single cell with regard to reverse transcription, relates to the nucleic acids within such an isolated cell.
- the nucleic acids can for example be in the form of RNA, mRNA, DNA or genomic DNA.
- the nucleic acids can either be isolated from the cell or still be with the remaining contents ofthe cell, where the cell is in an intact form or a lysed form.
- One feature ofthe present invention reduces the number of tubes necessary to amplify the nucleotide sequences of interest, utilizing a variant of PCR in which two or more target sequences are amplified simultaneously in the same tube, by including more than one set of primers, for example all the primers necessary to amplify variable region encoding sequences, in the same reaction.
- this approach is known as multiplex polymerase chain reaction (multiplex PCR).
- Multiplex PCR amplification and multiplex PCR preceded by reverse transcription are well known techniques within the diagnostic field, for example in the analysis of mutations, deletions and polymorphisms of DNA, for quantitative assays of mRNA levels and for identification of viruses, bacteria and parasites (reviewed in
- immunoglobulin light chain variable region encoding sequences has been amplified in the same vessel as immunoglobulin heavy chain variable region encoding sequences using a multiplex primer mix composed of more than four primers constituting a VK and/or V*. primer set together with a V H primer set (Chapal, N. et al. 1997.
- a further feature ofthe present invention is that two or more target sequences amplified by multiplex PCR are linked in close proximity to the amplification process. In particular cognate pairs of variable region encoding sequences are linked by this process.
- One embodiment ofthe present invention exploits that a multiplex primer mix can be designed to work in an overlap-extension PCR procedure, resulting in a simultaneous amplification and linkage of nucleotide sequences of interest. This multiplex overlap- extension PCR technique serves to reduce the number of reactions necessary to isolate and link nucleotide sequences of interest, in particular cognate pairs of linked variable regions.
- the multiplex overlap-extension PCR differ from conventional overlap-extension PCR in that the sequences to be linked are generated simultaneously in the same tube, thereby providing immediate linkage ofthe target sequences during amplification, without any intermediate purification. Further, conventional overlap-extension PCR requires a separate linking PCR reaction either with an outer primer set or a nested primer set in order to generate the linked product (Horton, R.M. et al. 1989. Gene 77, 61-68). Such an additional amplification step is optional in the multiplex overlap- extension PCR ofthe present invention.
- a further feature ofthe present invention is a reverse transcription (RT) step preceding the multiplex PCR or multiplex overlap-extension PCR amplification, utilizing a template derived from an isolated single cell or a population of isogenic cells.
- RT reverse transcription
- a further feature ofthe present invention is the use of nucleotide sequences derived from an isolated single cell or a population of isogenic cells as template for the multiplex PCR amplification.
- RNA from a single cell is reverse transcribed into cDNA prior to the multiplex PCR.
- genomic DNA may be used as an alternative to mRNA.
- WO 99/16904 discloses the linkage of exons from a genomic sequence in a single reaction, thereby generating cDNA without utilizing reverse transcription.
- the process as described utilized one primer set (constituted of two primers) per exon to be linked, thereby composing a multiplex overlap- extension primer mix.
- Each individual primer set was capable of overlapping with the adjacent primer set by complementary overlap-extension tails.
- the cDNA was generated from a template of genomic DNA by performing an overlap-extension PCR reaction utilizing the multiplex overlap-extension primer mix followed by a nested PCR, which was described as a necessary step.
- cDNA from the exons of genomic DNA as described in WO 99/16904 is a different field than the cloning of sequences encoding for heteromeric proteins.
- heteromeric proteins are generally expressed from different genes, whereas the exon linkage as described in WO 99/16904 relates to the linkage of exons from a single gene.
- the present invention facilitates the generation of libraries of linked nucleic acid sequences of interest, in particular combinatorial libraries and libraries of cognate pairs of variable regions; a completely different situation than linking a series of exons from a single gene, resulting in a single non- variable cDNA.
- the present invention utilizes nucleic acids derived from single cells, preferably in the form of RNA that does not need to be isolated from the remaining cell contents before it can be utilized as template.
- the methods described by Thirion and Mullinax utilized reverse transcription of mRNA with oligo-dT primers on total RNA extracted from the hybridoma cell line followed by a separate linkage step.
- the linkage step was performed with a total of four primers, constituting two primer pairs for amplification of heavy chain variable region and light chain variable region encoding sequences, respectively.
- the V L forward primer and the VH or C H reverse primer contained complementary overlap-extension tails, thereby enabling simultaneous amplification and linkage ofthe heavy chain variable region and light chain variable region encoding sequences.
- One embodiment ofthe present invention encompasses the linkage of a plurality of non-contiguous nucleotide sequences of interest.
- the method comprises amplifying, in a multiplex PCR or multiplex RT-PCR amplification procedure, nucleotide sequences of interest using a template derived from an isolated single cell or a population of isogenic cells and effecting linkage ofthe amplified nucleotide sequences of interest. Further, the method comprises an optional step of performing an additional amplification ofthe linked products.
- a further embodiment ofthe present invention encompasses a method of producing a library of cognate pairs comprising linked variable region encoding sequences.
- the method comprises providing a lymphocyte-containing cell fraction from a donor, which is optionally enriched for a particular lymphocyte population from said cell fraction. Further, a population of isolated single cells is obtained by distributing cells from the lymphocyte-containing cell fraction, or the enriched cell fraction, individually among a plurality of vessels. Multiplex molecular amplification (multiplex RT-PCR amplification) ofthe variable region encoding sequences contained in the population of isolated single cells is performed and linkage of pairs of variable region encoding sequences, wherein an individual pair is derived from a single cell, within the population of isolated single cell, is effected.
- the technique comprises two optional steps: in the first step the individual isolated single cell in the population of single cells is expanded to a population of isogenic cells prior to performing multiplex RT-PCR amplification. Thereby obtaining a plurality of vessels with a diverse population of isogenic cells (one population of isogenic cells in one vessel).
- the second optional step encompasses performing an additional amplification ofthe linked variable region encoding sequences.
- an individual member of said library of cognate pairs comprised of an immunoglobulin light chain variable region encoding sequence is associated with an immunoglobulin heavy chain variable region encoding sequence, originating from the same cell or of sequences encoding a T cell receptor binding domain, constituted of an alpha chain variable region associated with a beta chain variable region or a gamma chain variable region associated with a delta chain variable region, where the associated variable regions originate from the same cell.
- the multiplex RT-PCR amplification ofthe present invention can be performed either as a two-step process, where reverse transcription (RT) is preformed separate from the multiplex PCR amplification (or alternative multiplex molecular amplification), or as a single-step process, where the RT and multiplex PCR amplification steps are performed with the same primers in one tube.
- the reverse transcription (RT) is performed with an enzyme containing reverse transcriptase activity resulting in the generation of cDNA from total RNA, mRNA or target specific RNA from an isolated single cell.
- Primers which can be utilized for the reverse transcription are for example oligo-dT primers, random hexamers, random decamers, other random primers, or primers that are specific for the nucleotide sequences of interest.
- the two-step multiplex RT-PCR amplification procedure allows for the cDNA generated in the RT step, to be distributed to more than one vessel permitting for the storage of a template fraction before proceeding with the amplification. Additionally, the distribution of cDNA to more than one tube, allows for the performance of more than one multiplex PCR amplification of nucleic acid derived from the same template. Although, this results in an increased number of separate reactions, it opens for the possibility to decrease the complexity ofthe multiplex primer mix if this should be desired.
- This two-step approach can for example be applied to amplify and link heavy chain variable region and kappa light chain variable region encoding sequences in one tube and heavy chain variable region and lambda light chain variable region encoding sequences in a different tube utilizing the same template.
- a single cell usually only expresses one ofthe light chains. However, it will often be easier to perform the reactions simultaneously instead of awaiting the result of one ofthe reactions before performing the other. Further, the amplification of both kappa and lambda serves as an internal negative control, since it would be expected that only kappa or lambda amplify from a single cell.
- the composition needed for the single-step multiplex RT-PCR comprises a nucleic acid template, an enzyme with reverse transcriptase activity, an enzyme with DNA polymerase activity, deoxynucleoside triphosphate mix (dNTP mix comprising dATP, dCTP, dGTP and dTTP) and a multiplex primer mix.
- the nucleic acid template is preferably total RNA or mRNA derived from an isolated single cell either in a purified form, as a lysate ofthe cell or still within the intact cell.
- the exact composition ofthe reaction mixture requires some optimization for each multiplex primer mixture to be used with the present invention. This applies both for the two-step and the single-step multiplex RT-PCR procedures.
- genomic DNA instead of RNA as template.
- reverse transcription step is omitted, and the remaining steps ofthe invention are performed as described throughout the application.
- nucleotide sequences of interest can be linked to one another by several methods, such as multiplex overlap-extension RT-PCR, ligation or recombination, using different multiplex primer mixes.
- the multiplex RT-PCR amplification and linkage process is a single step or a two step process.
- the linkage process may also be performed as a multi step process, using for example a stuffer fragment to link the nucleic acid sequences of interest, either with PCR, ligation or recombination.
- a stuffer fragment may contain cis-elements, promoter elements or a relevant coding sequence or recognition sequence.
- the linkage process is performed in the same vessel as the multiplex RT-PCR amplification.
- the linkage of a plurality of non- contiguous nucleotide sequences of interest is performed in association with the multiplex PCR amplification, utilizing a multiplex overlap-extension primer mix. This results in the combined amplification and linkage ofthe target sequences.
- the composition needed for the multiplex overlap-extension PCR comprises, a nucleic acid template, an enzyme with DNA polymerase activity, deoxynucleoside triphospate mix (dNTP mix comprising dATP, dCTP, dGTP and dTTP) and a multiplex overlap-extension primer mix.
- the linkage of a plurality of noncontiguous nucleotide sequences of interest is performed by multiplex overlap-extension RT- PCR using a template derived from an isolated single cell or a population of isogenic cells.
- the method comprises an optional step of performing an additional molecular amplification of linked products.
- the multiplex overlap-extension RT-PCR is performed as a single-step/one-tube reaction.
- a multiplex overlap-extension primer mix ofthe present invention comprises at least two primer sets capable of priming the amplification and linkage of at least two variable region encoding sequences, for example, amplification and linkage of sequences from immunoglobulin heavy chain variable region families with kappa or lambda light chain variable region families, or amplification and linkage of sequences from T cell receptor families ⁇ , ⁇ , ⁇ , or ⁇ .
- the plurality of nucleotide sequences of interest, amplified by multiplex RT-PCR are linked by ligation.
- the multiplex primer mix used for the multiplex RT-PCR is designed such that the amplified target sequences can be cleaved with appropriate restriction enzymes, and covalent linkage by DNA ligation can be performed (the primer design is described in the section "Primer Mixtures and Design ").
- the restriction enzymes needed to form compatible ends ofthe target sequences are added to the mixture together with the ligase. No purification ofthe PCR products is needed prior to this step, although purification may be performed.
- the reaction temperature for the combined restriction cleavage and ligation is approximately between 0 and 40°C. However, if the polymerase from the multiplex PCR reaction is still present in the mixture, an incubation temperature below room temperature is preferred, most preferred are temperatures between 4 and 16°C.
- the plurality of nucleotide sequences of interest, amplified by multiplex RT-PCR are linked by recombination.
- the target sequences amplified can be joined using identical recombination sites. Linkage is then performed by adding the recombinases facilitating recombination.
- Some suitable recombinase systems are Flp recombinase with a variety of FRT sites, Cre recombinase with a variety of lox sites, integrase ⁇ C31 which carries out recombination between the attP site and the attB site, the ⁇ -recombinase-six system as well as the Gin-gix system. Linkage by recombination has been exemplified for two nucleotide sequences (V H linked with V L ) (Chapal, N. et al. 1997 BioTechniques 23, 518-524), hereby incorporated by reference.
- the nucleotide sequences of interest comprise variable region encoding sequences and the linkage generates a cognate pair of variable region encoding sequences. Such a cognate pair may comprise one or more constant region encoding sequences in addition to the variable regions.
- the nucleotide sequences of interest comprise immunoglobulin variable region encoding sequences and the linkage generates a cognate pair of light chain variable region and heavy chain variable region encoding sequences.
- Such a cognate pair may comprise one or more constant region encoding sequences in addition to the variable regions.
- such a cognate pair may be isolated from template derived from cells ofthe B-lymphocyte lineage enriched from a lymphocyte-containing cell fraction, such as whole blood, mononuclear cells or white blood cells.
- the nucleotide sequences of interest comprise TcR variable region encoding sequences and the linkage generates a cognate pair of ⁇ chain variable region and ⁇ chain variable region encoding sequences or ⁇ chain variable region and ⁇ chain variable region encoding sequences.
- a cognate pair may comprise one or more constant region encoding sequences in addition to the variable regions.
- such a cognate pair may be isolated from template derived from cells ofthe T-lymphocyte lineage enriched from a lymphocyte-containing cell fraction, such as whole blood, mononuclear cells or white blood cells.
- Another aspect ofthe present invention is to utilize the multiplex RT-PCR with a population of genetically diverse cells as template source.
- the majority of heteromeric protein encoding sequences do not vary from cell to cell as is the case with variable region encoding sequences from binding proteins.
- variable region encoding sequences from binding proteins.
- a plurality of non-contiguous nucleotide sequences of interest are linked randomly by a method comprising, performing multiplex RT- PCR amplification of nucleotide sequences of interest using a template derived from a population of genetically diverse cells and effecting linkage ofthe amplified nucleotide sequences of interest. Further, the method comprises an optional step of performing an additional amplification ofthe linked products. As with the single cell approach the linkage can either be performed utilizing a multiplex overlap-extension primer mix for the amplification or alternatively by ligation or recombination.
- the template derived from the population of cells is not strictly contained within the cells. The population of cells may for example be lysed.
- the population of cells constitutes cells that express variable region binding proteins, such as B lymphocytes, T lymphocytes, hybridoma cells, plasma cells, or a mixture of these cells.
- the population of cells in the above mentioned embodiment can for example be permeabilized or lysed, without additional purification, or the template nucleic acids can be isolated from the cells by standard procedures.
- the single-step multiplex RT-PCR procedure is preferred. However, the two-step procedure may also be used in the embodiment.
- the invention also provides a combinatorial library comprised of linked pairs of immunoglobulin light chain variable region and heavy chain variable region encoding sequences.
- An efficient way to increase the specificity, sensitivity, and yield ofthe multiplex RT- PCR-linkage process is by performing an additional molecular amplification ofthe linked nucleotide sequences obtained from the multiplex RT-PCR followed by linkage by ligation or recombination or linkage using the multiplex overlap-extension RT-PCR.
- This additional amplification is preferably performed with PCR amplification, utilizing a primer mix adapted for amplifying the linked nucleic acid sequences of interest.
- the primer mix utilized may be the outer primers ofthe multiplex primer mix or multiplex overlap-extension primer mix, meaning the primers which anneal to the outermost 5' end and 3' end ofthe sense strand of the linked variable region encoding sequences, thereby enabling the amplification ofthe entire linked product.
- the outer primers can also be described as the primers ofthe multiplex overlap-extension primer mixture that do not contain overlap extension tails.
- a nested or semi-nested primer set can be used for the additional amplification ofthe linked nucleotide sequences. Such a nested PCR especially serves to increase the specificity ofthe method as well as to increase the amount of linked product.
- semi- nested PCR (as described in the section entitled Primer Mixtures and Design) is considered to function as well as the nested PCR.
- an additional PCR amplification ofthe linked products from the multiplex overlap-extension RT-PCR or ofthe products linked by ligation or recombination preferably using nested PCR or semi-nested PCR.
- the additional amplification can either be performed directly using a fraction or the entire multiplex overlap-extension RT-PCR reaction product or ligation product or recombination product, or a fraction of any one of these products or using partially purified linked products from any one of these reactions, e.g.
- the additional amplification is preferably performed directly on a fraction from the multiplex overlap-extension RT-PCR reaction, since this would assist linkage ofthe individual target sequences that were not linked in the first reaction.
- the nucleotide sequences of interest ofthe present invention can be selected from sequences that encode different subunits or domains, which when expressed, forms a protein or part of a protein.
- Such proteins that are composed of at least two non-identical subunits are known as heteromeric proteins.
- Heteromeric proteins are common in all kinds of species. Some ofthe classes to which such proteins belong are for example enzymes, inhibitors, structural proteins, toxins, channel proteins, G-proteins, receptor proteins, immunoglobulin superfamily proteins, transportation proteins etc.
- the nucleotide sequences encoding such heteromeric proteins are non-contiguous, meaning for example that they originate from different genes, or different mRNA molecules.
- non-contiguous as used in the present invention may also mean nucleotide sequences encoding domains ofthe same protein, where the domains are separated by nucleotide sequences which are not of interest.
- the nucleotide sequencess of interest contain variable region encoding sequences from the immunoglobulin superfamily, such as immunoglobulins (antibodies), B cell receptors and T cell receptors (TcR's).
- variable region encoding sequences from immunoglobulins are of interest.
- Such variable region encoding sequences comprise full-length antibodies as well as Fab's, Fv's, scFv's and combinations of fragments ofthe variable region encoding sequences, e.g.
- CDR's complementarity determining regions
- joining genes or V-genes or combinations of these can be applied with any combinations of variable region encoding sequences and fragments thereof.
- the present application exemplifies the linkage ofthe entire light chain with the variable domain ofthe heavy chain.
- the present invention also allow for the linkage of only the variable domains ofthe heavy and light chains generating Fv or scFv encoding sequences, or the linkage ofthe entire light chain with the heavy chain variable region + constant region domain CHI + parts ofthe hinge region, generating Fab, Fab' or F(ab) 2 .
- variable region encoding sequences comprise one type of immunoglobulin light chain (kappa or lambda) encoding sequence and one immunoglobulin heavy chain variable region encoding sequence.
- TcR's T cell receptors
- Such TcR encoding sequences comprise encoding sequences for full-length alpha and beta chains or gamma and delta chains as well as soluble TcR's or only the variable domains of these chains or single chain fusion proteins thereof (e.g. single chain ⁇ or single chain ⁇ ).
- One feature ofthe present invention is the ability to link nucleotide sequences derived from an isolated single cell, a population of isogenic cells, or a genetically diverse population of cells which have not been separated into single vessels.
- the cells utilized in the present invention can for example be bacteria, yeast, fungi, insect cells, plant cells or mammalian cells or fractions of such cells. Blood cells derived from mammals are one example of a fraction of cells that can be utilized in the present invention.
- a preferred feature ofthe present invention is the use of isolated single cells or a population of isogenic cells as template source, since scrambling ofthe nucleic acid sequences of interest, in particular variable region encoding sequences is avoided. This is of importance if one wishes to obtain an original pair of for example variable region encoding sequences.
- Another preferred feature ofthe present invention is obtaining a single cell or population of single cells from a cell fraction comprising lymphocytes, such as B lymphocytes, T lymphocytes, plasma cells and/or various developmental stages of these cell lineages. Other populations of cells that express binding proteins from the immunoglobulin superfamily might also be used to obtain single cells.
- Cell lines such as hybridoma cells, cell lines of B lymphocyte or T lymphocyte lineage or virus immortalized cell lines or donor derived cells participating in the immune response are also applicable in the present invention.
- Donor derived lymphocyte-containing cell fractions may be obtained from natural tissue or fluid which is rich in such cells, e.g.
- Suitable cell donors for the present invention can be selected from vertebrates that all contain an acquired immune system. Donors can either be na ⁇ ve or hyperimmune with respect to a desired target. For the isolation of antigen binding proteins with binding specificities toward a desired target, hyperimmune donors are preferred. Such hyperimmune donors can either be donors immunized with the target, or fragments ofthe target, or it can be convalescent patients, or non-healthy individuals which are running a natural immune response towards the target e.g. autoimmune patients, cancer patients, patients with infectious diseases e.g.
- recombinant proteins for treatment it is preferable that they are derived from sequences that have species identity with the individual to be treated (e.g. human sequences for treatment of humans). Firstly, because recombinant proteins derived from a foreign sequence (i.e. non-human) will be recognized by the immune system leading to an immune response implicating polyclonal anti-protein antibodies. These anti-protein antibodies can block the drug action by occupying the active site, they will accelerate drug clearance and they could potentially induce adverse reactions such as hypersensitivity reactions upon repeated exposure.
- Immunogenicity may however, also be seen in cases where the recombinant protein is derived from a sequence that have species identity. Such immunogenicity can for example be induced by post-translational modifications that might differ from those seen in vivo. Combinatorial libraries of variable region encoding sequences might also give rise to immunogenicity, since they consist of random pairs of variable region encoding sequences created in vitro. The rules that govern formation of antibody heavy and light chain encoding sequence pairs (or T cell receptors) in vivo are not completely understood. Hence, it follows that some ofthe in vitro formed pairs could be recognized as foreign by the immune system, even though both sequences constituting the pair are perfectly human.
- Binding proteins obtained from cognate libraries do on the other hand not create said abnormal combinations and they are consequently of lesser potential immunogenicity than binding proteins from combinatorial libraries. This does not mean that products from combinatorial libraries are unsuitable for treatment, they just require a larger degree of monitoring with respect to the above mentioned side effects.
- cell donors should preferably be ofthe same species as the species to be treated with the products obtainable from the linked nucleotide sequences ofthe present invention.
- a cell donor is a domestic animal, a pet, a human or a transgenic animal.
- Transgenic animals carrying human immunoglobulin loci are described in U.S. Patent No. 6,111,166 and Kuroiwa, Y. etal. Nature Biotechnology; 2002; 20: 889-893.
- Such transgenic animals are capable of producing human immunoglobulins.
- fully human antibodies against a specific target can be raised by usual immunization techniques of such transgenic animals.
- the lymphocyte-containing cell fraction is constituted of whole blood, bone marrow, mononuclear cells, or white blood cells obtained from a donor.
- Mononuclear cells can be isolated from blood, bone marrow, lymph nodes, spleen, infiltrations around cancer cells and inflammatory infiltrations. Mononuclear cells can be isolated by density centrifugation techniques, e.g. Ficoll gradients.
- the tissue is disintegrated before the gradient centrifugation is performed.
- Disintegration can be performed, for example, by mechanical methods such as grinding, electroporation and/or by chemical methods such as enzymatic treatments.
- the isolation of white blood cells can be performed directly from donors using leukopheresis.
- Raw preparations of for example bone marrow or tissue, which contain lymphocytes, can also be used in the present invention. Such preparations will need to be disintegrated, for example as described above, in order to facilitate single cell distribution.
- a further feature ofthe present invention is enrichment ofthe lymphocyte-containing cell fraction e.g. whole blood, mononuclear cells, white blood cells or bone marrow, with respect to a particular lymphocyte population, such as cells from the B lymphocyte or T lymphocyte lineage.
- a particular lymphocyte population such as cells from the B lymphocyte or T lymphocyte lineage.
- Enrichment of B lymphocytes can for example be performed, using magnetic bead cell sorting or fluorescence activated cell sorting (FACS) taking advantage of lineage-specific cell surface marker proteins such as CD 19 or other B cell lineage-specific markers.
- Enrichment of T lymphocytes can for example be performed, utilizing a cell surface marker such as CD3 or other T cell lineage-specific markers.
- a preferred feature ofthe present invention is to sort the enriched B lymphocytes further in order to acquire plasma cells, before distributing the cells individually among a plurality of vessels.
- Isolation of plasma cells is generally performed by FACS sorting, utilizing surface markers such as CD38 possibly in combination with CD45.
- Other plasma cell-specific surface markers or combinations thereof can be utilized as well, for example CD138, CD20, CD21, CD40, CD9, HLA-DR or CD62L, the exact choice of marker depends on the plasma cell source, e.g. tonsils, blood or bone marrow.
- Plasma cells can also be obtained from a non-enriched lymphocyte-containing cell population obtained from any of these sources. The plasma cells isolated from blood are sometimes called early plasma cells or plasmablasts.
- these cells are also termed plasma cells although they are CD 19 positive in contrast to plasma cells residing in the bone marrow.
- Plasma cells are desired for the isolation of cognate pairs of immunoglobulin encoding sequences because a higher frequency of these cells produces antigen-specific antibodies that reflect the acquired immunity toward the desired antigen and most ofthe cells have undergone somatic hypermutation and therefore encode for high-affinity antibodies. Further, the mRNA levels in plasma cells are elevated compared to the remaining B lymphocyte population, thus the reverse transcription procedure is more efficient when using single plasma cells.
- memory B cells may be isolated from a lymphocyte containing cell fraction utilizing a cell surface marker such as CD22.
- An alternative feature ofthe present invention is selecting the enriched B lymphocytes for antigen specificity before distributing the cells among a plurality of vessels.
- Isolation of antigen-specific B lymphocytes is performed by contacting the enriched B lymphocytes with the desired antigen or antigens enabling binding of antigen to surface exposed immunoglobulin, followed by isolation of binders. This can be done, for example, by coating magnetic beads with the desired antigen or antigens followed by magnetic bead cell sorting, by FACS, by coating a column with the antigens followed by affinity chromatography, by filter screening assays or other methods known in the art.
- Plasma cells as well as B lymphocytes, non-enriched mononuclear cells, white blood cells, whole blood, bone marrow or tissue preparations can be subjected to isolation with respect to antigen specificity if this is desired.
- T lymphocytes e.g. CD3 positive cells
- CD45R0 and/or CD27 surface markers CD45R0 and/or CD27
- T lymphocytes can also be selected for MHC-antigen specificity using MHC-peptide complexes (e.g. Callan, M.F. et al. 1998. J. Exp. Med. 187, 1395-1402; Novak, E.J. et al. 1999. J. Clin. Invest 104, R63-R67).
- a further feature ofthe present invention is immortalization of any ofthe isolated cell fractions described in the above (e.g. B lymphocytes, plasma cells, memory cells or T lymphocytes).
- Immortalization may for example be performed with Epstein-Barr virus (Traggiai, E., et al, 2004. Nat Med 10, 871-875) prior to cell distribution.
- isolated single cells may be immortalized and expanded prior to reverse transcription. Traggiai et al, Nat Med. 2004 Aug; 10(8): 871-5.
- a further feature ofthe present invention is the distribution of a population of desired cells (e.g. hybridoma cells, cell lines of B lymphocyte or T lymphocyte lineage, whole blood cells, bone marrow cells, mononuclear cells, white blood cells, B lymphocytes, plasma cells, antigen-specific B lymphocytes, memory B cells, T lymphocytes, antigen/MHC-specific T lymphocytes, or memory T cells) individually, into a plurality of vessels, in order to obtain a population of isolated single cells.
- This isolation of single cells refers to the physical separation of cells from a population of cells in such a way that a single vessel contains a single cell, or a micro array, chip or gelmatrix is loaded in a manner that produce single cells.
- the cells may be distributed directly into multitudes of vessels such as arrays of single vessels by limiting dilution.
- the single vessels utilized in the present invention are preferably those applicable in PCR (e.g. PCR tubes and 96 well or 384 well PCR plates or larger arrays of vessels). However other vessels may also be used.
- PCR e.g. PCR tubes and 96 well or 384 well PCR plates or larger arrays of vessels.
- other vessels may also be used.
- a population of single cells is obtained.
- Such a distribution may be performed, for example, by dispensing a volume into a single vessel that on average encompasses a cell concentration of one, 0.5 or 0.3 cell, thereby obtaining vessels that on average contain a single cell or less.
- variable region encoding sequences may occur among the cells present in the vessel.
- it is a minor event it will not affect the overall utility ofthe present invention.
- combinations of variable region encoding sequences which do not posses the desired binding affinity and specificity will most likely not be selected and hence eliminated during a screening process. Therefore, minor events of scrambling will not significantly affect the final library ofthe present invention.
- a further feature of the present invention is the performance of a reverse transcription using template derived from cells distributed individually among a plurality of vessels.
- the nucleic acids within a single cell that is to serve as template source for the RT are considered to be derived from a single cell although they have not necessarily been separated from the remaining contents of that single cell.
- the single cells may be expanded in order to obtain a population of isogenic cells prior to reverse transcription.
- This process yields more mRNA to be used as template, which might be important if a rare target is to be amplified and linked.
- the cells should remain genetically identical with respect to the target gene during the expansion.
- the isolated cells or the population of isogenic cells can either be kept intact or lysed, as long as the template for the reverse transcription is not degraded. Preferentially, the cells are lysed in order to ease the following reverse transcription and PCR amplification.
- the disclosed multiplex overlap- extension RT-PCR method or multiplex RT-PCR followed by linkage by ligation or recombination may also be utilized on template derived from a genetically diverse population of cells which have not been separated into single vessels, but all remain together as a pool of cells.
- This method may be used for the generation of combinatorial libraries. Such an approach will not require the distribution of single cells.
- the cells which may be used in this approach are the same as those described for the single cell approach, for example a population (pool) of sorted B lymphocytes or T lymphocytes.
- RNA or mRNA may be isolated from the lysate.
- the sensitivity ofthe single-step multiplex overlap-extension RT-PCR ofthe present invention enables the use of a very low amount of template.
- single-step multiplex overlap-extension RT-PCR may be carried out on an amount of template corresponding to the lysate of a single cell.
- the primer mixtures ofthe present invention comprise at least four primers that form primer sets two by two, which are capable of amplifying at least two different target sequences of interest. Mixtures of two or more of such primer sets constitute a multiplex primer mix.
- a multiplex mix comprise at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, 30, 40, 50, 60, 70, 80, 90 100, 110, 120, 130, 140 or 150 primer sets (primer pairs).
- an individual primer set within the multiplex primer mix constitute several more than two primers.
- an individual primer set comprise at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 45, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 220, 240, 260, 280 or 300 primers.
- the total number of primers in a multiplex primer mix is at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 45, 50, 60, 70, 80, 90, 100, 125, 150 or 200 and at the most 225, 250, 275, 300, 325, 350, 375 or 400 primers.
- All the primers ofthe present invention comprise a gene-specific region, and preferably all primers are additionally equipped with a primer tail at the 5' end ofthe primer, i.e. 5' non-coding sequences which are fused to the 3' end ofthe gene-specific primer part.
- a primer tail is approximately from 6 to 50 nucleotides long, but it may also be longer if desired.
- the primer tails are added to the target sequences.
- Primer tails ofthe present invention are for example, cloning tails and linkage tails such as, tails adapted for linkage by ligation, tails adapted for linkage by recombination or overlap-extension tails.
- Cloning tails may be from 6 to 20 nucleotides long or longer and comprise restriction sites and/or recombination sites, which are useful for the insertion ofthe linked product into an appropriate vector.
- the primer sets ofthe multiplex primer mix are designed such that one part (forward or reverse primer(s)) ofthe first primer set is equipped with a linkage-tail containing a restriction site that upon cleavage will be compatible with a restriction site located in the linkage tail of one part ofthe second primer set.
- the second part ofthe second primer set is equipped with a restriction site that upon cleavage will be compatible with a restriction site located in one part ofthe third primer set.
- This second restriction site located in the second primer set should be non-compatible with that ofthe first primer set. A considerable number of target sequences can be linked by designing primer sets this way.
- Restriction sites with a low frequency or no occurrence, in the target sequences should be chosen. Further, it is preferable that compatible restriction sites are not identical, such that the site of ligation becomes cleavage-resistant for the particular restriction enzymes used. This will drive the reaction towards linkage of target sequence one with target sequence two, since linkage between identical target sequences will be cleavable by the restriction enzymes. Suitable pairs of restriction sites are for example, Spel with Xbal (alternatively Nhel or Avrll can substitute one or both of these), Ncol with BspHI , EcoRI with Mfel or Pstl with Nsil.
- Spel can for example be located in target sequence one
- Xbal can be located in target sequence two
- Ncol can be located at the other end of target sequence two
- BspHI in target sequence three and so forth.
- the restriction enzymes function in the same buffer.
- tails adapted for overlap-extension PCR are added to at least one primer of each primer set ofthe multiplex primer mix, thereby generating a multiplex overlap-extension primer mixture.
- the overlap-extension tails are typically longer, ranging from 8 to 75 nucleotides in length and may contain restriction sites or recombination sites which allow for subsequent insertion of regulatory elements such as promoters, ribosomal binding sites, termination sequences, or linker sequences such as in a scFv.
- the overlap-extension tail may also contain a stop codon if that is desired.
- overlap-extension tails there are three types of overlap-extension tails, as illustrated in Figure 1.
- type I the overlap-extension tails of two primer sets solely overlap with each other. Not necessarily all ofthe nucleotides of two overlap-extension tails are complementary to each other. In one aspect ofthe present invention the complementary nucleotides represent between 60 to 85% ofthe overlap-extension tail.
- type II overlap- extension tails 4 to 6 ofthe 5' nucleotides are complementary to the gene-specific region of the adjacent target sequence.
- type III overlap-extension tails the entire overlap is complementary to the adjacent target sequence.
- the type I and II overlap-extension tails are preferred when regulatory elements and the like are later to be inserted between the linked target sequences. Type II overlap-extension tails are preferred if the target sequences are to be linked by a defined linker as seen with scFv. Type III overlap-extension tails are preferred if the target sequences are to be linked in-frame to each other.
- Design of overlap-extension tails is dependent on sequence features such as length, relative GC content (GC%), presence of restriction sites, palindromes, melting temperature, the gene-specific part to which they are coupled etc.
- the length ofthe overlap-extension tails should be between 8 and 75 nucleotides long, preferably they are from 15 to 40 nucleotides long. Even more preferred they are from 22 to 28 nucleotides long.
- the use of very long overlap-extension tails (50 to 75 nucleotides) could favor the linkage ofthe products produced by each primer set. However, the proportion between the length ofthe overlap- extension tail and the gene-specific region probably will need to be adjusted when using very long overlap-extension tails.
- the GC% preference is dependent on the length ofthe overlap- extension tail. Since shorter tails have a shorter area where they are complementary they need a higher GC% to strengthen the interaction than longer tails. Other principles of primer design should likewise be observed, e.g. primer dimerization and hairpin formation should be minimized. Neither shall they engage in false priming. Further, it is known that Taq DNA polymerase often adds an adenosine (A) at the 3' end ofthe newly synthesized DNA strand, and this can be accommodated for in overlap-extension tail design by enabling overlap- extension tails to accommodate 3' non-template A addition. [00137] The choice of primers that carry the linkage tail, e.g.
- the overlap-extension tail, tail adapted for linkage by ligation or tail adapted for linkage by recombination defines the order and direction of linkage ofthe target sequences. It is not essential to the invention whether it is the forward primer(s) or reverse primer(s) of a primer set or possibly both forward and reverse primers that are equipped with the linkage tail. However, some consideration should be given to this anyway since the order and direction ofthe target sequences in the final product might be of relevance e.g. for the insertion of regulatory elements such as promoters and termination sequences or for the in-frame linkage ofthe individual target sequences.
- the linkage tail may be added either to the reverse primer(s) or forward primer(s) of each primer set used for the PCR amplification of each target sequence.
- the present invention exemplifies addition of overlap- extension tails and tails adapted for linkage by ligation, to the VH and V L forward primers of each set (e.g. Figure 2 and example 9, respectively). This results in a linking direction ofthe products that is 5' to 5' (head-to-head and bi-directional).
- linkage tails might as well be added to the reverse primer(s) of each set (e.g. C ⁇ and/or C . in the first set and CH or J H in the second set).
- a third option is adding the linkage tails to the reverse primer(s) of the first primer set (e.g. C ⁇ and/or C ⁇ primers ) and the forward primer(s) ofthe second primer set (e.g. VH primer(s)) or visa versa. This results in a 3' to 5' orientation (head-to-tail and uni-directional).
- Figure 3 illustrates the possible directions that can be generated depending on which primer of each primer set that is equipped with the linkage tail.
- the primer sets need to have linkage tails on both the forward and reverse primers, such that one tail is complementary to a tail ofthe preceding primer set and the other tail is complementary to one ofthe primers ofthe subsequent primer set. This principle holds for all the primer sets that amplify target sequences that are to be linked between two other target sequences.
- the design ofthe gene-specific primer part generally should observe known primer design rules such as minimizing primer dimerization, hairpin formation and non-specific annealing. Further, multiple G or C nucleotides as the 3' bases are to be avoided when possible.
- the melting temperature (Tm) ofthe gene-specific regions in a primer set should preferably be equal to each other plus/minus 5°C.
- Tm values between 45°C and 75°C are desirable and Tm values of about 60°C are optimal for most applications.
- the initial primer design can be aided by computer programs developed for this task.
- primer designs generally need laboratory testing and routine optimization. This may be done, for example, by analyzing size, restriction fragment length polymorphism (RFLP) and sequencing ofthe amplification products obtained using the primer sets.
- RFLP restriction fragment length polymorphism
- the use of degenerate positions within primers is a useful approach when amplifying sequences with variable regions or when searching for new family members belonging to a specified class of proteins. The numbers of degenerate positions may also require optimization.
- the present invention encompasses improved primer sets that can be used together in a highly multiplexed format.
- the primer set described by de Haard (de Haard, H. J. et al. 1999. J. Biol. Chem.274, 18218-18230) were used as starting point, and was modified by trimming the 3' ends ofthe primers to reduce non-specific interactions and adding overlap- extension tails or tails adapted for linkage by ligation.
- primer mixes composed of at least two primer sets that are able to prime amplification and promote linkage of at least two nucleotide sequences of interest.
- the primer mixes ofthe present invention are capable of priming the amplification of at least two subunits or domains from heteromeric proteins, e.g. belonging to the class of enzymes, inhibitors, structural proteins, toxins, channel proteins, G-proteins, receptor proteins, immunoglobulin superfamily proteins, transportation proteins etc.
- a further feature ofthe present invention is a multiplex overlap-extension primer mix comprising primer sets wherein at least one primer set member of each primer set comprises an overlap-extension tail capable of hybridizing to the overlap-extension tail of a primer set member of a second primer set.
- the overlap-extension tails enables the immediate linkage ofthe nucleotides of interest during the multiplex overlap-extension PCR amplification by equipping each individual product arising from the primer sets with a tail that is complementary to an adjoining product. This however does not mean that the linkage necessarily occur during this first PCR amplification. Depending on the reaction setup, the majority ofthe actual linkage may be performed during an additional amplification with the outer primers ofthe first PCR amplification (multiplex PCR amplification).
- a further feature ofthe present invention is a primer set designed to amplify a family of nucleotide sequences containing variable region encoding sequences. Examples of such families are kappa light chains (e.g.
- a primer set for the amplification of a family of nucleotide sequences containing variable region encoding sequences often comprise a plurality of primers where several primers can be degenerate primers.
- Amplification of families of immunoglobulin light chain variable region encoding sequences is for example performed using a primer set comprised of a plurality of primers complementary to the 5' end ofthe variable region ofthe kappa chain (VL K primer(s)) or the kappa leader sequence (V LKL primer(s)) and/or the lambda chain (V L ⁇ primer(s)) or the lambda leader sequence (VL ⁇ L primer(s)) (forward primers) together with constant region kappa (C ⁇ primer(s)) and/or lambda primers (C ⁇ primer(s)) (reverse primers) or a plurality of such primers.
- light chain joining region primers (J LK and/ or JL ⁇ ⁇ rimer(s)) may be used as reverse primers instead ofthe constant region primers.
- forward primers anneal in the UTR region preceding the leader sequence ofthe variable light chain.
- families of immunoglobulin heavy chain variable region encoding sequences can be amplified with one primer set utilizing various primer combinations. For example, a plurality of primers complementary to the 5' end ofthe heavy chain variable region (VH primer(s)) or the leader sequence of this region (V HL primer(s)) (forward primers) together with a plurality of heavy chain joining region primers (JH primer(s)) or heavy chain constant region primer(s) (reverse primers).
- the C H primer may be isotype-specific and in principle any CH primer can be utilized (e.g. C H _, QH E. C H3 , or CH ), also one that would result in a full-length heavy chain.
- forward primers anneal in the UTR region preceding the leader sequence ofthe variable heavy chain.
- One feature ofthe present invention are primers which anneal in the 3' end ofthe leader encoding sequence preceding a variable region encoding sequence, and their use for amplification of variable region encoding sequences.
- a preferred feature ofthe present invention is the application of primers with at least 90% sequence identity (preferably at least 95% identity) with the gene-specific region of SEQ ID NO 86 to 92, which correspond to primers annealing in the C-terminal of heavy chain leader encoding sequences (VH L primers).
- the gene-specific sequence of these SEQ ID NO's correspond to base number 18 to the 3' end ofthe sequences (see also table 11).
- Another preferred feature ofthe present invention is the application of primers with at least 90% sequence identity (preferably at least 95% identity) with the gene-specific region of SEQ ID NO 93 to 98, which correspond to primers annealing in the C-terminal of kappa light chain leader encoding sequences (V LKL primers).
- the gene-specific sequence of these SEQ ID NO's correspond to base number 25 to the 3' end ofthe sequences (see also table 11).
- the multiplex overlap-extension primer mix utilized for the multiplex overlap-extension PCR and possibly for the reverse transcription step as well comprises a) at least one CL or J L primer complementary to the sense strand of an immunoglobulin light chain region encoding sequence; b) at least one VL 5' primer or V L leader primer complementary to the antisense strand of an immunoglobulin light chain variable region encoding sequence and capable of forming a primer set with the primer(s) in a); c) at least one CH or J H primer complementary to the sense strand of an immunoglobulin constant heavy chain domain encoding sequence or the heavy chain joining region and d) at least one VH 5' primer or VH leader primer complementary to the antisense strand of an immunoglobulin heavy chain variable region encoding sequence, and capable of forming a primer set with the primer(s) in c).
- Primer sets ofthe present invention can for example be VL K + C ⁇ , V L ⁇ + C , VL K + J LK .
- the C (J L ) primer(s) and V L (V L L) primer(s) adapted for amplifying sequences comprising kappa light chain variable regions or lambda light chain variable regions.
- the forward primers for heavy chain amplification are VH L primers with at least 90% identity (preferably at least 95%) with the gene-specific region of SEQ ID 86 to 92.
- the forward primers for heavy chain amplification are VH L primers with at least 90% identity (preferably at least 95%) with the gene-specific region of SEQ ID 86 to 92.
- variable region encoding sequences in a head-to-tail fashion either the CL/JL and VH/VHL primers contain linkage tails or the VL/VLL and CH/ JH primers contain linkage tails, preferably in the form of complementary overlap-extension tails.
- the C L /JL and CH/JH primers contain linkage tails, preferably in the form of complementary overlap-extension tails ( Figure 3).
- the multiplex primer mixes, including multiplex overlap-extension primer mixes, ofthe present invention comprise two primer sets.
- a multiplex primer mix comprises at least four different primers.
- a multiplex primer mix comprises more than four different primers.
- a multiplex primer mix of the present invention is used for the amplification of target sequences in a single vessel. For example are kappa, lambda and heavy chain variable regions all amplified in the same vessel.
- One multiplex primer mix ofthe present invention was comprised of 16 different degenerate primers distributed as follows: eight VH primers, one C H I primer, six V LK primers, and one C ⁇ primer ( Figure 2).
- Another set was comprised of 19 degenerate primers distributed as follows: eight VH primers, four JH primers, six VL K primers, and one C ⁇ primer.
- a third set was comprised of 22 degenerate primers distributed as follows: eight VH primers, one C HI primer, eleven V L primers, and two C ⁇ primers.
- a fourth set was comprised of 27 degenerate primers distributed as follows: eight V H primers, one C H I primer, six V LK primers, one C ⁇ primer, eleven V L ⁇ primers, and two C ⁇ primers.
- the present invention also encompasses primers for an additional PCR amplification ofthe linked products obtained by multiplex RT-PCR followed by linkage by ligation or recombination or by multiplex overlap-extension RT-PCR.
- This additional PCR amplification can be performed using a primer mix adapted for amplifying the linked target sequences.
- a primer mix may comprise the outer primers ofthe multiplex primer mix or multiplex overlap-extension primer mix, meaning the primers that anneals to the outermost 5' end and 3' end ofthe sense strand ofthe linked nucleotide sequences, thereby enabling the amplification ofthe entire linked product.
- primers that can be utilized as outer in the present invention are the C ⁇ /J ⁇ and/or C ⁇ / primers forming a primer set with the J H or C H primers. This process generally serves to increase the amount of linked product obtained from the multiplex RT-PCR followed by linkage by ligation or recombination or from the multiplex overlap-extension RT-PCR.
- a primer set which is nested compared to the outer primers used in the primary multiplex RT-PCR or multiplex overlap-extension RT-PCR reaction can be used for the additional amplification ofthe linked nucleotide sequences.
- a primer set is termed a nested primer set.
- the design of nested primers generally observes the same design rules as for the gene-specific primers previously described, except that they prime 3' to the annealing position ofthe outer primers used in the multiplex RT-PCR or multiplex overlap-extension RT-PCR.
- the product resulting from a nested PCR is therefore shorter than the linked product obtained by the multiplex RT-PCR followed by linkage by ligation or recombination or by multiplex overlap-extension RT-PCR.
- the nested PCR further serves to increase the overall specificity, especially ofthe multiplex overlap-extension RT-PCR technology.
- the outer primers ofthe multiplex primer mix/multiplex overlap-extension primer mix can be used for the additional amplification or a semi-nested PCR can be applied as described later.
- Nested primer sets ofthe present invention can also be comprised of a reverse (or forward) outer primer(s) from the first multiplex primer mix/multiplex overlap-extension primer mix and a second nested primer that prime 3' to the annealing position ofthe forward (or reverse) outer primer(s) ofthe first multiplex primer mix/multiplex overlap-extension primer mix.
- the use of such a primer set for an additional PCR amplification is generally known as a semi-nested PCR.
- Semi-nested PCR can for example be applied if it is difficult to design a nested primer in one specific region e.g. for the variable region sequences (V and J primers), because such a primer would have to anneal in the complementarity determining regions (CDRs). Further, semi-nested PCR can be used when it is desirable to keep one end ofthe linked sequences intact e.g. for cloning purposes.
- V and J primers variable region sequences
- CDRs complementarity determining regions
- One feature ofthe present invention keeps the constant light chain encoding sequence kept intact during the additional amplification reaction.
- the CL (reverse) primer(s) used for the additional amplification is only slightly modified compared to the outer primer(s) used for the primary reaction (the multiplex RT-PCR or multiplex overlap-extension RT-PCR reaction).
- the modification comprises the addition of a few bases to the 3' end ofthe C L primer(s) used for the primary amplification.
- a different cloning tail might be added to the nested C L primer(s).
- the forward primer(s) used in the additional amplification is completely nested compared to the constant heavy chain-specific outer primer(s) used in the primary reaction.
- the nested PCR is performed with JH primer(s) and modified CL primer(s) where between 2 and 10 gene-specific base pairs have been added at the 3 'end compared to the first CL primer(s) ofthe multiplex primer mix/multiplex overlap-extension primer mix.
- the concentration ofthe primers carrying the overlap-extension tail is preferably lower than the concentration ofthe outer primers without overlap-extension tail (for example J H and kappa primers).
- one ofthe target sequences amplifies with a lower efficiency than the others, for example, as a result of a higher GC%, it may be possible to equalize the amplification efficacy. This may be done by using a higher concentration ofthe primer set which mediates amplification with low efficiency, or lowering the concentration ofthe other primer set. For example, sequences encoding for heavy chain variable regions tend to have a higher GC% and hence lower amplification efficiency than light chain variable regions. This points towards using V L primers at a lower concentration than the V H primers. [00166] Further, when using a large number of primers the total primer concentration might be an issue. The upper limit is determined experimentally by titration experiments.
- the cycling conditions are as follows: Denaturation: 10-30 s 94°C Annealing: 30-60 s 50-70°C Approximately 5°C below Tm of primers. Extension: 1 min x EPL 65-72°C EPL is Expected Product Length in kb. Cycle number: 30-80 Final extension: 10 min 65-72°C
- dNTP Deoxynucleoside triphosphate
- the best dNTP concentration is between 200 and 400 ⁇ M of each dNTP (dATP, dCTP, dGTP and dTTP), above which the amplification is rapidly inhibited.
- Lower dNTP concentrations (100 ⁇ M of each dNTP) suffice to achieve PCR amplification.
- dNTP stocks are sensitive to thawing/freezing cycles. After three to five such cycles, multiplex PCR often do not work well. To avoid such problems, small aliquots of dNTP can be made and kept frozen at -20°C.
- Mg 2+ concentration is critical since most DNA polymerases are magnesium-dependent enzymes. In addition to the DNA polymerase, the template DNA primers and dNTP's bind Mg 2+ . Therefore, the optimal Mg 2+ concentration will depend on the dNTP concentration, template DNA, and sample buffer composition. If primers and/or template DNA buffers contain chelators such as EDTA or EGTA, the apparent Mg 2+ optimum may be altered. Excessive Mg 2+ concentration stabilizes the DNA double strand and prevents complete denaturation of DNA, which reduces yield. Excessive Mg 2+ can also stabilize spurious annealing of primer to incorrect template sites, thereby decreasing specificity.
- a good balance between dNTP and MgCl 2 is approximately 200 to 400 ⁇ M dNTP (of each) to 1.5 to 3 mM MgCl 2 .
- KC1 based buffers suffice for multiplex overlap-extension PCR; however, buffers based on other components such as (NH 4 ) 2 SO 4 , MgSO 4, Tris-HCI, or combinations thereof may also be optimized to function with the multiplex overlap-extension PCR.
- Primer pairs involved in the amplification of longer products work better at lower salt concentrations (e.g. 20 to 50 mM KC1), whereas primer pairs involved in the amplification of short products work better at higher salt concentrations (e.g. 80 to 100 mM KC1). Raising the buffer concentration to 2X instead of IX may improve the efficiency ofthe multiplex reaction.
- the present invention is exemplified with Taq polymerase.
- other types of heat-resistant DNA polymerases including, for example, Pfu, Phusion, Pwo, Tgo, Tth, Vent, Deep-vent may be used.
- Polymerases without or with 3 'to 5 'exonuclease activity may either be used alone or in combination with each other.
- nucleotide sequences of interest produces a nucleotide segment comprising the linked nucleotide sequences of interest. Further, libraries of such linked nucleic acid sequences of interest are produced by the methods ofthe present invention, in particular libraries of variable region encoding sequences.
- One feature ofthe present invention is the insertion of a segment containing linked nucleotide sequences of interest or a library of linked nucleotide sequences of interest, generated by a method ofthe present invention, into suitable vectors.
- the libraries may be combinatorial libraries or libraries of cognate pairs of variable region encoding sequences.
- the restriction sites generated by the outer primers, nested primers or semi-nested primers are preferably designed to match appropriate restriction sites ofthe vector of choice.
- the linked nucleic acid sequences of interest can also be inserted into vectors by recombination, if one ofthe semi-nested, nested primers or outer primers were equipped with a suitable recombination site and the vector of choice contains one as well.
- Vectors that can be used as carriers ofthe products generated by one ofthe multiplex RT-PCR-linkage methods ofthe present invention.
- Vectors of choice may be those suitable for amplification and expression in cells including, for example, bacteria, yeast, other fungi, insect cells, plant cells, or mammalian cells. Such vectors may be used to facilitate further cloning steps, shuttling between vector systems, display ofthe product inserted into the vector, expression ofthe inserted product and/or integrate into the genome of a host cell.
- Cloning and shuttle vectors are preferably bacterial vectors. However, the other types of vectors may also be applied in cloning and shuttle procedures.
- Display vectors can for example be phage vectors or phagemid vectors originating from the class of fd, Ml 3, or IT filamentous bacteriophages. Such vectors are capable of facilitating the display of a protein including, for example, a binding protein or a fragment thereof, on the surface of a filamentous bacteriophage.
- Display vectors suitable for display on ribosomes, DNA, yeast cells or mammalian cells are also known in the art. These comprise for example viral vectors or vectors encoding for chimeric proteins.
- Expression vectors exist for all the mentioned species and the one to be chosen completely depend on the protein to be expressed.
- Some expression vectors are additionally capable of integrating into the genome of a host cell either by random integration, or by site- specific integration, utilizing appropriate recombination sites.
- Expression vectors may be designed to provide additional encoding sequences that, when the linked product is inserted in-frame to these sequences, enable the expression of a larger protein, e.g. a full-length monoclonal antibody, when introduced into an appropriate host cell. This in-frame insertion may also facilitate the expression of chimeric proteins that facilitate the display on the surface of a filamentous bacteriophage or cell.
- the linked nucleotide sequences of interest may be inserted in-frame to a sequence encoding a coat protein such as pill or pVIII (Barbas, CF. et al. 1991. Proc. Natl. Acad. Sci. USA 88, 7978- 7982; Kang, A.S. etal. 1991. Proc. Natl. Acad. Sci. USA 88, 4363-4366).
- the individual segments of linked nucleotide sequences of interest is comprised of an immunoglobulin heavy chain variable region encoding sequence associated with a light chain variable region encoding sequence.
- these linked sequences are inserted into a vector that contains sequences encoding one or more immunoglobulin constant domains.
- the insertion is engineered such that the linked heavy chain variable region and/or light chain variable region encoding sequences are inserted in-frame to the constant region encoding sequences.
- Such an insertion can for example generate a Fab expression vector, a full-length antibody expression vector or an expression vector encoding a fragment of a full-length antibody.
- a vector is an expression vector suitable for screening (e.g. E.
- the vector may also contain a constant light chain encoding sequence chosen from human lambda or kappa chains. This is appropriate when the linked nucleotide sequences only encode the immunoglobulin variable region encoding sequences (Fv's).
- the individual segments ofthe linked nucleotide sequences is comprised of a TcR ⁇ chain variable region encoding sequence associated with a ⁇ chain variable region encoding sequence or a ⁇ chain variable region encoding sequence associated with a ⁇ chain variable region encoding sequence.
- these linked sequences are inserted into a vector that contains sequences encoding one or more TcR constant domains. The insertion is engineered such that the inserted linked variable region encoding sequences are in-frame to the corresponding TcR constant region encoding sequences.
- such a vector is a chimeric expression vector comprising sequences that encode a leucine zipper in-frame to the TcR constant regions. It has been shown that such constructs increase stability of soluble TcR's (Willcox, B. ⁇ . et al. 1999. Protein Sci 8, 2418-2423). [00187] Libraries of cognate pairs ofthe present invention may be introduced into vectors by two different approaches. In the first approach, the single cognate pairs are inserted individually into a suitable vector. This library of vectors may then either be kept separate or be pooled.
- One aspect ofthe present invention is a library of cognate pairs of linked variable region encoding sequences.
- the individual cognate pairs ofthe library comprise an immunoglobulin light chain variable region encoding sequence associated with a heavy chain variable region encoding sequence.
- Another preferred library of cognate pairs comprise linked TcR region encoding sequences, where each individual TcR region encoding sequences comprise an alpha chain variable region encoding sequence associated with a beta chain variable region encoding sequence and/or a TcR gamma chain variable region encoding sequence associated with a delta chain variable region encoding sequence.
- An embodiment ofthe present invention is a sub-library of cognate pairs of linked variable region encoding sequences which encode for desired binding specificities directed against a particular target.
- these cognate pairs comprise linked immunoglobulin light chain variable region and heavy chain variable region encoding sequences, TcR alpha chain variable region and beta chain variable region encoding sequences and/or TcR gamma chain variable region and delta chain variable region encoding sequences.
- a further embodiment is a sub-library selected from a parent library of cognate pairs of variable region encoding sequences as described throughout the invention.
- a preferred embodiment ofthe present invention is a library or sub-library encoding for cognate pairs of full-length immunoglobulins selected from human immunoglobulin classes IgAl, IgA2, IgD, IgE, IgGl, IgG2, IgG3, IgG4, or IgM.
- Another preferred feature ofthe present invention is a library or sub-library encoding for soluble and stable cognate pairs of TcRs.
- a feature ofthe present invention is the diversity of said libraries, which are comprised of at least 5, 10, 20, 50, 100, 1000, 10 4 , 10 5 or 10 6 different cognate pairs.
- said libraries of cognate pairs of linked variable region encoding sequences are obtainable by a method comprising the steps described herein. This library is also termed the parent library.
- the parent library of pairs of linked variable region encoding sequences isolated from a donor, utilizing one ofthe methods ofthe present invention, is expected to represent a diversity of binding proteins ofwhich some will be irrelevant, i.e. not binding to a desired target, in particular for combinatorial libraries. Therefore, the present invention encompasses enrichment and screening, for a sub-library encoding a subset of diversities of binding specificities directed against a particular target.
- the diversity ofthe library is expected to represent the diversity present in the donor material, with only a minor number of randomly linked variable regions. Thus, an enrichment step may not be necessary prior to the screening for target-specific binding affinities in a library composed of cognate pairs.
- the method of generating a library of pairs of linked variable region encoding sequences further comprises creating a sub- library by selecting a subset of pairs of linked variable region sequences that encode binding proteins with a desired target specificity. Such a selection of linked variable region encoding sequences, is also termed a library of target-specific cognate pairs.
- a library of target-specific cognate pairs is also termed.
- Immunological assays are generally suitable for the selection of target-specific immunoglobulin variable region encoding sequences.
- Such assays are well know in the art and constitute for example ELISPOTS, ELISA, membrane assays (e.g. Western blots), arrays on filters, or FACS.
- the assays can either be performed in a direct manner, utilizing the polypeptides produced from the immunoglobulin variable region encoding sequences.
- the immunoassays can be performed in combination with or following enrichment methods such as phage display, ribosome display, bacterial surface display, yeast display, eukaryotic virus display, RNA display or covalent display (reviewed in FitzGerald, K., 2000. Drug Discov.
- cognate Fab expression libraries and cognate full-length antibody expression libraries can be subjected to screening, thereby generating a sub-library of positive clones.
- screening assays and enrichment procedures are also suitable for Fv or scFv fragments or combinatorial libraries of linked variable regions.
- the selection of a sub-library of target-specific cognate pairs or combinatorial pairs of variable region encoding sequences is performed by using a high-throughput screening assay.
- High-throughput screening assays could be, but are not restricted to, ELISA assays performed with semi-automated or fully automated equipment. It could also be a membrane assays in which bacteria are robotically picked and gridded onto an appropriate membrane on top of agar plates generating arrays of colonies expressing antigen-binding molecules.
- the molecules are secreted through the membrane onto a second underlying antigen-coated membrane which can be developed separately and used to identify clones that secrete antigen binding molecules towards the desired target (de Wildt, R.M., et al. 2000. Nat. Biotechnol. 18, 989-994).
- DNA sequencing ofthe linked immunoglobulin light chain variable region and heavy chain variable region encoding sequences. First of all such a DNA sequencing will provide information about the library diversity such as germline origin, family distribution and maturation within the CDR regions. Such an analysis will enable the selection of clones which represent a broad diversity, and leaving out repeated clones. Secondly, DNA sequencing will reveal mutations introduced during the isolation process.
- variable region encoding sequences there are three types of mutations to consider when assessing whether a mutation is acceptable: i) The most frequent type of mutations result from intra-family cross-priming, where V gene primers prime to the wrong subset within one particular V gene family. The changes introduced are mainly substitutions of naturally occurring codons at one particular position. Due to the high degree of sequence homology within a V gene family these changes usually can be regarded as conservative and acceptable changes; ii) Less frequent mutations are induced by inter-family cross-priming (e.g., a VH3 family primer primes a VH1 family encoding sequence) and induces more significant structural changes, sometimes with no natural counterpart.
- inter-family cross-priming e.g., a VH3 family primer primes a VH1 family encoding sequence
- the sub-library of target-specific and possibly sequence analysed pairs of linked immunoglobulin light chain variable region and heavy chain variable region encoding sequences are transferred to a mammalian expression vector. Such a transfer can be performed into any ofthe vectors described in the previous section, enabling the expression of a full-length recombinant antibody. If the screening is performed with a mammalian cognate full-length antibody expression library such a transfer may not be needed.
- the parent library is generated from a lymphocyte-containing cell fraction which is enriched for T lymphocytes.
- the pairs of linked variable region encoding sequences constituting the parent library may be selected for encoding a subset of pairs of linked variable region sequences, composed of alpha and beta and/or gamma and delta chains that encode binding proteins with a desired target specificity, generating a sub-library of cognate pairs or combinatorial pairs.
- Antigen-specific T cell receptors can subsequently be identified from a pool of transfected cells using standard methodology such as staining with tetrameric MHC-peptide complexes (e.g., Callan, M.F. et al. 1998. J. Exp. Med. 187, 1395-1402; Novak, E.J. et al. 1999. J. Clin. Invest 104, R63- R67), by measuring cellular responses in the form of IL-2 release or by more sophisticated means such as yeast or retroviral display techniques.
- the libraries ofthe present invention can be transferred to vectors suitable for expression and production of proteins encoded from the linked nucleic acid sequences of interest, in particular variable region containing binding proteins or fragments thereof.
- vectors suitable for expression and production of proteins encoded from the linked nucleic acid sequences of interest in particular variable region containing binding proteins or fragments thereof.
- Such vectors are described in the Vectors and Libraries section, and provide for the expression of for example full-length antibodies, Fab fragments, Fv fragments, scFv, membrane bound or soluble TcRs or TcR fragments of a species of choice.
- One feature ofthe present invention is the introduction into a host cell of a library or a sub-library of vectors of cognate pairs of linked variable region encoding sequences or a single clone encoding a cognate pair of linked variable region encoding sequences, for amplification and/or expression.
- Host cells can be chosen from bacteria, yeast, other fungi, insect cells, plant cells, or mammalian cells.
- mammalian cells such as Chinese hamster ovary (CHO) cells, COS cells, BHK cells, myeloma cells (e.g., Sp2/0 cells, NSO), NIH 3T3, fibroblast or immortalized human cells such as HeLa cells, HEK 293 cells, or PER.C6 are preferred.
- CHO Chinese hamster ovary
- COS cells COS cells
- BHK cells BHK cells
- myeloma cells e.g., Sp2/0 cells, NSO
- NIH 3T3 fibroblast or immortalized human cells such as HeLa cells, HEK 293 cells, or PER.C6 are preferred.
- the introduction of vectors into host cells may be accomplished by a number of transformation or transfection methods known to those skilled in the art, including calcium phosphate precipitation, electroporation, microinjection, liposome fusion, RBC ghost fusion, protoplast fusion, viral infection and the like.
- transformation or transfection methods including calcium phosphate precipitation, electroporation, microinjection, liposome fusion, RBC ghost fusion, protoplast fusion, viral infection and the like.
- the production of monoclonal full-length antibodies, Fab fragments, Fv fragments and scFv fragments is well known.
- the production of recombinant polyclonal antibodies to be used for treatment is a quite new area.
- a recombinant polyclonal manufacturing technology has been described in PCT application WO 2004/061104. In brief, this technology involves the generation of a collection of cells, suitable as a manufacturing cell line.
- the following description ofthe technique is made for a library of cognate pairs, it is however just as applicable for a combinatorial library.
- the individual cells in the collection of cells are capable of expressing a distinct member ofthe recombinant polyclonal binding protein for example from a library of cognate pairs.
- the nucleic acid sequences encoding the cognate pairs are introduced into a single site-specific site in the genome of each individual cell.
- Cre beta-recombinase, Gin, Pin, PinB, PinD, R/RS, lambda integrase, or phage ⁇ C31 integrase that can be used in combination with their corresponding recombination sites.
- appropriate vectors contain a selection marker that enables the selection of site-specific integrants.
- the generation of a polyclonal manufacturing cell line and the production of a recombinant polyclonal protein from such a cell line can be obtained by several different transfection and manufacturing strategies.
- One way is to use a library of vectors mixed together into a single composition, for the transfection of a host cell line with a single integration site per cell.
- This method is termed bulk transfection or transfection in bulk.
- the vector and host cell design previously described will ensure that a polyclonal cell line capable of unbiased growth will be obtained upon appropriate selection.
- a frozen stock ofthe polyclonal cell line will be generated before initiation ofthe recombinant polyclonal protein manufacturing.
- Another way is to use a library of vectors split into fractions, containing approximately 5 to 50 individual vectors ofthe library in a composition, for transfection.
- a fraction ofthe library constitutes 10 to 20 individual vectors.
- Each composition is then transfected into an aliquot of host cells. This method is termed semi-bulk transfection.
- the number of aliquots transfected will depend on the size ofthe library and the number of individual vectors in each fraction. If the library for example constitutes 100 distinct cognate pairs, which are split into fractions containing 20 distinct members in a composition, 5 aliquots of host cells would need to be transfected with a library composition constituting a distinct fraction ofthe original library.
- the aliquots of host cells are selected for site-specific integration. Preferably, the distinct aliquots are selected separately. However, they can also be pooled before selection. The aliquots can be analyzed for their clonal diversity and only those with sufficient diversity will be used to generate a polyclonal cognate pair library stock.
- the aliquots can be mixed before generating the freezing stock, immediately after they have been retrieved from the stock or after a short proliferation and adaptation time.
- the aliquots of cells are kept separate throughout production, and the polyclonal protein composition is assembled by combining the products of each aliquot rather than the aliquots of cells before production.
- a third way is a high throughput method in which host cells are transfected separately using the individual vectors constituting the library of cognate pairs. This method is termed individual transfection.
- the individually transfected host cells are preferably selected for site specific integration separately.
- the individual cell clones generated upon selection may be analyzed with respect to proliferation time and preferably, those with similar growth rates are used to generate a polyclonal cognate pair library stock.
- the individual cell clones can be mixed to obtain the desired polyclonal cell line before generating the stock, immediately after they have been retrieved from the stock, or after a short proliferation and adaptation time. This approach may eliminate any possible residual sequence bias during transfection, integration and selection. Alternatively the individually transfected host cells are mixed before selection is performed, this will enable control of sequence bias due to transfection.
- a shared feature in the manufacturing strategies outlined in the above is that all the individual cognate pairs constituting the recombinant polyclonal protein can be produced in one, or a limited number of bioreactors. The only difference is the stage at which one chooses to generate the collection of cells that constitutes the polyclonal manufacturing cell line.
- One embodiment ofthe present invention is a population of host cells comprising a cognate library or sub-library of linked pairs of variable region encoding sequences.
- a population of host cells comprises a library obtained from a population of isolated single cells constituting lymphocytes, utilizing the multiplex RT- PCR amplification followed by linkage by ligation or recombination or the multiplex overlap-extension RT-PCR technology ofthe present invention, to link the cognate pairs.
- Another embodiment ofthe present invention is a population of host cells comprising a combinatorial library or sub-library of linked pairs of variable region encoding sequences.
- a population of host cells according to the present invention will encompass a diverse population of cells corresponding to the diversity ofthe library the cells have been transformed/transfected with.
- each cell ofthe population of cells only constitutes one cognate pair ofthe entire library of cognate pairs, and no individual member ofthe library of cognate pairs exceeds more than 50%, more preferred 25%, or most preferred 10%, ofthe total number of individual members expressed from the population of host cells.
- the population of host cells is mammalian cells.
- a population of host cells as described in the above can be utilized for the expression of a recombinant polyclonal binding protein, since individual cells ofthe population constitute variable region encoding sequences of different diversity.
- One embodiment ofthe present invention is a recombinant polyclonal protein expressed from a population of host cells comprising a library of vectors encoding diverse cognate pairs of linked variable region encoding sequences, where such a library is obtainable by the method ofthe present invention.
- a recombinant polyclonal protein ofthe present invention is comprised of at least 2, 5, 10, 20, 50, 100, 1000, 10 4 , 10 5 or 10 proteins composed of different cognate pairs.
- a preferred embodiment ofthe present invention is a recombinant polyclonal immunoglobulin expressed from a population of host cells comprising a library of vectors encoding diverse cognate pairs of heavy chain variable region and light chain variable region encoding sequences.
- Another preferred embodiment ofthe present invention is a recombinant polyclonal TcR expressed from a population of host cells comprising a library of vectors encoding diverse cognate pairs of TcR alpha chain variable region linked with beta chain variable region encoding sequences and/or TcR gamma chain variable region linked with delta chain variable region encoding sequences.
- Another embodiment ofthe present invention is a host cell suitable for production of a monoclonal protein.
- a monoclonal antibody comprised of a cognate pair of a light chain variable region with a heavy chain variable region or a monoclonal TcR comprised of a cognate pair of an alpha variable region with a beta variable region or a delta variable region with a gamma variable region.
- a monoclonal production cell line is not a hybridoma cell line.
- Such a monoclonal antibody or TcR can be generated by adding the following steps to the method of linking a plurality of non-contiguous nucleotide sequences of interest a) inserting said linked nucleic acid sequences into a vector; b) introducing said vector into a host cell; c) cultivating said host cells under conditions suitable for expression; and d) obtaining the protein product expressed from the vector inserted into said host cell.
- the vector introduced into the host cell encodes an individual cognate pair of variable region encoding sequences.
- One ofthe major applications ofthe present invention is the linkage of cognate pairs of variable region encoding sequences, especially immunoglobulin heavy and light chain variable region encoding sequences or TcR alpha and beta chain or gamma and delta chain variable region encoding sequences, by a high-throughput method for the generation of libraries of cognate pairs.
- the multiplex RT-PCR followed by linkage by ligation or recombination or the multiplex overlap-extension RT-PCR techniques ofthe present invention may be utilized in the generation of combinatorial libraries by performing the technique on a population of genetically diverse cells, cell lysates from such a population of cells, or on RNA purified from such a population of cells.
- the libraries, sub-libraries, or single clones from one of these libraries facilitate the expression of polyclonal or monoclonal proteins. Especially monoclonal or polyclonal antibodies may be obtained from the libraries ofthe present invention.
- a pharmaceutical composition comprising a polyclonal recombinant immunoglobulin as active ingredient, combined with at least one pharmaceutically acceptable excipient, can be produced by means ofthe present invention. More preferred are pharmaceutical compositions where the polyclonal recombinant immunoglobulin is comprised of cognate pairs of variable region encoding sequences. Such pharmaceutical compositions of polyclonal recombinant immunoglobulins can be used as medicaments.
- the polyclonal recombinant immunoglobulin ofthe composition can be specific for or reactive against a predetermined disease target, and the composition can thus be used for the treatment, amelioration or prevention of diseases such as cancer, infections, inflammatory diseases, allergy, asthma and other respiratory diseases, autoimmune diseases, immunological malfunctions, cardiovascular diseases, diseases in the central nervous system, metabolic and endocrine diseases, transplant rejection, or undesired pregnancy, in a mammal such as a human, a domestic animal, or a pet.
- diseases such as cancer, infections, inflammatory diseases, allergy, asthma and other respiratory diseases, autoimmune diseases, immunological malfunctions, cardiovascular diseases, diseases in the central nervous system, metabolic and endocrine diseases, transplant rejection, or undesired pregnancy, in a mammal such as a human, a domestic animal, or a pet.
- the present invention has a further application which cannot be obtained with conventional monoclonal combinatorial antibody techniques. In situations where protective antigens are either poorly characterized or completely unknown, such as in emerging infectious diseases, it is impossible to screen for a monoclonal antibody that will provide protection against the disease.
- Another application ofthe techniques for linking cognate pairs of variable regions, described in the present invention is for diagnostic and analytical purposes.
- This immunogenecity can be assessed by conventional techniques, such as medicament-specific binding assays with serum or plasma derived from the individual treated with the medicament.
- the methods ofthe present invention can be used to mirror the patients' immune response shortly after administration ofthe medicament, by isolating cognate pairs of variable heavy chain and light chain encoding sequences.
- Antibodies expressed from such a library can then be screened for reactivity towards the medicament or components ofthe medicament. This method is particular useful if the presence ofthe medicament in plasma or serum would interfere with the conventional method.
- Such medicaments are for example antibodies.
- identification of an anti-medicament immune response e.g. an anti- idiotypic, anti-framework or anti-Fc immune response
- sequences encoding such anti- medicament antibodies can be isolated and analyzed from the individual treated with the medicament within a couple of weeks.
- a further application ofthe present invention is in the validation and comparison of vaccines and immunization programmes.
- the present invention also finds applications outside the field of variable region containing binding proteins. It is merely a matter of optimization for one skilled in the art to adapt the technique disclosed in the present invention to link two or more transcribed nucleotide sequences encoding a heteromeric protein other that a binding protein.
- Such a linkage of sequences encoding for domains or subunits from a heteromeric protein may be an advantage in the isolation of these protein encoding sequences since it would reduce the number of steps considerably. Further, it is possible to isolate for example splice variants, mutations or new family members of such proteins by using only one multiplex primer mix/multiplex overlap-extension primer mix. [00237]
- the linkage of sequences which encode distant domains of a single protein is also a possibility. Such a technique would ease the research in relation to the importance of certain domains in a multidomain protein, since it would ease the deletion of intermediate domains.
- the generation of chimeric or coupled proteins is also an area where the present invention may be applied.
- the present invention may be utilized by mixing the cells prior to reverse transcription.
- a cell mixture may constitute either a population of cells from each species or a single cell from each species.
- Example 1 Two-step Multiplex Overlap-extension RT-PCR
- reverse transcription was performed using a template derived from an isolated single cell and the cDNA produced was used as template for more than one multiplex overlap-extension PCR.
- IgGl -kappa expressing Chinese hamster ovary (CHO) cell line was generated using the Flp-In technology (Invitrogen, Carlsbad, CA, USA).
- IgG-kappa mammalian expressing plasmid vector pLLl 13 ( Figure 4) was constmcted based on the Flp-In expression vector, pcDNA5/FRT.
- CHO-Flp-In cells were co- transfected, using Lipofectamin2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instmctions, with pLLl 13 containing the antibody encoding genes and pOG44 conferring transient expression ofthe Flp recombinase. Transformants were selected and verified for production of IgG-kappa by immunoassays.
- the selected cell line was named CHO Flp-In pLLl 13, and maintained in Ham's F-12 medium, supplemented with 2 mM L-glutamine, 10% FCS and 900 Hygromycin B (maintenance media).
- CHO Flp-In pLLl 13 cells were harvested using trypsin and washed 3x in maintenance media. After the final wash the cells were re-suspended in the original volume of maintenance media. The cell concentration was determined using a Casy-1 System (Scharfe System GmbH, Reutlingen, Germany) and diluted in maintenance media to a concentration of 1 cell/5 ⁇ l.
- CHO Flp-In pLLl 13 cell suspension on average containing one cell, was dispensed into single wells of a 96-well PCR plate (Thermo-Fast 96, skirted AB-0800, ABgene, Epsom, Surrey, UK).
- the cDNA was synthesized from the distributed cells by utilizing the reverse transcriptase (RT) step in the Qiagen One-Step RT-PCR protocol (Qiagen OneStep RT-PCR Kit, Cat# 210210, Hilden, Germany), [00245]
- RT reverse transcriptase
- Each well contained the following reagents in a total volume of 20 ⁇ l: 1 x One Step RT-PCR buffer, dNTP's in a final concentration of 1 mM of each, 5 pmol Oligo poly-dT (18), 26 U RNase inhibitor (RNasin, Promega, Madison USA, cat.
- a fraction ofthe cDNA products generated in step b) was used as template for multiplex overlap-extension PCR.
- the reactions were performed in 96-well plates.
- Each well contained, in a total volume of 40 ⁇ l, the following reagents: 1 x One Step RT-PCR buffer, dNTP's in a final concentration of 500 ⁇ M of each, Multiplex overlap-extension primer mix in the concentrations as indicated in Table 1, 26 U RNase inhibitor (RNasin, Promega, Madison USA, cat. No N2111), 2 ⁇ l One Step RT-PCR enzyme mix, and 1 ⁇ l cDNA template (derived from a single cell (step b)).
- the multiplex overlap-extension primer mix used comprised the primers shown in table 1.
- Nested PCR was performed using the multiplex overlap-extension products as template. The reactions were performed in 96-well plates.
- each well contained, in a total volume of 50 ⁇ l, the following reagents: 1 x BioTaq buffer, dNTP's in a final concentration of 400 ⁇ M of each, 2 mM MgCl 2 , Nested PCR primer mix, 1.25 U BIOTAQ DNA Polymerase (Cat. No BIO-21040, Bioline, UK.), and 1 ⁇ l Multiplex overlap-extension PCR product (step c).
- the primers used are shown in table 2. Table 2
- Figure 5B illustrates the fragments of Figure 5 A, which are relevant to the present experiment.
- the present experiment illustrates one way to perform two-step multiplex overlap- extension PCR, utilizing template derived from a single cell. Further, it was shown that it is possible to perform approximately twenty multiplex overlap-extension PCR's using cDNA generated from an isolated single cell.
- Example 2 Single-step Multiplex Overlap-extension RT-PCR
- reverse transcription and multiplex overlap-extension PCR was performed in a single step using template from lysed cells, in concentrations corresponding to 100, 10, or 1 cells.
- a. Cells The human hybridoma cell line HB-8501 producing an anti-tetanus IgGl -kappa antibody was acquired from American Type Culture Collection and cultured in Iscove's Modified Dulbecco's Medium (Vitacell, Kiev, Ukraine, cat. No 30-2005) containing 10% fetal bovine serum.
- RT-PCR Single-step Multiplex Overlap-extension RT-PCR
- the Qiagen One-Step RT-PCR kit (Qiagen cat. No 210212, Hilden, Germany) was used for the multiplex overlap-extension RT-PCR essentially according to the manufacturer's recommendation.
- cell lysates were thawed and diluted in H O to yield a lysate concentration corresponding to 100, 10, and 1 cells per 5 ⁇ l.
- Each PCR tube contained the following reagents in a total volume of 50 ⁇ l: 1 x One-Step RT-PCR buffer, dNTP's in a final concentration of 400 ⁇ M of each, Multiplex overlap-extension primer mix in the concentrations as indicated in table 3, 2 ⁇ l One-step RT-PCR enzyme mix, 50 U RNase inhibitor (RNasin, Promega, Madison USA, cat. No N2515), and 5 ⁇ l diluted cell lysate [00261]
- Example 3 Combined Single-step Multiplex Overlap-extension RT-PCR and Nested PCR
- Capitalized sequences correspond to the gene-specific region
- Example 4 Combined Single-step Multiplex Overlap-extension RT-PCR and Nested PCR Using Enriched Human B Lymphocytes as Template Source
- a human male donor was immunized with Tetanus toxoid.
- a blood sample of 120 ml was collected from the donor 6 days post immunization and peripheral blood mononuclear cells (PBMC's) were isolated using Lymphoprep (Axis-Shield, Oslo Norway, prod. No 1001967) according to the manufacturer's instructions.
- the CD19-positive cell population was enriched utilizing magnetic bead cell sorting.
- the PBMC's were stained with FITC- conjugated anti-CD 19 antibody (Becton Dickinson, NJ, USA, cat. No 345776).
- Magnetic bead cell sorting using anti-FITC-conjugated magnetic microbeads and column purification was performed according to manufactures instmctions (Miltenyi Biotec, Gladbach, Germany, cat. No 130-042-401).
- the cells were diluted to a concentration of 200 cells per ml in PBS containing 2 nM EDTA and 0.5% BSA.
- Five microliters ofthe diluted cells was distributed to PCR tubes obtaining approximately a single cell pr. tube.
- the tubes were stored at -80°C until use.
- the 1 kb fragments of lane 5 and 6 were excised from the agarose gel, purified using a Qiaex II kit (Qiagen cat. No 20051) and inserted into pCR2.1-TOPO using the Invitrogen TOPO TA cloning kit (Invitrogen cat. No 45-0641, Carlsbad, CA, USA). Two clones from each isolated fragment had inserts ofthe correct size. Restriction enzyme digestion (Ncol and Nhel, separately) showed fragments ofthe expected sizes (410 and 680 bp) indicating a correct linkage between the heavy chain variable region and the light chain variable and constant region encoding sequences. [00283] The two clones originating from the fragment in lane 5 were sequenced and shown to be identical, indicating that the linked VH and LC were cognate pairs.
- IgGl -lambda expressing Chinese hamster ovary (CHO) cell lines were generated using the Flp-In technology (Invitrogen, Carlsbad, CA, USA).
- IgG 1 -lamda mammalian expressing vectors pEm465/01P581 and pEm465/01 P582 ( Figure 9A) representing two lambda gene families were constructed based on the Flp-In expression vector, pcDNA5/FRT.
- CHO-Flp-In cells were co-transfected, using Fugene 6 (Roche, Mannheim, Germany) according to the manufacturer's instmctions, with the above mentioned plasmids containing the antibody encoding genes and pOG44 conferring transient expression ofthe Flp recombinase. Transformants were selected for insertions.
- the selected cell lines were named CHO Flp-In/Em464/01P581 & CHO Flp-In/Em464/01P582, and maintained in Ham's F-12 medium, supplemented with 2mM L-glutamine, 10% FCS and 900 ⁇ g/ml Hygromycin B (maintenance media).
- RNA samples were harvested using trypsin and washed 3x in maintenance media. Approximately 10 cells were used for Total RNA purification using Nucleo Spin L kit (Macherey- Nagel, D ⁇ ren, Germany) according to the manufacturer's description. The final RNA concentrations were determined by OD 260 measurements.
- Nucleo Spin L kit Mecleo Spin L kit (Macherey- Nagel, D ⁇ ren, Germany) according to the manufacturer's description. The final RNA concentrations were determined by OD 260 measurements.
- the present experiment illustrates that the lambda multiplex overlap-extension primer mix shown in Table 6 is applicable in single-step multiplex overlap-extension RT-PCR independent on the template used. Further, specific overlap-extension PCR products were produced at 0.5 pg total RNA. This sensitivity suggest that cognate linked heavy chain variable region and light chain variable region encoding sequences can be amplified from a single cell.
- Tetanus vaccine Statens Serum Institut, Denmark. Six days post the Tetanus vaccine boost a blood sample of approximately 200 ml is drawn from the donors into a tube containing anticoagulant.
- PBMC Peripheral Blood Mononuclear Cells
- the B-cell lineage (CD 19+ cells) ofthe PBMC's is enriched by magnetic bead cell sorting using the following procedure.
- the isolated PBMC are stained with anti-CD 19-FITC (Becton Dickenson, NJ, USA, cat. No 345776). All steps are performed at 4°C in the dark. Staining is performed with 10 ⁇ l anti-CD 19-FITC pr. lxlO 6 cells in a volume of 100 ⁇ l per 1x10° cells using M-buffer (PBS, pH 7.2, 0.5% BSA, 2 mM EDTA). This will stain the B-cell lineage ofthe PBMCs. Cells are incubated for 20 min followed by two washing steps with M-buffer.
- M-buffer PBS, pH 7.2, 0.5% BSA, 2 mM EDTA
- the anti-CD 19-FITC stained cells are magnetically labeled with anti-FITC conjugated microbeads, using 10 ⁇ l of anti-FITC magnetic beads (Miltenyi Biotec, Gladbach, Germany, cat. No 130-042-401) per lxlO 6 cells in a volume of 100 ⁇ l M-buffer per lxl 0 6 cells. Incubation is performed for 15 min followed by a single washing step with M-buffer. The cells are resuspended in degassed M-buffer.
- a MACS LS column (Miltenyi Biotec, Gladbach, Germany, cat. No 130-042-401) is pretreated with degassed M-buffer according to the manufactures prescriptions.
- the suspension of cells stained with anti-CD 19-FITC and labeled with anti-FITC-magnetic beads are applied to the column and allowed to run through. Stained and labeled cells (CD 19+) will be retained in the magnetic field surrounding the column while unstained cells (CD 19-) will pass through the column.
- the column is washed with degassed M-buffer. The magnetic field is removed and the CD 19+ cells are collected. d.
- Sorting of plasma cells [00300] The eluate from the MACS column is centrifuged and resuspended in FACS buffer (PBS, pH 7.2, 2% BSA) in a concentration of lxlO 6 cells/60 ⁇ l FACS buffer.
- FACS buffer PBS, pH 7.2, 2% BSA
- Anti-CD19- FITC Becton Dickenson, NJ, USA, cat. No 345776
- anti-CD38-PE Becton Dickenson, NJ, USA, cat. No 555460
- Anti-CD45-PerCP (Becton Dickenson, NJ, USA, cat. No 345809) (20 ⁇ l/10 6 cells) are added.
- FACS fluorescence activated cell sorting
- FACS sorted cells are collected as single cells directly in single wells of 96 well plates containing 5 ⁇ l PBS buffer supplemented with 5 U RNase inhibitor (RNasin, Promega, Madison USA, cat. No N2515) per well. At this point the cells may be frozen for later RT- PCR or the cells may proceed immediately for RT-PCR. e. Linkage of Cognate Pairs of Immunoglobulin Variable Region Encoding Sequences
- the multiplex overlap-extension RT-PCR technology is applied to the single cells, thereby achieving cognate linkage of transcribed anti-Tetanus Toxoid heavy chain variable region and light chain variable region encoding sequences.
- e-1. Single-step Multiplex Overlap-extension RT-PCR [00303] The Qiagen One-Step RT-PCR kit (Qiagen cat. No 210212, Hilden, Germany) is used for the multiplex overlap-extension RT-PCR essentially according to the manufacturer's recommendation. Frozen 96-well plates containing a single cell per well are removed from the freezer and when the wells are free of ice crystals 15 ⁇ l RT-PCR reaction mixture is added immediately to each sample (single cell).
- the RT-PCR reaction mixture contains, in a total volume of 20 ⁇ l, the following reagents: 1 x One-Step RT-PCR buffer, dNTP's in a final concentration of 400 ⁇ M of each, Multiplex overlap-extension primer mix in the concentrations as indicated in table 8, 0.8 ⁇ l One-step RT-PCR enzyme mix, and 20 U RNase inhibitor (RNasin, Promega, Madison USA, cat. No N2515).
- the composition ofthe multiplex overlap-extension primer mix is shown in table 8. Table 8
- Capitalized sequences correspond to the gene specific region.
- Cycling conditions are as follows: Reverse transcription: 30 min 55°C Polymerase activation: 15 min 95°C inactivates reverse transcriptase and activates Taq polymerase. [00307] PCR reaction: Denature 30 sec 94°C " Anneal 30 sec 52°C 35 cycles Extend 5 min 72°C J Final extension 10 min 72°C e-2. Additional Amplification [00308] One microliter ofthe multiplex overlap-extension RT-PCR reaction product, from each sample, is subjected to semi-nested PCR (Biotaq kit, Bioline, UK cat. No BIO-21040), essentially as proposed by the manufacturer utilizing 96 well plates.
- each reaction is 50 ⁇ l, containing a final concentration of lx Biotaq buffer, 200 ⁇ M dNTP's (of each), 2 mM MgCl 2 , 1.25 U Bio Taq polymerase and the primers shown in Table 9.
- Cycling conditions are as follows: Denature 30 sec 95°C Anneal 30 sec 55°C 30 cycles Extend 1.5 min 72°C Final extension 5 min 72°C Table 9
- the digested overlap-extension fragments are purified by preparative 1% agarose gel electrophoresis; the overlap-extension fragments are excised from the agarose gel and purified using a Qiaex II kit (Qiagen cat. No 20051 , Hilden, Germany). It is not necessary to pool the cognate pairs at this stage if this is not desired. In that case each individual reaction will be subjected to restriction cleavage and the products are cloned individually into the vector described below.
- Cognate Fab Expression Library [00313] A library of Fab vectors is generated by inserting the pool of Xhol/Notl digested overlap-extension fragments into E. coli vector JSK301 ( Figure 11) by ligation.
- TOP 10 transformation coli
- TOP 10 transformation coli
- Plasmid DNA is prepared from colonies directly off the agar plates.
- the plasmid preparation is derived from a minimum number of colonies per donor, corresponding to 3x the total number of single plasma cells originally sorted, in order to maintain diversity.
- An Fab expression library is generated by inserting a prokaryotic promoter and leader cassette derived from phh3 (Den, W. et al. 1999. J. Immunol.
- Methods 222, 45-57 into the resulting plasmid preparation by digesting the plasmid preparation with Ascl and Nhel and subsequent ligation.
- the library generation process is outlined in Figure 12.
- E. coli (TGI) is transformed by electroporation with the resulting Fab expression library and the transformants are selected on 2xYT agar containing 100 ⁇ g/ml carbenicillin. The individual donors are kept separate during the described procedure in Den etal, J Immunol Methods. 1999 Jan l;222(l-2):45-57. They can, however, be combined at any stage where this might be desired.
- Fab expressing clones are screened for TT antigen-binding by antigen-specific ELISA assays.
- g-1 Master Plate Generation and Fab Expression
- the master plates are used for inoculation of one or more 384 well plates containing 2 x YT/100 ⁇ g/mL Amp 0.1 % glucose using a 96 pin replicator. The plates are sealed and shaken for 2 - 3 h at 37°C.
- Fab expression is induced by adding an equal volume of 2 x YT/100 ⁇ g/mL Amp/ 0.2 mM IPTG, obtaining a final IPTG concentration of 0.1 mM. The plates are sealed and shaken overnight at 30°C. The following day, the Fab containing supematants are analyzed for TT antigen-binding specificity by ELISA. g-2. ELISA Analysis
- the Fab containing bacterial supematants from g-1. are diluted 1:2 in 2 % M-PBS-T, and transferred to the ELISA wells in duplicate. Incubation is performed for 1 h at RT. The wells are washed 4 times with PBS-T. Goat-anti-human Fab/ ⁇ RP (Sigma, St. Louis, MO, USA, cat. No A0293) 1:10.000 dilution in 2 % M-PBS-T is added to the wells. Incubation is performed for 1 h at RT. The wells are washed 4 times with PBS-T. TMB Plus (KemEnTec, Copenhagen, Denmark, cat.
- the clones may also be analyzed by an anti-light chain ELISA assay, in order to get a correlation between the number of antigen-binding clones and the number of Fab expressing clones. Further, such an analysis provides information of kappa and lambda light chain representation in the clones.
- the cognate variable regions from the bacterial Fab expression vector must be transferred to a mammalian expression vector containing the constant domains from one ofthe human immunoglobulin isotypes. Such a transfer can either be performed clone by clone or in mass. Below it is described how to perform the mass transfer.
- the mass transfer is performed in two steps. First, the plasmid preparations ofthe individually isolated antigen-binding Fab clones are pooled.
- the prokaryotic promoter and leader containing cassette is exchanged with a mammalian promoter and leader cassette consisting of human alkaline phosphatase leader sequence (AP Leader), human elongation factor 1 -alpha promoter (EFP), adenovims major late promoter (AdMLP), IgK leader sequence by digesting the pooled Fab expression sub-library with Ascl and Nhel followed by insertion of a mammalian promoter and leader cassette by a subsequent ligation.
- AP Leader human alkaline phosphatase leader sequence
- EFP human elongation factor 1 -alpha promoter
- AdMLP adenovims major late promoter
- IgK leader sequence by digesting the pooled Fab expression sub-library with Ascl and Nhel followed by insertion of a mammalian
- coli TOP 10
- TOP 10 transformations with the resulting promoter exchanged Fab expression library and the transformants are selected on 2xYT agar containing lOO ⁇ g/ml carbenicillin.
- Plasmid DNA is prepared from colonies directly off the agar plates.
- the plasmid preparation is derived from a minimum number of colonies per donor, corresponding to approximately 3x the total number of clones in the original library, in order to maintain diversity.
- the cognate variable regions from the promoter exchanged Fab expression vector are isolated by digesting the plasmid preparation with Xhol and Notl. The isolated fragment is inserted by ligation into a mammalian expression vector resulting in a cognate antibody expression library.
- the vector used is essentially the same as in Figure 9A, except that IgL in this case corresponds to the kappa light chain encoding sequence.
- the mammalian expression vector used above is based on the site-specific Flp-In system (Invitrogen
- E. coli (TOP10) is transformed by electroporation with the resulting cognate antibody expression library and the transformants are selected on 2xYT agar containing lOO ⁇ g/ml carbenicillin. Plasmid DNA is prepared from colonies directly off the agar plates. The plasmid preparation is again derived from a minimum number of colonies per donor, corresponding to approximately 3x the total number of clones in the original library, in order to maintain diversity. The resulting plasmid preparation ofthe cognate antibody expression library can be used to transfect a mammalian host cell , e.g.
- Example 7 Screening by High Density Membrane Assay [00325] The Fab expressing clones from Example 6 f are screened by a high density membrane assay. a. Master Plate Generation
- PVDF membranes (Amersham, Uppsala, Sweden, cat. NoRPN2020F) are coated according to the manufacturer's instmctions overnight at 4°C with TT antigen diluted to a final concentration of 1 ⁇ g/ml in PBS. Excess binding sites on the membranes are blocked for 1 h in 2 % M-PBS (2 % skim milk powder in PBS). The membranes are rinsed 3 times in PBS. The membranes are soaked in 2 x YT for a few minutes. c. Clone Consolidation
- Consolidation of clones into 384 well plates is performed by transferring clones from the master plates into one or more 384 well plates containing 20 ⁇ l 2 x YT/well, using a 96 pin replicator.
- the PVDF membranes prepared in step b are placed on a 2 x YT/Carb/0,1 mM IPTG agar plates.
- the nylon membranes with the growing bacterial colonies are placed on top of the PVDF membranes (one nylon membrane per PVDF membrane) on the IPTG-containing agar plate.
- the IPTG-containing agar plate is incubated at 30°C overnight to facilitate IPTG induced Fab expression from the colonies.
- the Fab molecules diffuse through the nylon membrane onto the PVDF membrane, where TT-antigen binding Fab's will be retained on the membrane. e.
- the nylon membranes are removed and the PVDF membranes are washed 2 x 5 minutes with PBS-T (PBS, 0.05 % Tween 20). The membranes are incubated for 30 minutes with 2 % M-PBS. The PVDF membranes are washed 2 x 5 minutes with PBS-T, followed by incubation for 1 h with goat-anti-human IgG/HRP (Sigma, St. Louis, MO, USA, cat. No A0293), 1 : 10.000 diluted in 2 % M-PBS. The PVDF membranes are washed 3 x 5 minutes with PBS-T.
- PBS-T PBS, 0.05 % Tween 20
- the PVDF membranes are washed 2 x 5 minutes with PBS-T, followed by incubation for 1 h with goat-anti-human IgG/HRP (Sigma, St. Louis, MO, USA, cat. No A0293), 1 : 10.000 diluted in 2 % M-PBS.
- the PVDF membranes are incubated for 5 minutes with SuperSignal West Femto chemiluminiscent substrate (Pierce, Rockford, II, USA, cat. No 34095) according to the manufactures instmctions. Excess substrate is removed and the PVDF membranes are placed under a CCD camera for detection ofthe chemiluminescent signal generated at positions on the PVDF membrane where a Fab fragment binds the TT-antigen. [00332] Positive TT-antigen binding clones will appear as dots on the image. The original bacterial clone is subsequently retrieved from the original master plates. Plasmid DNA is prepared from the isolated antigen positive Fab clones, generating a cognate Fab expression sub-library of TT-antigen binding clones. f. Correlation Between Antigen Binding Clones and Fab Expressing Clones
- step e. The nylon membranes removed in step e. are placed on a second series of PVDF membranes coated with anti-light chain antibody or anti-Fab antibody according to the procedure in step b. Step d. and e. are then repeated.
- Fab positive clones will then appear as dots on the image and a correlation between the number of TT-antigen binding clones and the number of Fab expressing clones can be made.
- Example 8 Illustrative Example Describing the Isolation of Sequences Encoding a Heteromeric Protein
- the present example illustrates how a trimeric guanine nucleotide binding protein (G-protein) can be isolated in a single step utilizing the multiplex overlap-extension RT-PCR technique ofthe present invention.
- G-protein trimeric guanine nucleotide binding protein
- the family of G-protein subunits is large, alone in humans there are approximately 16 different alpha subunits, 5 beta subunits and 12 gamma subunits.
- subunit G ⁇ S GenBank accession No X04408
- subunit G ⁇ 1 subunit G ⁇ 1
- RNA L kit Macherey - Nagel, D ⁇ ren, Germany, cat. No 740 962.20
- the Qiagen One-Step RT-PCR kit (Qiagen cat. No 210212, Hilden, Germany) is used for the multiplex overlap-extension RT-PCR essentially according to the manufacturer's recommendation.
- Each PCR tube contains, in a total volume of 50 ⁇ l, the following reagents: 1 x One Step RT-PCR buffer, dNTP's in a final concentration of 400 ⁇ M of each, Multiplex overlap-extension primer mix in the concentrations as indicated in table 10, 2 ⁇ l One step RT-PCR enzyme mix, 1 U/ ⁇ l RNase inhibitor (RNasin, Promega, Madison USA, cat. No N2515), and 50 ng total RNA.
- the multiplex overlap-extension primer mix used comprises the primers shown in table 10. Table 10
- reaction product is subjected to 1 % agarose gel electrophoresis using ethidium bromide for detection and the overlap-extension fragment of 2215 bp is excised from the agarose gel, purified using a Qiaex II kit (Qiagen, Hilden, Germany, cat. No 20051) and inserted into pCR2.1-TOPO using Invitrogen's TOPO TA cloning kit (Invitrogen cat. No 45-0641, Carlsbad, CA, USA).
- Qiaex II kit Qiagen, Hilden, Germany, cat. No 20051
- Invitrogen's TOPO TA cloning kit Invitrogen cat. No 45-0641, Carlsbad, CA, USA.
- promoter sequences or ribosome binding sites might be inserted upstream of each subunit encoding sequence in order to facilitate their expression from the vector.
- the restriction sites present in the overlap-extension sequences are applicable for such insertion.
- the linkage of sequences encoding subunits constituting a heteromeric protein, as described above, can be performed for most heteromeric proteins where the sequence ofthe individual subunits is known.
- a multiplex overlap-extension primer mixture capable of amplifying several members of a particular family, e.g.
- the above example can be performed utilizing template derived from isolated single liver cells employing a multiplex overlap-extension primer mix capable of amplifying and linking all 16 G ⁇ subunits with the 5 G ⁇ subunits and 12 G ⁇ subunits, thereby identifying which combination of subunits are expressed in each cell and simultaneously isolating the encoding sequences responsible for that combination of subunits.
- a multiplex overlap-extension primer mix capable of amplifying and linking all 16 G ⁇ subunits with the 5 G ⁇ subunits and 12 G ⁇ subunits, thereby identifying which combination of subunits are expressed in each cell and simultaneously isolating the encoding sequences responsible for that combination of subunits.
- degenerate primers might even serve to identify new members of a particular family.
- the overall size ofthe linked product should be considered, since there are limits to the number of base pairs a DNA polymerase can amplify.
- the Deep Vent polymerase from New England Biolabs, MA, USA is one DNA polymerase capable of generating very long primer extensions, of up to 14,000 bp in length. Theoretically, 14,000 bp can encode a protein with an average weight of 510 kDa.
- the extension capability could possibly be increased even further by utilizing mixtures of DNA polymerases.
- Hybrid sequences generated as a result of cross-priming, will be eliminated during intra-cellular processing ofthe antibody, in which the peptide leader containing the potential immunogenic sequences will be cleaved off, and hence will not be present in the secreted antibody product.
- Previous sets of leader primers for antibody cloning have been located in the 5' end ofthe leader encoding sequence, allowing for direct eukaryotic expression (Campbell M.J. et al. 1992 Mol Immunol. 29, 193-203). Unfortunately, eukaryotic leader peptides are poorly suited for prokaryotic processing.
- the basic concept ofthe primer design in the present example was to place the site of priming at the last six codons ofthe C-terminal region ofthe leader peptide.
- the remaining part ofthe leader encoding sequence, up-stream ofthe site of priming should be supplied by the appropriate expression vector matching the host species.
- vectors suitable for expression in gram negative bacteria can be designed with a partial or full-length PelB leader sequence.
- a vector with a partial native antibody heavy chain leader encoding sequence and a partial variable kappa chain leader encoding sequence will be suitable. Regardless of expression system, the last six amino acids ofthe leader, will originate from the endogenous antibody leader encoding sequence contained in the nucleic acid segment inserted into the vector.
- Capitalized sequences correspond to the gene-specific region.
- the restriction sites in this primer design were slightly modified compared to the primers described in the previous examples.
- the overlap sequence between the heavy chain and light chain variable region encoding sequences comprised a Notl and a Nhel restriction site, and in the constant kappa primer (C L ⁇ ) .
- the previous Notl site has been exchanged with an Ascl site.
- the later modification should of course be observed when designing the primers for the additional PCR amplification.
- the Notl site in the cloning vector, shown in Figure 11 should be changed to a Ascl site, and the Ascl site in the promoter unit should be changed to a Notl site.
- the chimeric leader peptides tested for the variable heavy chain were encoded by nucleic acid sequences composed of a truncated PelB sequence, a C-terminal Notl site (SEQ ID NO 100: ATG AAA TAT CTT CTA CCA ACA GCG GCA GCT GGA TTA TTG GCG GCC GCC), and in association with the Notl site the gene specific part of one of SEQ ID NO 86 to 92, encoding the six C-terminal amino acids from native VHL family members. All seven sequences showed signal peptide cleavage in gram negative bacteria, using the SignalP program.
- the chimeric leader peptides tested for the variable light chain were encoded by nucleic acid sequences composed of a truncated PelB sequence, a C-terminal Nhel site (SEQ ID NO 101 : ATG AAA TAT TTG CTA CCA ACA GCG GCA GCT GGA TTA TTG TTA CTA GCG), and in association with the Nhel site the gene specific part of one of SEQ ID NO 93 to 98, encoding the six C-terminal amino acids from native V L KL family members. All six sequences showed signal peptide cleavage in gram negative bacteria, using the SignalP program.
- sequences of SEQ ID NO 100 and 101 are suitable for the constmction of a bacterial expression vector similar to the one illustrated in Figure 11, in that the Ascl site illustrated in figure 11 is substituted with SEQ ID NO 100 and the Nhel site is substituted with SEQ ID NO 101. Further, the Notl site illustrated in figure 11 needs to be substituted for a Ascl site.
- the mammalian expression vector ( Figure 9) can likewise be re-designed to enable expression in mammalian cells following transfer ofthe variable region encoding segments from the bacterial vector just described.
- Example 10 One tube multiplex RT-PCR and linkage by ligation
- the present example illustrates how a cognate pair comprising linked heavy chain variable region and light chain variable region encoding sequences can be generated in a single tube reaction using ligation instead of overlap-extension PCR, to obtain linkage.
- each PCR tube contains the following reagents in a total volume of 20 ⁇ l: 1 x Phusion HF buffer dNTP's in a final concentration of 200 ⁇ M each Multiplex primer mix in the concentrations as indicated in table 12 0.8 U Phusion polymerase (FinnZymes Cat. No F-530-L) 1 ⁇ l Sensiscript reverse transcriptase (Qiagen Cat. No 205213 20 U Rnase inhibitor
- restriction enzymes and ligase are added directly to the multiplex RT-PCR reaction products.
- the multiplex RT-PCR can be purified prior to this addition in order to free the mixture from the polymerase.
- the following reagents are added to each tube in a total volume of 40 ⁇ l: l x NEBII buffer I mM ATP 50 U Xbal (New England Biolabs Cat. No R0145L) 25 U Spel (New England Biolabs Cat. No R0133S) 100 ⁇ g/ml BSA 400U T4 DNA ligase (New England Biolabs Cat. No M0202S) [00368] The reaction is incubated at 16°C over night.
- the linked heavy chain and light chain variable region encoding sequences are purified from the reaction by gel electrophoresis and excision ofthe band of approximately lOOObp.
- the multiplex RT-PCR reaction is performed with a C H primer instead ofthe J H primers in the multiplex primer set.
- This primer may either be equipped with a cloning tail that allows in-frame insertion ofthe heavy chain variable region into an expression vector, or a semi nested PCR may be performed with the primers of table 5.
- Example 11 Generation of a recombinant polyclonal immunoglobulin with specificity towards Tetanus Toxoid
- Tetanus vaccine Statens Serum Institut, Denmark. The donors were assigned with numbers TT01 to TT08. Six days after the Tetanus vaccine boost a blood sample of approximately 200 ml was drawn from the donors into a tube containing anticoagulant. [00373] The donors were healthy without chronic infections, autoimmune disease, or immunosuppressive medication, and they had not had any vaccinations within the last 3 months. a-l. Monitoring Donor Quality [00374] Pre-bleedings ofthe donors were taken at the time of immunization. Fourteen days later additional bleedings were taken to determine the serum titer.
- ELISPOT Assay for donor TT03 an ELISPOT was performed using the CD 19+ cell fraction (see section c). The ELISPOT assay was performed as described by Lakew (Lakew, M. et al. 1997. J. Immunol.
- PBMC Peripheral Blood Mononuclear Cells
- the B-cell lineage (CD19+ cells) ofthe PBMC's was enriched by magnetic bead cell sorting using the following procedure.
- the isolated PBMC ' s were stained with anti-CD 19-FITC (Becton Dickenson, NJ, USA, cat. No 345776). All steps were performed at 4°C in the dark. Staining was performed with 10 ⁇ l anti-CD 19-FITC pr. lxlO 6 cells in a volume of 100 ⁇ l per lxlO 6 cells using M-buffer (PBS, pH 7.2, 0.5% BSA, 2 mM EDTA). This will stain the B-cell lineage ofthe PBMC's.
- M-buffer PBS, pH 7.2, 0.5% BSA, 2 mM EDTA
- the anti-CD38/anti-CD45 plot showed a distinct population of CD38hi, CD45in cells (R2) corresponding to 1.1% of Rl. This population contained the plasma cells and was collected during the later sorting step. This indicated that in the PBMC fraction 0.12% ofthe cells corresponded to plasma cells.
- the CDl 9 positive cell fraction was frozen in FCS ( Invitrogen, Cat. No. 16000-044) +10% DMSO (Sigma, Cat. No. D2650) for later sorting.
- FCS Invitrogen, Cat. No. 16000-044
- DMSO Sigma, Cat. No. D2650
- An analysis like the one seen in Figure 14 was made on the MACS purified cells that had been frozen to make sure that the cells were intact ( Figure 15).
- the staining patterns seen in Figure 15 were the same as seen in Figure 14C although a slightly broader staining intensity were observed.
- the cells that were collected by sorting is the subset of Rl and R2. This corresponds to approx. 1.1 % ofthe MACS purified cells.
- the cells were sorted by fluorescence activated cell sorting (FACS) using the following gating parameters: 1. Forward scatter and side scatter in order to retain lymphocytes and monocytes including plasma blasters and plasma cells and to avoid dead cells and cells with very high side scatter which may be aggregates or granulocytes. 2. Cells that are CD 19 positive and express increased levels of CD38 (CD38hi) This is basically only a gate on CD38 since the PBMC s have been enriched on a MACS column for CD 19 expression, but this will disclose any contaminants. 3. CD45 intermediate positive cells. All lymphocytes express CD45. However, plasma cells down regulate their CD45 expression compared to earlier lymphocyte differentiation stages. Therefore, a discrete population of cells corresponding to plasma cells can be obtained when gating on CD45.
- FACS fluorescence activated cell sorting
- FACS sorted cells from donor TT03 were collected as the subset ofthe two gates P2 and PI ( Figure 16A and 16B, respectively).
- the cells were CD38hi (FL2-A), CD45in (FL3- A) and CD 19+, the latter due to the MACS purification. Briefly, the cells were collected in bulk, counted and diluted in RPMI (Invitrogen, Cat No. 21875-034) containing 10% FCS (Invitrogen Cat. No.16000-044), 100 units/ml Penicillin-streptomycin (Invitrogen, cat. No. 15140-122), 2mM L-glutamine (cat No. 25030-024).
- the multiplex overlap-extension RT-PCR technology was applied to the single cells obtained from donor TT03, thereby achieving cognate linkage of transcribed anti-Tetanus Toxoid heavy chain variable region and light chain variable region encoding sequences.
- Single-step Multiplex Overlap-extension RT-PCR [00387] The Qiagen One-Step RT-PCR kit (Qiagen cat. No 210212, Hilden, Germany) was used for the multiplex overlap-extension RT-PCR essentially according to the manufacturer's recommendation.
- the RT-PCR reaction mixture contained, in a total volume of 20 ⁇ l, the following reagents: 1 x One Step RT-PCR buffer dNTP's in a final concentration of 400 ⁇ M of each Multiplex overlap-extension primer mix in the concentrations as indicated in table 13 0.8 ⁇ l One-step RT-PCR enzyme mix 20 U RNase inhibitor (RNasin, Promega, Madison USA, cat. No N2515) [00389] The composition ofthe multiplex overlap-extension primer mix is shown in table 13. Table 13
- each reaction was 50 ⁇ l, containing a final concentration of lx Biotaq buffer, 200 ⁇ M dNTP's (of each), 2 mM MgCl 2 , 1.25 U Bio Taq polymerase and the primers shown in table 14.
- Table 14 The total volume of each reaction was 50 ⁇ l, containing a final concentration of lx Biotaq buffer, 200 ⁇ M dNTP's (of each), 2 mM MgCl 2 , 1.25 U Bio Taq polymerase and the primers shown in table 14.
- RT- PCR fragments were estimated to approximately 400.
- the purified pool of overlap PCR products was digested with Xhol and Notl and subsequently purified by preparative 1% agarose gel electrophoresis; the overlap-extension fragments are excised from the agarose gel and purified using a Qiaex II kit (Qiagen cat. No 20051, Hilden, Germany).
- Qiaex II kit Qiagen cat. No 20051, Hilden, Germany.
- a Fab expression library was generated by a two-step ligation procedure. Initially the pool of digested overlap-extension fragments described above was ligated into the Xhol/Notl digested E. coli vector JSK301 ( Figure 11). The ligation reaction was subsequently transformed into electrocompetent E.
- E. coli cells (XL 1 -Blue electroporation competent, Stratagen, cat. No. 200228, La Jolla, USA), according to manufactures instructions.
- the transformed E. coli cells were plated onto 2xYT agar containing lOO ⁇ g/ml carbenicillin. Biomass corresponding to approximately 10 10 -10 ⁇ cells originating from a number of independent colonies that exceeded at least 5 times the total number of overlap PCR products was used as starting material for plasmid preparation using Qiagen Plasmid preparation Maxi kit (Qiagen cat. No. 12163, Hilden, Germany).
- a prokaryotic promoter and leader cassette was inserted in a second ligation step.
- the used bi-directional promoter fragment (SEQ ID NO 321) was extracted from the parental JSK301 by Ascl/Nhel digestion.
- the purified pool of plasmids was likewise digested with Ascl /Nhel restriction endonucleases and gel purified as previously described.
- the purified fragments were subsequently ligated and transformed into electrocompetent E. coli cells (TGI, Stratagene, cat. No. 200123, La Jolla, USA) and plated on 2xYT agar containing lOO ⁇ g/ml carbenicillin, and 1% glycose.
- the Fab expression library generation process is outlined in Figure 12.
- Fab expressing clones were screened for TT antigen-binding by antigen-specific ELISA assays.
- g-1 Master Plate Generation and Fab Expression
- the masterplates were used for inoculation of 384 Deep Well plates containing 2 x YT/100 ⁇ g/ml Carb 0.1 % glucose using a 96 pin replicator. The plates were sealed and incubated for 2 - 3 h at 37°C with shaking.
- Fab expression was induced by adding an equal volume of 2 x YT/100 ⁇ g/ml Carb/ 0.2 mM IPTG, obtaining a final IPTG concentration of 0.1 mM. The plates were sealed and incubated overnight at 30°C with shaking. The following day, the Fab-containing supematants were analyzed for TT antigen-binding specificity by ELISA. g-2. ELISA Analysis
- the Fab-containing bacterial supematants from section (g-1) were diluted 1:2 in 2 % M-PBS-T, and transferred to the ELISA wells in duplicate. Incubation was performed for 1 h at RT. The wells were washed 4 times with PBS-T. Goat-anti-human Fab/HRP (Sigma, St. Louis, MO, USA, cat. No A0293) 1:10.000 dilution in 2 % M-PBS-T was added to the wells. Incubation was performed for 1 h at RT. The wells were washed 4 times with PBS-T. TMB Plus (KemEnTec, Copenhagen, Denmark, cat.
- the original bacterial clones corresponding to TT antigen-binding clones may subsequently be retrieved from the original master plates.
- Plasmid DNA can be prepared from the isolated antigen positive Fab clones, generating a cognate Fab expression sub- library of TT antigen-binding clones.
- a subset ofthe clones were further analyzed by an anti-kappa ELISA assay, in order to get a correlation between the number of antigen-binding clones and the number of Fab expressing clones.
- the anti-kappa assay was generally performed as the TT-assay, except that the wells were coated with a 1:1000 dilution of goat anti-human kappa antibody (Caltag, California, USA, Cat. No H16000), using a carbonate buffer, pH 9.6. g-3. Screening results [00404] Clones from four 384 well plates were screened for reactivity with anti-kappa Ab and TT using ELISA assays according to the procedure described in g-2.
- the results obtained results are summarized in the tables 15 through 19.
- the anti-kappa ELISA results inform about the expression of Fab fragments in a given clone
- the TT ELISA results inform about the functionality ofthe Fab fragments.
- Table 15 ELISA screening, anti-kappa coat (1440 clones in total)
- the resulting sequence data ofthe heavy chain was trimmed to one base pair 5' ofthe upstream Ascl restriction site and immediately 3' ofthe downstream Xhol restriction site.
- the light chain sequence data was trimmed to the second 5' base pair ofthe upstream Nhel restriction site and 3' ofthe last codon "AAA" encoding the variable chain C-terminal lysine. The trimming was performed in order to facilitate further analysis such as translation of each DNA sequence.
- variable heavy and light chain encoding sequences were analyzed for germline gene usage by comparing the sequences to the V-base germline variable region sequence database (MRC Centre for Protein Engineering, Cambridge, UK). The closest related germline allele was thus determined for each sequence showing a V-gene repertoire originating from 12 different variable heavy chain germline alleles belonging to VH-family VH1 through VH5 and 8 different variable kappa light chain germline alleles belonging to VKI, VKIII and VKIV (Table 20).
- the variable gene sequences were translated into protein sequences which were aligned using the AlignX software (Informax, Frederick, MD, USA) as depicted in Figure 22 and Figure 23.
- variable chain sequences could be categorized into groups according to V(D)J rearrangement events, designated with H for the variable heavy chain sequence and L for the variable kappa chain sequence followed by a unique number.
- the sequences were categorized according to the maturation genotype (M-type in table 20) within the CDR1, 2 and 3 regions, represented by a lower case letter in alphabetical order.
- the 47 analyzed V-region sequences could be divided into 20 unique V(D)J rearrangement groups (designated "groups" in table 20) both for the variable heavy and variable kappa gene.
- Four ofthe rearrangement groups could further be divided into 1 to 4 maturation types (a through d), resulting in 27 unique antibody encoding sequences (Table 12).
- specific heavy chain rearrangement groups combine with specific light chain rearrangement groups (e.g. HI with Ll, H12 with L24 and so forth).
- the maturation type match among pairs of variable heavy chain and the variable light encoding sequences (e.g. H4c match with L13c).
- Such stringency in paring among rearrangement groups and maturation types indicating cognate paring ofthe variable region encoding sequences.
- heavy chain rearrangement group H4 is an exception. H4 pairs with two different light chains L28 and L13. L13 was unique to H4, comprising maturation types a, b and c that matches with L13 maturations types. L28, on the other hand, was also found paired with the single member in heavy chain group H2. Two out of seven H4a heavy chain sequences pair with heavy chain L13a and five out of seven H4a heavy chain sequences pair with L28a. In summary, these observations suggested a multiplex overlap-extension RT-PCR event where two TT-specific antibody producing plasma cells, with the genotype combinations H2-L28 and H4a-L13a, were present in a single well.
- variable heavy chain and variable light chain encoding sequences from the same group and maturation type is at least 90 % and preferably at least 95 %. Take for example g060g03 and g060a01 from group HI maturation type a. Clone g060g03 correspond to nucl. SEQ ID pair 168:215, where the variable heavy chain encoding sequence correspond to SEQ ID NO 168 and the variable light chain encoding sequences correspond SEQ ID NO 215.
- Clone g060a01 correspond to nucl. SEQ ID pair 133:180.
- SEQ ID NO 168 is aligned with SEQ ID NO 133 (the variable heavy chains) 4/369 bases are not identical and for the variable lights chains (SEQ ID NOs 215 and 180) 8/327 bases are not identical, this correspond to a sequence identity of 98.3 % between these two cognate pairs (g060g03 and g060a01).
- sequence identity 98.3 % between these two cognate pairs (g060g03 and g060a01).
- the lowest identity among the cognate pairs is approximately 40 % (e.g. g060bl 1 and g060hl 1 have a sequence identity of 39.5%).
- One embodiment ofthe present invention is a sub-library of cognate pairs of immunoglobulin heavy chain variable region and light chain variable region encoding sequences, where the immunoglobulins obtainable from said library are capable of reacting with or binding to Tetanus Toxin.
- a further embodiment ofthe present invention is such a sub-library of cognate pairs of immunoglobulin heavy chain variable region and light chain variable region encoding sequences, comprising individual cognate pairs with at least 90 % sequence identity with one individual SEQ ID pair, selected from the group consisting of SEQ ID pairs 135:182,
- a competition assay was set up in order to determine the apparent affinity or IC 50 of selected clones from plate G060.
- Fab fragments were expressed in 50 ml cultures as follows: 50 ml 2 x YT/100 ⁇ g/ml Carb/ 0.1 % glucose was added 0.5 ml overnight culture, and shaken for approximately 2 h at 37°C. IPTG was added to a final concentration of 0,1 mM, and shaking was continued overnight at 30°C. The next day, the bacteria were collected by centrifugation at 4000 rpm for 15 minutes, and the pellet was resuspended in 1 ml 0.8 mM EDTA, 0.4 x PBS, 0.8 M NaCI, and incubated on ice for 15 minutes. The periplasmic extract was collected by centrifugation, and stored at -20°C.
- the competition assay was performed as follows: the periplasmic extracts in appropriate dilutions estimated by titration were added to a series of tubes.
- the phage display derived Fab fragment mp584 derived from the human hybridoma cell line HB8501 expressing an anti-TT antibody was used.
- Soluble TT was added to the first tube at 100 nM concentration, and subsequently diluted at four-fold steps in the following tubes, making a total of seven dilutions of TT (from 100 nM to 25 pM).
- the reactions were incubated for approximately 45 minutes at room temperature.
- the samples were transferred to ELISA plates coated with TT at 1 ⁇ g/ml, and blocked as previously described.
- the Fab fragments have apparent affinities in the lower nano- molar or upper pico-molar range. Furthermore, all cognate paired Fab fragments exhibit a higher apparent affinity than that ofthe phage display derived Fab fragment.
- j. Summary [00428] In donor TT03 the frequency of TT specific plasma cells in the peripheral blood monocyte cell fraction was calculated to 0.022% . Approximately 400 cognate pairs were generated from TT03. 3600 clones from the cells transformed with the cognate pair library were screened using ELISA, of these 339 clones showed TT reactivity in the ELISA screening. 47 of these clones have been analysed with respect to their clonal diversity.
- the Tetanus Toxin is one ofthe most toxic substances known with a lethal dose of a few nanogram.
- the toxin is produced by Clostridium tetani, a soil bacteria also present in the digestive tract of up to 25% of humans.
- Clostridium tetani a soil bacteria also present in the digestive tract of up to 25% of humans.
- the tetanus immunization program has effectively abolished the disease in the western world, although 100-200 cases are still observed in the major western countries annually, with a case-fatality ratio of 50%. In the developing world the number of cases is significantly greater. Bacterial growth in contaminated penetrating wounds may lead to toxin release, ultimately leading to rigidity, spasms, respiratory arrest and death.
- Hyperimmune immunoglobulin products isolated from human blood donors with a high titer of antibody response against Tetanus Toxoid may be used to prevent tetanus or if instituted early to treat established tetanus, also in conjunction with active immunization.
- equine hyperimmune anti-Tetanus Toxoid is used in the developing world.
- Recombinant monoclonal or polyclonal antibodies against Tetanus Toxoid have potential to substitute hyperimmune globulin products for therapeutic and/or prophylactic use.
- One embodiment ofthe present invention is a recombinant polyclonal immunoglobulin or fragments thereof capable of reacting with or binding to Tetanus Toxin.
- a preferred embodiment ofthe present invention is a recombinant polyclonal immunoglobulin capable of reacting with or binding to Tetanus Toxin comprised of cognate pairs of immunoglobulin heavy chain variable region and light chain variable region.
- a further embodiment ofthe present invention is a recombinant polyclonal immunoglobulin capable of reacting with or binding to Tetanus Toxin obtained by the method according to the present invention.
- a further embodiment ofthe present invention is a recombinant polyclonal immunoglobulin capable of reacting with or binding to Tetanus Toxin comprising individual cognate pairs of immunoglobulin heavy chain variable region and light chain variable region with at least 90 % sequence identity with one individual SEQ ID pair, selected among SEQ ID pairs 229:276, 262:309, 240:287, 245:292, 267:314, 246:293, 258:305, 242:289, 231:278, 263:310, 232:279, 237:284, 255:302, 260:307, 251:298, 233:280, 228:275, 244:291, 250:297, 252:299, 264:311, 272:319, 235:282 or 238:285.
- Another embodiment ofthe invention is a pharmaceutical composition
- a pharmaceutical composition comprising a recombinant polyclonal antibody capable of reacting with or binding to Tetanus Toxin as active ingredient intended for the treatment or prevention of a tetanus.
- the recombinant polyclonal antibody is combined with a pharmaceutically acceptable excipient.
- a further embodiment ofthe present invention is the use of a recombinant polyclonal immunoglobulin capable of reacting with or binding to Tetanus Toxin as a medicament for the treatment or prophylactic protection of a patient at risk of developing tetanus.
- An additional embodiment is a method of preventing or treating a patient at risk of developing tetanus by administering to a patient in need thereof a composition comprising a recombinant polyclonal antibody capable of reacting with or binding to Tetanus Toxin.
- Example 12 Comparing results obtained from two donors [00438] In the following example results obtained from donor TT08 are compared with the results obtained from donor TT03 in Example 11. The results are summarized in table 22. Table 22
- Example 13 Comparing the library of cognate pairs from Example 11 with a combinatorial phage display library generated from the same donor
- a combinatorial phage display library was prepared from the same donor previously used to prepare the library of cognate pairs, in order to compare library diversity, affinity and specificity between libraries of cognate pairs and combinatorial libraries.
- a. Combinatorial phage library construction [00442] A phage display library was generated from the CD19 + fraction of cells from donor TT03 (identical to the cell fraction obtained in Example l ie). [00443] Total RNA was prepared from app. 5x10 6 CD19 + cells using NucleoSpin RNA L kit (Machery-Nagel cat. no. 740 962.20).
- cDNA was subsequently synthesized in an oligo(dT)- primed reaction using ThermoScript reverse transcriptase (Invitrogen cat. no. 11146-016).
- ThermoScript reverse transcriptase Invitrogen cat. no. 11146-016
- the VH and Kappa chains were PCR amplified using HotMasterTaq DNA polymerase (Eppendorf cat. no. 0032 002.692) and primers essentially as described by de Haard et al. (J. Biol. Chem. 274, 18218-18230; 1999), only modified with respect to restriction enzyme recognition sequences in the 5 '-end.
- the combinatorial phage display library was generated by successive insertion of Kappa and V H PCR products into Em351 phage display vector (modified from phh3 described in Den,W. et al. 1999 J. Immunol. Methods 222, 45-57).
- the final library was electroporated into TGI E.coli strain (Stratagene).
- the size of the combinatorial library contained 3 x 10 6 independent clones with a high insert frequency.
- Fab displaying phage particles were prepared according to standard procedures (e.g.
- Panning was performed on tetanus toxoid (TT; SSI batch no. 89-2) diluted to 1 ⁇ g/mL in PBS, and immobilized in MaxiSorp immunotubes (Nunc cat. no. 444202). Following a one hour incubation period and several washing steps, bound phage particles were eluted using
- TGI cells from which Fab displaying phage particles enriched for TT specificity were obtained.
- a second round of panning using the eluted phages was performed following the general procedure outlined above.
- Panning ofthe phage display library against TT revealed an increasing number of TT specific clones when increasing the number of panning rounds, and only a few clones were identified in the unselected library. No clones were found to be reactive with the teatanus toxoid C-fragment from the unselected library or after two rounds of panning ofthe library against TT. To obtain Fab fragments with C-fragment specificity from the combinatorial phage display library, this library had to be panned against the C-fragment specifically. [00454] For comparison, thirteen TT-specific clones from Example 11 were subjected to C- fragment-specific ELISA, of these seven showed reactivity above 2 x background.
- Fab fragments with specificity towards the tetanus toxin C-fragment could be expressed from a library of cognate pairs obtained from a TT-immunized individual.
- apparent affinities ofthe combinatorial clones were measured as described in the assay of Example Hi. Ten ofthe combinatorial clones obtained after two rounds of panning on TT were analyzed, revealing apparent binding affinities between 1 and 15 nM. [00457] For comparison four ofthe nine clones analyzed from the library of cognate pairs (table 21), showed affinities in the pico-molar range.
- V H and V L sequence pairs from the library of cognate pairs show a clustered appearance indicating co-evolution of V genes as expected for cognate pairs. Also, the genetic diversity is much greater for the V-genes in the library of cognate pairs compared to the V-genes from the combinatorial library, indicating that the method of isolating cognate paired V-genes is less biased.
- Example 14 Combined Single-step Multiplex Overlap-extension RT-PCR and Nested PCR Using T-cells as Template Source
- a blood sample is obtained from human donors who have been subjected to the desired antigen, for example by immunization, natural infection, malignancy, through an autoimmune reaction, or other diseases.
- the peripheral blood mononuclear cells (PBMC's) are isolated using Lymphoprep (Axis-Shield, Oslo Norway, prod. No 1001967) according to the manufacturer's instructions.
- antigen-specific T cells are generated by further stimulation of the PBMC fraction.
- the multiplex overlap-extension RT-PCR can also be performed directly on single cells from the PBMC fraction or on a cell fraction enriched for T cells (e.g. by FACS-sorting for CD3-positive cells).
- the PBMC cell fraction is re-suspended in an appropriate culture medium containing relevant cytokines such as IL2. Further, the desired antigen is added to the culture, where it will be presented to the T lymphocytes by antigen presenting cells (APC) present in the PBMC fraction.
- APC antigen presenting cells
- APC feeder cells treated in beforehand such that they are presenting the desired antigen may be added to the PBMC fraction.
- Such APC feeder cells can be APC exposed to the desired antigen in the form of for example peptide, protein or other molecular form, or microbially infected APC or cells transfected to express and present the antigen, or APC co-cultured with other antigenic cells, e.g. such as cancer cell in the form of primary tissue or cell lines.
- Many different types of APC feeder cell are known from the literature, including transformed cell lines, B cell lines, dendritic cells, etc.
- the PBMC fraction is cultivated for approximately 3 to 5 weeks, during which fresh antigen presenting cells are added together with cytokines, e.g. on a weekly basis. This results in T lymphocyte proliferation, activation and maturation. At the end ofthe cultivation period the cell culture will be dominated by antigen-specific T cells. Whether these cells are CD4+ or CD8+ depends on the disease, the antigen, the APC cells, and the cytokine mixtures used during the stimulation period.
- the antigen specificity can for example be tested with a CTL assay, proliferation assays and MHC tetramers loaded with the desired antigen (Altman, J.D., et al. 1996. Science 274, 94-96).
- the antigen-specific T cells are distributed to PCR tubes, either by limiting dilution or using a FACS in order to obtain a single cell pr. vessel. The vessel can be stored at -80°C until use.
- the Qiagen One-Step RT-PCR kit (Qiagen cat. No 210212, Hilden, Germany) is used for the multiplex overlap-extension RT-PCR essentially according to the manufacturer's recommendation. Before addition of PCR reaction mixture to the PCR tubes, the cells are thawed. I l l [00468] PCR reaction mixtures and cycling conditions are initially set up as described in
- Example 11 e-1 However, a certain amount of optimization may be expected for a new set of primers.
- the multiplex overlap-extension primer mix used comprise the primers shown in table 26. Table 26
- constant region primers (SEQ ID NO 376 and 377) used in the semi-nested PCR are designed for sub-cloning of semi-nested PCR product into a suitable vector.
- the design ofthe C ⁇ primer relies on changing a SER to Met at pos. 21 in the ⁇ chain constant region peptide, whereby aNsil site can be introduced into the nucleic acid sequence: Nsil tec cac -> atg cat
- Suitable vectors will therefore contain the remaining parts ofthe constant regions of the TcR ⁇ and ⁇ chains and will contain appropriate modification in terms of restriction sites.
- variable region primers may potentially interact in an inhibitory manner during the multiplex overlap-extension PCR amplification. To avoid this, variable region primers may be divided into sub-sets and used separately in proper combinations.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK04762853T DK1670912T3 (en) | 2003-09-18 | 2004-09-17 | Method of linking sequences of interest |
EP04762853A EP1670912B1 (en) | 2003-09-18 | 2004-09-17 | Method for linking sequences of interest |
US10/572,431 US7749697B2 (en) | 2003-09-18 | 2004-09-17 | Method for linking sequences of interest |
NZ545936A NZ545936A (en) | 2003-09-18 | 2004-09-17 | Method for linking variable region encoding sequences using multiplex molecular amplification using a template derived from a single cell |
BRPI0414282-9A BRPI0414282A (en) | 2003-09-18 | 2004-09-17 | method for binding sequences of interest |
DE602004012299T DE602004012299T2 (en) | 2003-09-18 | 2004-09-17 | METHOD FOR CONNECTING INTERESTING SEQUENCES |
CN2004800270289A CN1856571B (en) | 2003-09-18 | 2004-09-17 | Method for linking sequences of interest |
JP2006526523A JP4651619B2 (en) | 2003-09-18 | 2004-09-17 | Method for concatenating desired sequences |
AU2004286019A AU2004286019B2 (en) | 2003-09-18 | 2004-09-17 | Method for linking sequences of interest |
SI200430728T SI1670912T1 (en) | 2003-09-18 | 2004-09-17 | Method for linking sequences of interest |
KR1020067005488A KR101135134B1 (en) | 2003-09-18 | 2004-09-17 | Method for linking sequences of interest |
CA002539576A CA2539576A1 (en) | 2003-09-18 | 2004-09-17 | Method for linking sequences of interest |
PL04762853T PL1670912T3 (en) | 2003-09-18 | 2004-09-17 | Method for linking sequences of interest |
IL173688A IL173688A (en) | 2003-09-18 | 2006-02-13 | Method for linking sequences of interest |
NO20061373A NO20061373L (en) | 2003-09-18 | 2006-03-27 | Procedure for linking interesting sequences |
IS8415A IS2583B (en) | 2003-09-18 | 2006-04-12 | A method of connecting interesting sequences |
HK06107567A HK1085513A1 (en) | 2003-09-18 | 2006-07-05 | Method for linking sequences of interest |
HR20080197T HRP20080197T8 (en) | 2003-09-18 | 2008-04-30 | Method for linking sequences of interest |
US12/788,202 US20100310558A1 (en) | 2003-09-18 | 2010-05-26 | Method for Linking Sequences of Interest |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50458903P | 2003-09-18 | 2003-09-18 | |
US50445503P | 2003-09-18 | 2003-09-18 | |
US60/504,589 | 2003-09-18 | ||
US60/504,455 | 2003-09-18 | ||
DKPA200301867 | 2003-12-17 | ||
DKPA200301867 | 2003-12-17 | ||
DKPA200400782 | 2004-05-15 | ||
DKPA200400782 | 2004-05-15 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/788,202 Division US20100310558A1 (en) | 2003-09-18 | 2010-05-26 | Method for Linking Sequences of Interest |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005042774A2 true WO2005042774A2 (en) | 2005-05-12 |
WO2005042774A3 WO2005042774A3 (en) | 2005-06-09 |
Family
ID=44209637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2004/000633 WO2005042774A2 (en) | 2003-09-18 | 2004-09-17 | Method for linking sequences of interest |
Country Status (18)
Country | Link |
---|---|
US (2) | US7749697B2 (en) |
EP (3) | EP1516929A3 (en) |
JP (1) | JP4651619B2 (en) |
CN (2) | CN1856571B (en) |
AT (2) | ATE537256T1 (en) |
AU (1) | AU2004286019B2 (en) |
BR (1) | BRPI0414282A (en) |
CA (1) | CA2539576A1 (en) |
DE (1) | DE602004012299T2 (en) |
DK (2) | DK1921144T3 (en) |
ES (2) | ES2302542T3 (en) |
MY (1) | MY148907A (en) |
NZ (1) | NZ545936A (en) |
PL (2) | PL1921144T3 (en) |
PT (2) | PT1921144E (en) |
SI (2) | SI1921144T1 (en) |
TW (1) | TWI333977B (en) |
WO (1) | WO2005042774A2 (en) |
Cited By (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007065433A2 (en) | 2005-12-05 | 2007-06-14 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
EP1910513A1 (en) * | 2005-07-01 | 2008-04-16 | John Schrader | Methods of isolating cells and generating monoclonal antibodies |
WO2008104184A2 (en) | 2007-03-01 | 2008-09-04 | Symphogen A/S | Method for cloning cognate antibodies |
EP1967529A1 (en) | 2004-07-20 | 2008-09-10 | Symphogen A/S | Anti-rhesus D recombinant polyclonal antibody and methods of manufacture |
EP1997892A1 (en) | 2007-05-25 | 2008-12-03 | Symphogen A/S | Screening for expressible transfectants in a eukaryotic system |
WO2008145133A2 (en) | 2007-05-25 | 2008-12-04 | Symphogen A/S | Method for manufacturing a recombinant polyclonal protein |
US7504106B2 (en) | 2006-03-14 | 2009-03-17 | Boris Skurkovich | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis |
WO2010022738A1 (en) * | 2008-08-29 | 2010-03-04 | Symphogen A/S | Method for cloning avian-derived antibodies |
WO2010097435A1 (en) | 2009-02-25 | 2010-09-02 | Ucb Pharma, S.A. | Method for producing antibodies |
WO2010097437A1 (en) | 2009-02-25 | 2010-09-02 | Ucb Pharma, S.A. | Method for producing antibodies |
WO2010136598A1 (en) | 2009-05-29 | 2010-12-02 | Morphosys Ag | A collection and methods for its use |
US7879329B2 (en) | 2007-03-06 | 2011-02-01 | Symphogen A/S | Recombinant antibodies for treatment of respiratory syncytial virus infections |
US7887805B2 (en) | 2007-03-01 | 2011-02-15 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
EP2336328A1 (en) * | 2005-03-25 | 2011-06-22 | National Research Council of Canada | Method for isolation of soluble polypeptides |
WO2011102554A1 (en) * | 2010-02-18 | 2011-08-25 | Meiji Seika Kaisha, Ltd. | Antibody against serotype b lipopolysaccharide of pseudomonas aeruginosa |
WO2012066129A1 (en) | 2010-11-19 | 2012-05-24 | Morphosys Ag | A collection and methods for its use |
WO2012068317A2 (en) | 2010-11-16 | 2012-05-24 | Excelimmune, Inc. | Methods for producing recombinant proteins |
WO2012072705A1 (en) | 2010-12-01 | 2012-06-07 | Morphosys Ag | Simultaneous detection of biomolecules in single cells |
US8288109B2 (en) | 2004-07-20 | 2012-10-16 | Symphogen A/S | Procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line |
US8507205B2 (en) | 2008-11-07 | 2013-08-13 | Sequenta, Inc. | Single cell analysis by polymerase cycling assembly |
US8563305B2 (en) | 2009-04-30 | 2013-10-22 | Oklahoma Medical Research Foundation | Rapid generation of antibodies |
US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
US8663640B2 (en) | 2008-08-29 | 2014-03-04 | Symphogen A/S | Methods using recombinant anti-epidermal growth factor receptor antibody compositions |
US8691510B2 (en) | 2008-11-07 | 2014-04-08 | Sequenta, Inc. | Sequence analysis of complex amplicons |
CN103820430A (en) * | 2013-12-19 | 2014-05-28 | 河南科技大学 | Overlapping extension PCR (Polymerase Chain Reaction) method of DNA (Deoxyribonucleic Acid) fragment taking DNA with high GC (Gas Chromatography) content or complex structure as template |
US8748103B2 (en) | 2008-11-07 | 2014-06-10 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
US9043160B1 (en) | 2009-11-09 | 2015-05-26 | Sequenta, Inc. | Method of determining clonotypes and clonotype profiles |
US9150905B2 (en) | 2012-05-08 | 2015-10-06 | Adaptive Biotechnologies Corporation | Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions |
US9163232B2 (en) | 2003-01-07 | 2015-10-20 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
US9181590B2 (en) | 2011-10-21 | 2015-11-10 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
CN105087560A (en) * | 2015-08-07 | 2015-11-25 | 深圳市瀚海基因生物科技有限公司 | Multiplex PCR primers and method based on high-throughput sequencing to build pig BCR heavy chain library |
WO2016042412A1 (en) | 2014-09-16 | 2016-03-24 | Symphogen A/S | Anti-met antibodies and compositions |
US9365901B2 (en) | 2008-11-07 | 2016-06-14 | Adaptive Biotechnologies Corp. | Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia |
US9499865B2 (en) | 2011-12-13 | 2016-11-22 | Adaptive Biotechnologies Corp. | Detection and measurement of tissue-infiltrating lymphocytes |
US9506119B2 (en) | 2008-11-07 | 2016-11-29 | Adaptive Biotechnologies Corp. | Method of sequence determination using sequence tags |
US9528160B2 (en) | 2008-11-07 | 2016-12-27 | Adaptive Biotechnolgies Corp. | Rare clonotypes and uses thereof |
EP3156421A1 (en) | 2010-11-01 | 2017-04-19 | Symphogen A/S | Pan-her antibody composition |
US9670483B2 (en) | 2011-07-12 | 2017-06-06 | Xbiotech, Inc. | Immunoglobulin variable region libraries |
US9708657B2 (en) | 2013-07-01 | 2017-07-18 | Adaptive Biotechnologies Corp. | Method for generating clonotype profiles using sequence tags |
US9708654B2 (en) | 2012-06-15 | 2017-07-18 | Board Of Regents, The University Of Texas System | High throughput sequencing of multiple transcripts |
US9809813B2 (en) | 2009-06-25 | 2017-11-07 | Fred Hutchinson Cancer Research Center | Method of measuring adaptive immunity |
US9816088B2 (en) | 2013-03-15 | 2017-11-14 | Abvitro Llc | Single cell bar-coding for antibody discovery |
US9824179B2 (en) | 2011-12-09 | 2017-11-21 | Adaptive Biotechnologies Corp. | Diagnosis of lymphoid malignancies and minimal residual disease detection |
WO2018091661A1 (en) | 2016-11-18 | 2018-05-24 | Symphogen A/S | Anti-pd-1 antibodies and compositions |
US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
US10077478B2 (en) | 2012-03-05 | 2018-09-18 | Adaptive Biotechnologies Corp. | Determining paired immune receptor chains from frequency matched subunits |
US10150996B2 (en) | 2012-10-19 | 2018-12-11 | Adaptive Biotechnologies Corp. | Quantification of adaptive immune cell genomes in a complex mixture of cells |
US10221461B2 (en) | 2012-10-01 | 2019-03-05 | Adaptive Biotechnologies Corp. | Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization |
US10246701B2 (en) | 2014-11-14 | 2019-04-02 | Adaptive Biotechnologies Corp. | Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture |
US10309969B2 (en) | 2013-01-24 | 2019-06-04 | Abtlas Co., Ltd. | Protein combination-based FV library, and preparation method therefor |
US10323276B2 (en) | 2009-01-15 | 2019-06-18 | Adaptive Biotechnologies Corporation | Adaptive immunity profiling and methods for generation of monoclonal antibodies |
US10385475B2 (en) | 2011-09-12 | 2019-08-20 | Adaptive Biotechnologies Corp. | Random array sequencing of low-complexity libraries |
US10392663B2 (en) | 2014-10-29 | 2019-08-27 | Adaptive Biotechnologies Corp. | Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from a large number of samples |
US10428325B1 (en) | 2016-09-21 | 2019-10-01 | Adaptive Biotechnologies Corporation | Identification of antigen-specific B cell receptors |
US10513733B2 (en) | 2015-03-23 | 2019-12-24 | Board Of Regents, The University Of Texas System | High throughout sequencing of paired VH and VL transcripts from B cells secreting antigen-specific antibodies |
US10590483B2 (en) | 2014-09-15 | 2020-03-17 | Abvitro Llc | High-throughput nucleotide library sequencing |
US11041202B2 (en) | 2015-04-01 | 2021-06-22 | Adaptive Biotechnologies Corporation | Method of identifying human compatible T cell receptors specific for an antigenic target |
US11047008B2 (en) | 2015-02-24 | 2021-06-29 | Adaptive Biotechnologies Corporation | Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing |
US11066705B2 (en) | 2014-11-25 | 2021-07-20 | Adaptive Biotechnologies Corporation | Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing |
US11248253B2 (en) | 2014-03-05 | 2022-02-15 | Adaptive Biotechnologies Corporation | Methods using randomer-containing synthetic molecules |
US11254980B1 (en) | 2017-11-29 | 2022-02-22 | Adaptive Biotechnologies Corporation | Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements |
EP4105235A1 (en) | 2015-10-02 | 2022-12-21 | Symphogen A/S | Anti-pd-1 antibodies and compositions |
WO2023213787A1 (en) | 2022-05-02 | 2023-11-09 | Aarhus Universitet | Antibodies for prophylaxis or treatment of sars- cov-2 infections |
US11820979B2 (en) | 2016-12-23 | 2023-11-21 | Visterra, Inc. | Binding polypeptides and methods of making the same |
US11866785B2 (en) | 2017-10-27 | 2024-01-09 | Board Of Regents, The University Of Texas System | Tumor specific antibodies and T-cell receptors and methods of identifying the same |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE474915T1 (en) * | 2003-11-19 | 2010-08-15 | Us Gov Health & Human Serv | METHOD FOR INDUCING DEVELOPMENT AND TERMINAL DIFFERENTIATION OF MEMORY B CELLS |
EP1707628B1 (en) * | 2005-03-30 | 2009-11-11 | Sekisui Chemical Co., Ltd. | Methods for producing recombinant polyclonal immunoglobulins |
MX2008011280A (en) * | 2006-03-06 | 2008-09-12 | Symphogen As | Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections. |
RU2010113510A (en) * | 2007-09-07 | 2011-10-20 | Симфоген А/С (Dk) | METHODS FOR RECOMBINANT PRODUCTION OF ANTIBODIES AGAINST RESPIRATORY-CINCITIAL VIRUS (RSV) |
US8268564B2 (en) * | 2007-09-26 | 2012-09-18 | President And Fellows Of Harvard College | Methods and applications for stitched DNA barcodes |
US7792057B2 (en) * | 2007-12-21 | 2010-09-07 | At&T Labs, Inc. | Method and system for computing multicast traffic matrices |
WO2010000864A1 (en) * | 2008-07-04 | 2010-01-07 | Novo Nordisk A/S | Method for producing monoclonal antibodies |
BRPI0920032A2 (en) * | 2008-10-06 | 2017-06-27 | Symphogen As | method for identifying and selecting drug candidates for combinatorial pharmacological products |
DK2625295T3 (en) | 2010-10-08 | 2019-06-11 | Harvard College | HIGH-THROUGHPUT-IMMUNE SEQUENCING |
EP2632947A4 (en) * | 2010-10-29 | 2015-03-18 | Immunogen Inc | Non-antagonistic egfr-binding molecules and immunoconjugates thereof |
AU2011320314B2 (en) | 2010-10-29 | 2015-08-06 | Immunogen, Inc. | Novel EGFR-binding molecules and immunoconjugates thereof |
US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
EP2652155B1 (en) * | 2010-12-16 | 2016-11-16 | Gigagen, Inc. | Methods for massively parallel analysis of nucleic acids in single cells |
EP3961214A1 (en) * | 2010-12-31 | 2022-03-02 | BioAtla, Inc. | Comprehensive monoclonal antibody generation |
WO2012104851A1 (en) * | 2011-01-31 | 2012-08-09 | Yeda Research And Development Co. Ltd. | Methods of diagnosing disease using overlap extension pcr |
US20230287392A1 (en) * | 2011-04-28 | 2023-09-14 | The Board Of Trustees Of The Leland Stanford Junior University | Identification of Polynucleotides Associated with a Sample |
CA2833917C (en) * | 2011-04-28 | 2020-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Identification of polynucleotides associated with a sample. |
WO2012174214A1 (en) | 2011-06-15 | 2012-12-20 | The Regents Of The University Of California | High resolution analysis of mammalian transcriptome using gene pool specific primers |
SG11201402343SA (en) | 2011-11-21 | 2014-06-27 | Immunogen Inc | Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate |
EP2626433B1 (en) * | 2012-02-09 | 2017-04-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for linking nucleic acids in a microsome from endoplasmatic reticuli |
CN104428318B (en) | 2012-05-02 | 2018-09-25 | 西福根有限公司 | The general HER antibody compositions of humanization |
WO2013188772A1 (en) * | 2012-06-14 | 2013-12-19 | Gigagen, Inc. | Methods for antibody and cell therapeutic discovery |
WO2014124334A2 (en) | 2013-02-08 | 2014-08-14 | Misfolding Diagnostics, Inc. | Transthyretin antibodies and uses thereof |
KR20150132481A (en) | 2013-03-15 | 2015-11-25 | 테라노스, 인코포레이티드 | Nucleic Acid Amplification |
SG11201507261WA (en) | 2013-03-15 | 2015-10-29 | Theranos Inc | Nucleic acid amplification |
US10450595B2 (en) | 2013-03-15 | 2019-10-22 | Theranos Ip Company, Llc | Nucleic acid amplification |
CA2906824C (en) | 2013-03-15 | 2023-10-03 | Theranos, Inc. | Nucleic acid amplification |
MX356055B (en) | 2013-09-06 | 2018-05-11 | Theranos Ip Co Llc | SYSTEMS and METHODS FOR DETECTING INFECTIOUS DISEASES. |
GB201316644D0 (en) | 2013-09-19 | 2013-11-06 | Kymab Ltd | Expression vector production & High-Throughput cell screening |
EP4094834A1 (en) | 2013-12-30 | 2022-11-30 | Atreca, Inc. | Analysis of nucleic acids associated with single cells using nucleic acid barcodes |
WO2015120403A1 (en) * | 2014-02-08 | 2015-08-13 | The Regents Of The University Of Colorado, A Body Corporate | Multiplexed linking pcr |
GB201402591D0 (en) * | 2014-02-14 | 2014-04-02 | Memo Therapeutics Ag | Method for recovering two or more genes, or gene products, encoding an immunoreceptor |
US10533204B2 (en) | 2014-05-30 | 2020-01-14 | National University Corporatlon University of Toyama | Method for amplifying a T cell receptor (TCR) cDNA |
CN104560980B (en) * | 2015-01-20 | 2017-04-05 | 中国人民解放军第三军医大学 | The multiple PCR primer and method in Mus BCR light chain Lamda libraries are built based on high-flux sequence |
CA2988914A1 (en) | 2015-06-09 | 2016-12-15 | Gigagen, Inc. | Recombinant fusion proteins and libraries from immune cell repertoires |
US9422547B1 (en) | 2015-06-09 | 2016-08-23 | Gigagen, Inc. | Recombinant fusion proteins and libraries from immune cell repertoires |
US10793851B2 (en) | 2015-08-04 | 2020-10-06 | The Regents Of The University Of Colorado, A Body Corporate | Multiplexed binary assembly and quantitative tracking of bacterial populations |
US20190040381A1 (en) * | 2015-12-04 | 2019-02-07 | St. Jude Children's Research Hospital, Inc. | Cloning and expression system for t-cell receptors |
CN108473987B (en) * | 2016-01-08 | 2024-01-02 | 马可讯治疗有限公司 | Binding members with altered diverse scaffold domains |
US20190367585A1 (en) * | 2016-04-12 | 2019-12-05 | Medimmune, Llc | Immune repertoire mining |
JP2019531091A (en) * | 2016-09-15 | 2019-10-31 | オーグメンタ・バイオワークス・インコーポレーテッド | Immunorepertoire sequence amplification methods and applications |
KR20230034434A (en) * | 2016-11-29 | 2023-03-09 | 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | Methods and materials for cloning functional t cell receptors from single t cells |
AU2018235786B2 (en) | 2017-03-13 | 2020-05-28 | Gigagen, Inc. | Systems and methods for massively parallel combinatorial analysis of single cells |
WO2019061197A1 (en) * | 2017-09-28 | 2019-04-04 | 深圳华大生命科学研究院 | Pcr primer for amplifying a full length sequence of tcr and application thereof |
CN111344418A (en) * | 2017-09-28 | 2020-06-26 | 深圳华大生命科学研究院 | Kit for amplifying TCR full-length sequence and application thereof |
IL294471B2 (en) | 2018-08-13 | 2024-07-01 | Rootpath Genomics Inc | High throughput cloning of paired bipartite immunoreceptor polynucleotides and applications thereof |
WO2020077017A2 (en) | 2018-10-10 | 2020-04-16 | Augmenta Bioworks, Inc. | Methods for isolating immune binding proteins |
CN109972209B (en) * | 2019-01-18 | 2022-05-03 | 南开大学 | Method for rearranging single-chain antibody library into full-length antibody library by one-step method based on emulsion PCR |
EP3941491A4 (en) | 2019-03-21 | 2023-03-29 | Gigamune, Inc. | Engineered cells expressing anti-viral t cell receptors and methods of use thereof |
JP2022527364A (en) | 2019-04-05 | 2022-06-01 | ルートパス・ジェノミクス,インコーポレーテッド | Compositions and Methods for T Cell Receptor Gene Assembly |
WO2020223573A2 (en) * | 2019-04-30 | 2020-11-05 | Gigagen, Inc. | Recombinant polyclonal proteins and methods of use thereof |
CN111139286B (en) * | 2019-11-07 | 2023-11-21 | 南方医科大学南方医院 | Construction method of BCR high-throughput sequencing library |
CA3177152A1 (en) | 2020-06-12 | 2021-12-16 | David Scott Johnson | Recombinant polyclonal proteins targeting covid-19 and methods of use thereof |
WO2022031834A1 (en) | 2020-08-05 | 2022-02-10 | Gigagen, Inc. | Recombinant polyclonal proteins targeting zika and methods of use thereof |
CN114774405A (en) * | 2022-04-19 | 2022-07-22 | 上海赛唐生物技术有限公司 | Preparation method and application of single-chain antibody expansion library |
WO2024050450A1 (en) | 2022-08-31 | 2024-03-07 | Gigamune, Inc. | Engineered enveloped vectors and methods of use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992015678A1 (en) * | 1991-03-01 | 1992-09-17 | Stratagene | Pcr generated dicistronic dna molecules for producing antibodies |
WO1993003151A1 (en) * | 1991-08-10 | 1993-02-18 | Medical Research Council | Treatment of cell populations |
WO1999016904A1 (en) * | 1997-09-29 | 1999-04-08 | City Of Hope | Efficient linking of nucleic acid segments |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5576195A (en) * | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5906936A (en) * | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
DE4010839A1 (en) * | 1990-04-04 | 1991-10-10 | Bosch Gmbh Robert | DEVICE FOR GENERATING A TRIGGER SIGNAL FROM IGNITION PULSES FROM A IGNITION SYSTEM |
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US6284471B1 (en) * | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
EP1018649A3 (en) | 1992-03-31 | 2000-11-29 | Abbott Laboratories | Immunochromatographic device and method for multiplex detection of multiple analytes |
GB9220808D0 (en) * | 1992-10-02 | 1992-11-18 | Medical Res Council | Antibody genes |
US6096878A (en) * | 1993-05-10 | 2000-08-01 | Japan Tobacco Inc. | Human immunoglobulin VH gene segments and DNA fragments containing the same |
ES2247204T3 (en) | 1994-01-31 | 2006-03-01 | Trustees Of Boston University | BANKS OF POLYCLONAL ANTIBODIES. |
FR2724393A1 (en) | 1994-09-12 | 1996-03-15 | Inst Nat Sante Rech Med | OBTAINING A HUMANIZED RECOMBINANT MONOCLONAL ANTIBODY FROM A MURIN MONOCLONAL ANTIBODY, ITS PRODUCTION IN INSECT CELLS, AND USES THEREOF |
US6111166A (en) | 1994-09-19 | 2000-08-29 | Medarex, Incorporated | Transgenic mice expressing human Fcα and β receptors |
US6258529B1 (en) * | 1994-12-01 | 2001-07-10 | Oravax, Inc. | PCR amplification of rearranged genomic variable regions of immunoglobulin genes |
US5882856A (en) * | 1995-06-07 | 1999-03-16 | Genzyme Corporation | Universal primer sequence for multiplex DNA amplification |
DE69632056T2 (en) * | 1995-09-14 | 2004-12-30 | The Regents Of The University Of California, Oakland | FOR NATIVE PRP-SC SPECIFIC ANTIBODIES |
EP0985033A4 (en) * | 1997-04-04 | 2005-07-13 | Biosite Inc | Polyvalent and polyclonal libraries |
US6610293B1 (en) | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
JP4460155B2 (en) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | Humanization of mouse antibodies |
US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
WO2001042451A2 (en) * | 1999-12-08 | 2001-06-14 | Genset | FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS |
WO2001089563A1 (en) | 2000-05-26 | 2001-11-29 | Symphogen A/S | Recombinant or purified polyclonal antibodies for treating allergy |
IL136459A0 (en) | 2000-05-30 | 2001-06-14 | Galim Galil Immunology Ltd | Antibody library |
US6849259B2 (en) * | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
US6994963B1 (en) * | 2000-07-10 | 2006-02-07 | Ambion, Inc. | Methods for recombinatorial nucleic acid synthesis |
US6867021B2 (en) * | 2001-02-20 | 2005-03-15 | Board Of Trustees Of Michigan State University | Multiplex RT-PCR/PCR for simultaneous detection of bovine coronavirus, bovine rotavirus, Cryptosporidium parvum, and Escherichia coli |
US20040067532A1 (en) * | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
US20060275766A1 (en) * | 2003-01-07 | 2006-12-07 | Haurum John S | Method for manufacturing recombinant polyclonal proteins |
BRPI0406678A (en) | 2003-01-07 | 2005-12-20 | Symphogen As | Method for producing recombinant polyclonal proteins |
US20060228350A1 (en) * | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
ATE474915T1 (en) * | 2003-11-19 | 2010-08-15 | Us Gov Health & Human Serv | METHOD FOR INDUCING DEVELOPMENT AND TERMINAL DIFFERENTIATION OF MEMORY B CELLS |
WO2006007850A1 (en) * | 2004-07-20 | 2006-01-26 | Symphogen A/S | Anti-rhesus d recombinant polyclonal antibody and methods of manufacture |
ATE443870T1 (en) * | 2004-07-20 | 2009-10-15 | Symphogen As | METHOD FOR CHARACTERIZING A POLYCLONAL CELL LINE |
JP2008289483A (en) * | 2007-05-25 | 2008-12-04 | Symphogen As | Screening of transformant expressable in eukaryote system |
-
2004
- 2004-08-31 TW TW093126165A patent/TWI333977B/en not_active IP Right Cessation
- 2004-09-14 EP EP04021764A patent/EP1516929A3/en not_active Withdrawn
- 2004-09-17 US US10/572,431 patent/US7749697B2/en active Active
- 2004-09-17 WO PCT/DK2004/000633 patent/WO2005042774A2/en active Application Filing
- 2004-09-17 SI SI200431823T patent/SI1921144T1/en unknown
- 2004-09-17 PT PT08152066T patent/PT1921144E/en unknown
- 2004-09-17 PL PL08152066T patent/PL1921144T3/en unknown
- 2004-09-17 ES ES04762853T patent/ES2302542T3/en active Active
- 2004-09-17 AT AT08152066T patent/ATE537256T1/en active
- 2004-09-17 PL PL04762853T patent/PL1670912T3/en unknown
- 2004-09-17 AT AT04762853T patent/ATE388228T1/en active
- 2004-09-17 DK DK08152066.0T patent/DK1921144T3/en active
- 2004-09-17 PT PT04762853T patent/PT1670912E/en unknown
- 2004-09-17 MY MYPI2011001886A patent/MY148907A/en unknown
- 2004-09-17 CN CN2004800270289A patent/CN1856571B/en not_active Expired - Fee Related
- 2004-09-17 DE DE602004012299T patent/DE602004012299T2/en active Active
- 2004-09-17 SI SI200430728T patent/SI1670912T1/en unknown
- 2004-09-17 JP JP2006526523A patent/JP4651619B2/en active Active
- 2004-09-17 CA CA002539576A patent/CA2539576A1/en not_active Abandoned
- 2004-09-17 CN CN201110059890XA patent/CN102199593A/en active Pending
- 2004-09-17 EP EP08152066A patent/EP1921144B1/en active Active
- 2004-09-17 EP EP04762853A patent/EP1670912B1/en active Active
- 2004-09-17 ES ES08152066T patent/ES2375529T3/en active Active
- 2004-09-17 DK DK04762853T patent/DK1670912T3/en active
- 2004-09-17 AU AU2004286019A patent/AU2004286019B2/en active Active
- 2004-09-17 NZ NZ545936A patent/NZ545936A/en not_active IP Right Cessation
- 2004-09-17 BR BRPI0414282-9A patent/BRPI0414282A/en not_active Application Discontinuation
-
2010
- 2010-05-26 US US12/788,202 patent/US20100310558A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992015678A1 (en) * | 1991-03-01 | 1992-09-17 | Stratagene | Pcr generated dicistronic dna molecules for producing antibodies |
WO1993003151A1 (en) * | 1991-08-10 | 1993-02-18 | Medical Research Council | Treatment of cell populations |
WO1999016904A1 (en) * | 1997-09-29 | 1999-04-08 | City Of Hope | Efficient linking of nucleic acid segments |
Non-Patent Citations (6)
Title |
---|
BABCOOK J S ET AL: "A NOVEL STRATEGY FOR GENERATING MONOCLONAL ANTIBODIES FROM SINGLE, ISOLATED LYMPHOCYTES PRODUCING ANTIBODIES OF DEFINED SPECIFICITIES" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, no. 15, 23 July 1996 (1996-07-23), pages 7843-7848, XP000608647 ISSN: 0027-8424 * |
CORONELLA J A ET AL: "Amplification of IgG VH and VL (Fab) from single human plasma cells and B cells." NUCLEIC ACIDS RESEARCH. 15 OCT 2000, vol. 28, no. 20, 15 October 2000 (2000-10-15), pages E85.1-E85.7, XP002309252 ISSN: 1362-4962 cited in the application * |
EMBLETON M J ET AL: "IN-CELL PCR FROM MRNA AMPLIFYING AND LINKING THE REARRANGED IMMUNOGLOBULIN HEAVY AND LIGHT CHAIN V-GENES WITHIN SINGLE CELLS" NUCLEIC ACIDS RESEARCH, vol. 20, no. 15, 1992, pages 3831-3837, XP002309251 ISSN: 0305-1048 cited in the application * |
GHERARDI E ET AL: "Original and artificial antibodies." NATURE. 21 MAY 1992, vol. 357, no. 6375, 21 May 1992 (1992-05-21), pages 201-202, XP002309253 ISSN: 0028-0836 cited in the application * |
MULLINAX R L ET AL: "EXPRESSION OF A HETERODIMERIC FAB ANTIBODY PROTEIN IN ONE CLONING STEP" BIOTECHNIQUES, vol. 12, no. 6, 1992, pages 864-866, 868, XP002309250 ISSN: 0736-6205 cited in the application * |
THIRION S ET AL: "Mono- and bispecific single-chain antibody fragments for cancer therapy." EUROPEAN JOURNAL OF CANCER PREVENTION : THE OFFICIAL JOURNAL OF THE EUROPEAN CANCER PREVENTION ORGANISATION (ECP). DEC 1996, vol. 5, no. 6, December 1996 (1996-12), pages 507-511, XP008039898 ISSN: 0959-8278 cited in the application * |
Cited By (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9163232B2 (en) | 2003-01-07 | 2015-10-20 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
EP1967529A1 (en) | 2004-07-20 | 2008-09-10 | Symphogen A/S | Anti-rhesus D recombinant polyclonal antibody and methods of manufacture |
US8288109B2 (en) | 2004-07-20 | 2012-10-16 | Symphogen A/S | Procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line |
US8198415B2 (en) | 2004-07-20 | 2012-06-12 | Symphogen A/S | Anti-rhesus D recombinant polyclonal antibody |
US9029091B2 (en) | 2004-07-20 | 2015-05-12 | Symphogen A/S | Procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line |
EP2336328A1 (en) * | 2005-03-25 | 2011-06-22 | National Research Council of Canada | Method for isolation of soluble polypeptides |
US11091536B2 (en) | 2005-03-25 | 2021-08-17 | National Research Council Of Canada | Method for isolation of soluble polypeptides |
US8293233B2 (en) | 2005-03-25 | 2012-10-23 | National Research Council Of Canada | Method for isolation of soluble polypeptides |
US11993643B2 (en) | 2005-03-25 | 2024-05-28 | National Research Council Of Canada | Method for isolation of soluble polypeptides |
US10150807B2 (en) | 2005-03-25 | 2018-12-11 | National Research Council Of Canada | Method for isolation of soluble polypeptides |
US8945857B2 (en) | 2005-07-01 | 2015-02-03 | John Schrader | Methods of isolating cells and generating monoclonal antibodies |
EP1910513B1 (en) * | 2005-07-01 | 2016-08-10 | John Schrader | Methods of isolating antibody secreting cells from blood samples of immunized animals and generating monoclonal antibodies from said antibody secreting cells. |
EP1910513A1 (en) * | 2005-07-01 | 2008-04-16 | John Schrader | Methods of isolating cells and generating monoclonal antibodies |
EP2343363A1 (en) * | 2005-07-01 | 2011-07-13 | John Schrader | Methods of isolating cells and generating monoclonal antibodies involving single epitope multiple staining |
EP2314619A1 (en) | 2005-12-05 | 2011-04-27 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
WO2007065433A2 (en) | 2005-12-05 | 2007-06-14 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
US7850965B2 (en) | 2005-12-05 | 2010-12-14 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
WO2007065433A3 (en) * | 2005-12-05 | 2007-12-13 | Symphogen As | Anti-orthopoxvirus recombinant polyclonal antibody |
AU2006322445B2 (en) * | 2005-12-05 | 2011-05-12 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
US8784822B2 (en) | 2006-03-14 | 2014-07-22 | Boris Skurkovich | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis |
US7504106B2 (en) | 2006-03-14 | 2009-03-17 | Boris Skurkovich | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis |
RU2459868C2 (en) * | 2007-03-01 | 2012-08-27 | Симфоген А/С | Method of cloning cognate antibodies |
US7887805B2 (en) | 2007-03-01 | 2011-02-15 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
JP2010535150A (en) * | 2007-03-01 | 2010-11-18 | シムフォゲン・アクティーゼルスカブ | Methods for cloning cognate antibodies |
AU2008221119B2 (en) * | 2007-03-01 | 2013-11-14 | Les Laboratoires Servier | Method for cloning cognate antibodies |
WO2008104184A2 (en) | 2007-03-01 | 2008-09-04 | Symphogen A/S | Method for cloning cognate antibodies |
US8414896B2 (en) | 2007-03-01 | 2013-04-09 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
WO2008104184A3 (en) * | 2007-03-01 | 2008-10-16 | Symphogen As | Method for cloning cognate antibodies |
US8283294B2 (en) | 2007-03-01 | 2012-10-09 | Symphogen A/S | Method for cloning cognate antibodies |
US7879329B2 (en) | 2007-03-06 | 2011-02-01 | Symphogen A/S | Recombinant antibodies for treatment of respiratory syncytial virus infections |
WO2008145133A2 (en) | 2007-05-25 | 2008-12-04 | Symphogen A/S | Method for manufacturing a recombinant polyclonal protein |
EP1997892A1 (en) | 2007-05-25 | 2008-12-03 | Symphogen A/S | Screening for expressible transfectants in a eukaryotic system |
US7910332B2 (en) | 2007-05-25 | 2011-03-22 | Symphogen A/S | Method for manufacturing a recombinant polyclonal protein |
WO2008145133A3 (en) * | 2007-05-25 | 2009-02-05 | Symphogen As | Method for manufacturing a recombinant polyclonal protein |
US8663640B2 (en) | 2008-08-29 | 2014-03-04 | Symphogen A/S | Methods using recombinant anti-epidermal growth factor receptor antibody compositions |
WO2010022738A1 (en) * | 2008-08-29 | 2010-03-04 | Symphogen A/S | Method for cloning avian-derived antibodies |
US9416420B2 (en) | 2008-11-07 | 2016-08-16 | Adaptive Biotechnologies Corp. | Monitoring health and disease status using clonotype profiles |
US11021757B2 (en) | 2008-11-07 | 2021-06-01 | Adaptive Biotechnologies Corporation | Monitoring health and disease status using clonotype profiles |
US10246752B2 (en) | 2008-11-07 | 2019-04-02 | Adaptive Biotechnologies Corp. | Methods of monitoring conditions by sequence analysis |
US8507205B2 (en) | 2008-11-07 | 2013-08-13 | Sequenta, Inc. | Single cell analysis by polymerase cycling assembly |
US10266901B2 (en) | 2008-11-07 | 2019-04-23 | Adaptive Biotechnologies Corp. | Methods of monitoring conditions by sequence analysis |
US10519511B2 (en) | 2008-11-07 | 2019-12-31 | Adaptive Biotechnologies Corporation | Monitoring health and disease status using clonotype profiles |
US10760133B2 (en) | 2008-11-07 | 2020-09-01 | Adaptive Biotechnologies Corporation | Monitoring health and disease status using clonotype profiles |
US10865453B2 (en) | 2008-11-07 | 2020-12-15 | Adaptive Biotechnologies Corporation | Monitoring health and disease status using clonotype profiles |
US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
US11001895B2 (en) | 2008-11-07 | 2021-05-11 | Adaptive Biotechnologies Corporation | Methods of monitoring conditions by sequence analysis |
US9528160B2 (en) | 2008-11-07 | 2016-12-27 | Adaptive Biotechnolgies Corp. | Rare clonotypes and uses thereof |
US8691510B2 (en) | 2008-11-07 | 2014-04-08 | Sequenta, Inc. | Sequence analysis of complex amplicons |
US9523129B2 (en) | 2008-11-07 | 2016-12-20 | Adaptive Biotechnologies Corp. | Sequence analysis of complex amplicons |
US9512487B2 (en) | 2008-11-07 | 2016-12-06 | Adaptive Biotechnologies Corp. | Monitoring health and disease status using clonotype profiles |
US8748103B2 (en) | 2008-11-07 | 2014-06-10 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
US9506119B2 (en) | 2008-11-07 | 2016-11-29 | Adaptive Biotechnologies Corp. | Method of sequence determination using sequence tags |
US8795970B2 (en) | 2008-11-07 | 2014-08-05 | Sequenta, Inc. | Methods of monitoring conditions by sequence analysis |
US10155992B2 (en) | 2008-11-07 | 2018-12-18 | Adaptive Biotechnologies Corp. | Monitoring health and disease status using clonotype profiles |
US9365901B2 (en) | 2008-11-07 | 2016-06-14 | Adaptive Biotechnologies Corp. | Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia |
US9347099B2 (en) | 2008-11-07 | 2016-05-24 | Adaptive Biotechnologies Corp. | Single cell analysis by polymerase cycling assembly |
US9228232B2 (en) | 2008-11-07 | 2016-01-05 | Sequenta, LLC. | Methods of monitoring conditions by sequence analysis |
US9217176B2 (en) | 2008-11-07 | 2015-12-22 | Sequenta, Llc | Methods of monitoring conditions by sequence analysis |
US10323276B2 (en) | 2009-01-15 | 2019-06-18 | Adaptive Biotechnologies Corporation | Adaptive immunity profiling and methods for generation of monoclonal antibodies |
US9399671B2 (en) | 2009-02-25 | 2016-07-26 | Ucb Pharma S.A. | Method for producing proteins |
WO2010097435A1 (en) | 2009-02-25 | 2010-09-02 | Ucb Pharma, S.A. | Method for producing antibodies |
WO2010097437A1 (en) | 2009-02-25 | 2010-09-02 | Ucb Pharma, S.A. | Method for producing antibodies |
US8563305B2 (en) | 2009-04-30 | 2013-10-22 | Oklahoma Medical Research Foundation | Rapid generation of antibodies |
US8685896B2 (en) | 2009-05-29 | 2014-04-01 | Morphosys Ag | Collection and methods for its use |
WO2010136598A1 (en) | 2009-05-29 | 2010-12-02 | Morphosys Ag | A collection and methods for its use |
US10647757B2 (en) | 2009-05-29 | 2020-05-12 | Morphosys Ag | Collection and methods for its use |
US9624293B2 (en) | 2009-05-29 | 2017-04-18 | Morphosys Ag | Collection and methods for its use |
US11214793B2 (en) | 2009-06-25 | 2022-01-04 | Fred Hutchinson Cancer Research Center | Method of measuring adaptive immunity |
US11905511B2 (en) | 2009-06-25 | 2024-02-20 | Fred Hutchinson Cancer Center | Method of measuring adaptive immunity |
US9809813B2 (en) | 2009-06-25 | 2017-11-07 | Fred Hutchinson Cancer Research Center | Method of measuring adaptive immunity |
US9043160B1 (en) | 2009-11-09 | 2015-05-26 | Sequenta, Inc. | Method of determining clonotypes and clonotype profiles |
EP2536759A1 (en) * | 2010-02-18 | 2012-12-26 | Meiji Seika Pharma Co., Ltd. | Antibody against serotype i lipopolysaccharide of pseudomonas aeruginosa |
CN102858975A (en) * | 2010-02-18 | 2013-01-02 | 明治制果药业株式会社 | Antibody against serotype a lipopolysaccharide of pseudomonas aeruginosa |
EP2536759A4 (en) * | 2010-02-18 | 2013-09-18 | Meiji Seika Pharma Co Ltd | Antibody against serotype i lipopolysaccharide of pseudomonas aeruginosa |
WO2011102555A1 (en) * | 2010-02-18 | 2011-08-25 | Meiji Seika Kaisha, Ltd. | Antibody against serotype g lipopolysaccharide of pseudomonas aeruginosa |
WO2011102556A1 (en) * | 2010-02-18 | 2011-08-25 | Meiji Seika Kaisha, Ltd. | Antibody against serotype a lipopolysaccharide of pseudomonas aeruginosa |
WO2011102554A1 (en) * | 2010-02-18 | 2011-08-25 | Meiji Seika Kaisha, Ltd. | Antibody against serotype b lipopolysaccharide of pseudomonas aeruginosa |
CN102858977A (en) * | 2010-02-18 | 2013-01-02 | 明治制果药业株式会社 | Antibody against serotype g lipopolysaccharide of pseudomonas aeruginosa |
EP3156421A1 (en) | 2010-11-01 | 2017-04-19 | Symphogen A/S | Pan-her antibody composition |
US8617881B2 (en) | 2010-11-16 | 2013-12-31 | Excelimmune, Inc. | Methods for producing recombinant proteins |
US9447174B2 (en) | 2010-11-16 | 2016-09-20 | Excelimmune Liquidating Trust | Methods for producing recombinant proteins |
WO2012068317A2 (en) | 2010-11-16 | 2012-05-24 | Excelimmune, Inc. | Methods for producing recombinant proteins |
US8728981B2 (en) | 2010-11-19 | 2014-05-20 | Morphosys Ag | Collection and methods for its use |
US9541559B2 (en) | 2010-11-19 | 2017-01-10 | Morphosys Ag | Collection and methods for its use |
WO2012066129A1 (en) | 2010-11-19 | 2012-05-24 | Morphosys Ag | A collection and methods for its use |
US8367586B2 (en) | 2010-11-19 | 2013-02-05 | Morphosys Ag | Collection and methods for its use |
WO2012072705A1 (en) | 2010-12-01 | 2012-06-07 | Morphosys Ag | Simultaneous detection of biomolecules in single cells |
US9670483B2 (en) | 2011-07-12 | 2017-06-06 | Xbiotech, Inc. | Immunoglobulin variable region libraries |
US10385475B2 (en) | 2011-09-12 | 2019-08-20 | Adaptive Biotechnologies Corp. | Random array sequencing of low-complexity libraries |
US9279159B2 (en) | 2011-10-21 | 2016-03-08 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
US9181590B2 (en) | 2011-10-21 | 2015-11-10 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
US9824179B2 (en) | 2011-12-09 | 2017-11-21 | Adaptive Biotechnologies Corp. | Diagnosis of lymphoid malignancies and minimal residual disease detection |
US9499865B2 (en) | 2011-12-13 | 2016-11-22 | Adaptive Biotechnologies Corp. | Detection and measurement of tissue-infiltrating lymphocytes |
US10077478B2 (en) | 2012-03-05 | 2018-09-18 | Adaptive Biotechnologies Corp. | Determining paired immune receptor chains from frequency matched subunits |
US9371558B2 (en) | 2012-05-08 | 2016-06-21 | Adaptive Biotechnologies Corp. | Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions |
US10894977B2 (en) | 2012-05-08 | 2021-01-19 | Adaptive Biotechnologies Corporation | Compositions and methods for measuring and calibrating amplification bias in multiplexed PCR reactions |
US10214770B2 (en) | 2012-05-08 | 2019-02-26 | Adaptive Biotechnologies Corp. | Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions |
US9150905B2 (en) | 2012-05-08 | 2015-10-06 | Adaptive Biotechnologies Corporation | Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions |
US9708654B2 (en) | 2012-06-15 | 2017-07-18 | Board Of Regents, The University Of Texas System | High throughput sequencing of multiple transcripts |
US11180813B2 (en) | 2012-10-01 | 2021-11-23 | Adaptive Biotechnologies Corporation | Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization |
US10221461B2 (en) | 2012-10-01 | 2019-03-05 | Adaptive Biotechnologies Corp. | Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization |
US10150996B2 (en) | 2012-10-19 | 2018-12-11 | Adaptive Biotechnologies Corp. | Quantification of adaptive immune cell genomes in a complex mixture of cells |
US10309969B2 (en) | 2013-01-24 | 2019-06-04 | Abtlas Co., Ltd. | Protein combination-based FV library, and preparation method therefor |
US10392614B2 (en) | 2013-03-15 | 2019-08-27 | Abvitro Llc | Methods of single-cell barcoding and sequencing |
US10119134B2 (en) | 2013-03-15 | 2018-11-06 | Abvitro Llc | Single cell bar-coding for antibody discovery |
US11118176B2 (en) | 2013-03-15 | 2021-09-14 | Abvitro Llc | Single cell bar-coding for antibody discovery |
US10876107B2 (en) | 2013-03-15 | 2020-12-29 | Abvitro Llc | Single cell bar-coding for antibody discovery |
US9816088B2 (en) | 2013-03-15 | 2017-11-14 | Abvitro Llc | Single cell bar-coding for antibody discovery |
US9708657B2 (en) | 2013-07-01 | 2017-07-18 | Adaptive Biotechnologies Corp. | Method for generating clonotype profiles using sequence tags |
US10077473B2 (en) | 2013-07-01 | 2018-09-18 | Adaptive Biotechnologies Corp. | Method for genotyping clonotype profiles using sequence tags |
US10526650B2 (en) | 2013-07-01 | 2020-01-07 | Adaptive Biotechnologies Corporation | Method for genotyping clonotype profiles using sequence tags |
CN103820430A (en) * | 2013-12-19 | 2014-05-28 | 河南科技大学 | Overlapping extension PCR (Polymerase Chain Reaction) method of DNA (Deoxyribonucleic Acid) fragment taking DNA with high GC (Gas Chromatography) content or complex structure as template |
US11248253B2 (en) | 2014-03-05 | 2022-02-15 | Adaptive Biotechnologies Corporation | Methods using randomer-containing synthetic molecules |
US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
US11261490B2 (en) | 2014-04-01 | 2022-03-01 | Adaptive Biotechnologies Corporation | Determining antigen-specific T-cells |
US10435745B2 (en) | 2014-04-01 | 2019-10-08 | Adaptive Biotechnologies Corp. | Determining antigen-specific T-cells |
US10590483B2 (en) | 2014-09-15 | 2020-03-17 | Abvitro Llc | High-throughput nucleotide library sequencing |
WO2016042412A1 (en) | 2014-09-16 | 2016-03-24 | Symphogen A/S | Anti-met antibodies and compositions |
US10450376B2 (en) | 2014-09-16 | 2019-10-22 | Symphogen A/S | Anti-MET antibodies and compositions |
US10392663B2 (en) | 2014-10-29 | 2019-08-27 | Adaptive Biotechnologies Corp. | Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from a large number of samples |
US10246701B2 (en) | 2014-11-14 | 2019-04-02 | Adaptive Biotechnologies Corp. | Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture |
US11066705B2 (en) | 2014-11-25 | 2021-07-20 | Adaptive Biotechnologies Corporation | Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing |
US11047008B2 (en) | 2015-02-24 | 2021-06-29 | Adaptive Biotechnologies Corporation | Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing |
US10513733B2 (en) | 2015-03-23 | 2019-12-24 | Board Of Regents, The University Of Texas System | High throughout sequencing of paired VH and VL transcripts from B cells secreting antigen-specific antibodies |
US11041202B2 (en) | 2015-04-01 | 2021-06-22 | Adaptive Biotechnologies Corporation | Method of identifying human compatible T cell receptors specific for an antigenic target |
CN105087560A (en) * | 2015-08-07 | 2015-11-25 | 深圳市瀚海基因生物科技有限公司 | Multiplex PCR primers and method based on high-throughput sequencing to build pig BCR heavy chain library |
CN105087560B (en) * | 2015-08-07 | 2016-06-01 | 深圳市瀚海基因生物科技有限公司 | A kind of multiple PCR primer and method building pig BCR heavy chain library based on high-flux sequence |
WO2017024991A1 (en) * | 2015-08-07 | 2017-02-16 | 深圳市瀚海基因生物科技有限公司 | Swine bcr heavy-chain multiplex pcr primer and application thereof |
EP4105235A1 (en) | 2015-10-02 | 2022-12-21 | Symphogen A/S | Anti-pd-1 antibodies and compositions |
US10428325B1 (en) | 2016-09-21 | 2019-10-01 | Adaptive Biotechnologies Corporation | Identification of antigen-specific B cell receptors |
WO2018091661A1 (en) | 2016-11-18 | 2018-05-24 | Symphogen A/S | Anti-pd-1 antibodies and compositions |
US11820979B2 (en) | 2016-12-23 | 2023-11-21 | Visterra, Inc. | Binding polypeptides and methods of making the same |
US11866785B2 (en) | 2017-10-27 | 2024-01-09 | Board Of Regents, The University Of Texas System | Tumor specific antibodies and T-cell receptors and methods of identifying the same |
US11254980B1 (en) | 2017-11-29 | 2022-02-22 | Adaptive Biotechnologies Corporation | Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements |
WO2023213787A1 (en) | 2022-05-02 | 2023-11-09 | Aarhus Universitet | Antibodies for prophylaxis or treatment of sars- cov-2 infections |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7749697B2 (en) | Method for linking sequences of interest | |
EP2121920B1 (en) | Method for cloning cognate antibodies | |
JP4926054B2 (en) | Anti-RhD recombinant polyclonal antibody and production method | |
JP2010268806A (en) | Method for manufacturing recombinant polyclonal protein | |
US20100069262A1 (en) | Method for Cloning Avian-Derived Antibodies | |
RU2392324C2 (en) | Concerned sequences linkage method | |
KR101135134B1 (en) | Method for linking sequences of interest | |
MXPA06002894A (en) | Method for linking sequences of interest | |
AU2008201796A1 (en) | Method for manufacturing recombinant polyclonal proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480027028.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 173688 Country of ref document: IL Ref document number: 2004286019 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2004286019 Country of ref document: AU Date of ref document: 20040917 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004286019 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/002894 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 545936 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2539576 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067005488 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007141048 Country of ref document: US Ref document number: 2006526523 Country of ref document: JP Ref document number: 10572431 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004762853 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 891/KOLNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006/03032 Country of ref document: ZA Ref document number: 200603032 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006112833 Country of ref document: RU |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 2004762853 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067005488 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0414282 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 10572431 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2004762853 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 204167 Country of ref document: IL |